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Introduction 
The overall aim of this commission is to demonstrate why and how palliative care (PC) can be 
integrated with oncology for adults with cancer, irrespective of treatment intention in high and 
middle income countries. This integration will combine two main paradigms, the tumour-directed 
and the patient (host)-directed, by using the most competent and optimal resources from oncology 
and PC in well-planned patient-centred care pathways.  
 
The two paradigms may be understood as representing two different cultures. Oncology has its root 
in mainstream medicine, i.e. internal medicine, and is primarily based upon the acute care model. 
From the mid 1960’s hospice and palliative care were established outside the main health care 
systems often financed by charities. The primary focus was from the start end of life care and care 
has been provided by multidisciplinary teams targeting the patients and their families. The 
oncological and palliative care cultures are still mainly living apart, with separate journals, seminars 
and conferences.  
 
As will be demonstrated, the field of research on integration of oncology and PC is heterogeneous. 
Most or nearly all studies have been performed in high-income countries and still the variation across 
countries, systems and settings often limits the generalizability of findings. In a recent Lancet 
Commission on palliative care focusing on low and middle-income countries it is stated upfront: 
“Poor people in all parts of the world live and die with little or no palliative care or pain relief”. 1 The 
commission gives a series of recommendations such as how to quantify serious health-related 
suffering and proposes an Essential Package of palliative care which also may be relevant to apply in 
high-income countries , for example as a basic benchmark of successful implementation at patient 
level. It is also recommended an international and collective action to receive universal coverage of 
palliative care and pain relieve and better evidence and priority setting tools in order to measure the 
global need for palliative care and implementation policies. Given the empirical basis presented in 
this commission, the recommendations are primarily focused on high income countries but the 
findings, experiences and models presented might be highly relevant in other contexts as well.  
 
The WHO definition of PC clearly states that the competence, attitudes and skills of PC should be 
integrated in health care, in general, and in cancer care, specifically: “PC is an approach that 
improves the quality of life of patients and their families facing the problem associated with life 
threatening illness, and is applicable early in the course of the illness, in conjunction with other 
therapies that are intended to prolong life”. 2 The present paper builds on this definition, which 
differs substantially from the common perception of PC being synonymous with end of life-care.  
Studies have shown that hospital-based specialized PC, alongside tumour-directed and life-
prolonging treatment, can contribute to better oncology care for patients and families, in terms of 
better symptom management, quality of life and satisfaction with care, and less psychological 
distress; some studies even suggest survival benefits. 3-5 Thus, we think it is timely to rethink and 
reorganize the delivery of oncology and PC to improve treatment and to promote collaboration at 
the appropriate levels of care. We, therefore, propose models of integration that respectively fit the 
tasks and responsibilities of the two main hospital categories; i.e. university hospitals (3o) and local 
hospitals (2o), as well as community health care (1o). 
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Integration of care is a complex “intervention” based on organizational structure and patient-centred 
plans. Standardized Care Pathways (SCPs) is a method, a planning tool, for the implementation of 
such complex processes. The European Pathway Association (EPA) defines SCPs as “a complex 
intervention of the mutual decision making and organization of care processes for a well-defined 
group of patients during a well-defined period”.6 SCPs facilitate transitions within hospitals and 
between health care levels, which should be seamless to ensure the continuity and coordination of 
care. This commission proposes to use SCPs as a method for integration of oncology and palliative 
care. 
Supportive and palliative care focuses on the patient, the host of the cancer disease. The aim of such 
care is to prevent, treat and reduce the patient’s symptoms and suffering caused by treatment 
toxicity and tumour burden and to preserve and improve psychological and social well-being. There 
have been recent semantic discussions regarding definitions and distinctions between supportive and 
palliative care.  The European Society of Medical Oncology (ESMO) states that supportive care should 
be available at any stage of the cancer illness, while PC is focused on treatment when cure is no 
longer possible.7 The American Society of Clinical Oncology (ASCO) does not specify a particular time 
for delivery of one or the other 8 and neither ESMO nor ASCO differentiate between the content of 
supportive and palliative care. In spite of a similar focus, the starting points for palliative and 
supportive care differed. Whereas palliative care started as end of life care, supportive care initially 
focused side effects of anti-cancer treatment such as chemotherapy-induced nausea and vomiting, 
and neutropenia. 
Symptom management is a key element of both supportive and PC. Symptoms inform diagnosis and 
treatment in all parts of medicine and play a central role throughout the entire cancer disease 
trajectory.  They are a particular focus in PC, in which e symptom alleviation is the main target for 
interventions.2 Symptom assessment is often not performed systematically in oncology practice or 
routinely incorporated into the clinical decision-making processes.  
 
The World Health Organization (WHO) has defined the term integrated health services as: “the 
organization and management of health services, so that people get the care they need, when they 
need it, in ways that are user-friendly, achieve the desired results and promote value for money”. 
9 In oncology, the multidisciplinary team  approach that combines competence and skills in the 
planning of treatment care has become a standard.10 This approach represents an integration of 
disciplines at the hospital level of care, e.g. among surgeons, oncologists, pathologists, radiologists 
and specialist nurses. The multidisciplinary team  can include PC specialists at any stage of the 
disease trajectory when treatment intention is curative, life-prolonging or palliative. Given the 
definition of PC, interventions provided by PC have a broad focus and can therefore not be delivered 
by a single profession. Multiple professions organized in teams are therefore common in PC. The 
compositions of the teams might vary, partly depending upon local resources and traditions. The 
internal organization of the teams might also vary, but multidisciplinarity, which draws on knowledge 
from different disciplines but stays within their boundaries,11 are probably the most common internal 
organization. The term multidisciplinary teams (MDTs) will therefore be used throughout this 
commission.  
 
From a societal, ethical and political perspective, the escalating costs of health care represent a 
major problem. Although spending on cancer care comprises only 5% of the overall health care 
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budget 12, these costs continue to rise more rapidly than in other health care areas.13 The escalating 
costs can be attributed to the ageing of the population, new and expensive diagnostic and treatment 
options, more prolonged survival of patients with metastatic disease and a growing public demand 
for tumour directed treatment at all stages of the disease. The increased complexity and escalating 
costs also apply to care at the end of life. About one third of the cost of cancer care is spent during 
the patients’ last year.14 Planning and structure of cancer care and PC has the potential to reduce 
costs, especially when the complexity of treatment and care increases.15  
Evidence-based medicine is the norm in oncology practice,16 but evidence as to when to start and 
when to stop anti-cancer treatment near the end of life has been lacking.16 The quality and quantity 
of research in this area has been questioned 17,18 as is the case with regard to patient-centred 
outcomes for the newly registered targeted therapies and immunotherapies. The level of scientific 
evidence is also low with regard to the impact of chemotherapy in most areas of symptom 
management, including the treatment of pain,19 although palliative radiotherapy may be highly 
effective in that regard.20  
It is especially important during the patient’s last year of life that the attention given to the effect of 
tumour-directed treatment is congruent with the individual patient’s perception of benefits in terms 
of symptom burden and quality of life 21. Few, if any, trials give guidance for such choices. This has 
led to the recommendation that a set of criteria (e.g. disease progression, performance status, 
nutritional status, weight loss and symptom burden) should guide the discontinuation of tumour-
directed treatment.22,23 This could also apply to Phase 1 trials, which may have therapeutic intent, 
but for which the likelihood of benefit to the individual patient may be extremely small 24. As the 
disease progresses, there should be a redefinition of the main outcomes from tumour response to 
symptom control, preservation of functions and wellbeing. 25 
Shared decision-making is a key element of cancer care, but it has been questioned to what degree 
patients are able to  participate as active partners in the decision-making process when multiple  
options for tumour-directed treatment are available and when life-prolonging treatment with 
marginal benefits are offered 26. Some patients want to live as long as possible and are willing to try 
intensive treatment , even if the likelihood of benefit is extremely small and the risk of  side-effects 
that may impair quality of life, and reduce residual time at home is high.27 Active patient 
participation presupposes sufficient and relevant knowledge of the disease and the treatment 
options. This can only be reached by the continuous provision of realistic patient-centred 
information. This requires good communication skills among the oncologists and the palliative care 
specialists, with the needs and wishes of patients’ and families’ assessed systematically and used in 
the decision making processes.28 It has been found with decision-making for Phase 1 trials that 
fundamental components of communication and information sharing, including discussion of 
prognosis and options for supportive care, are often missing from interviews.29 A more patient-
centred focus might be enhanced by an MDT approach, with systematic collaboration among team 
members from different professions within and across levels of care. This implies an empathic 
approach by health care professionals with willingness and skills to assess and understand the 
patient’s needs. Since most patients want to spend as much time as possible at home during their 
last phase of life, health care providers need to understand, accept, communicate and plan for home 
care. 
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Background 
In the following section developmental and conceptual issues of relevance for the present focus on 
integration of oncology and PC are briefly outlined. 
 
PC and oncology care - development over last decades 
Cancer care has been criticized for years for its disproportionate focus on the tumour, compared to 
attention to the patient with the cancer. The concept of hospice care and later PC was introduced 
partly as a reaction to the lack of a patient-centred focus.  Attention to palliative cancer care 
emerged in the 1970s, partly through efforts of researchers, such as Jan Stjernswärd, who was 
attached to the WHO at that time.30 The term PC was probably first coined by the Canadian surgeon 
Balfour Mount in 1974.31 At the time, PC had a strong focus on end-of life-care and it is commonly 
still equated with this time frame,32 despite its subsequent redefinition. A dichotomized perception 
of oncology care and PC is outlined in figure 1a. This perception fits with PC as equal to end-of-life 
care but is not in line with the present definition of PC as formulated by WHO (“applicable earlier in 
the disease trajectory”). A perception in line with this definition, in which the two are integrated or 
given in parallel, is outlined in figure 1b. 
 
Supportive care emerged as a concept and a care approach in the late 1980s, somewhat later than 
PC, but with a similar focus on the host.33 Supportive care focused on the entire disease trajectory, 
including when curative treatments, often accompanied by multiple side effects, are still being 
delivered. Late effects began to receive attention during the 1980s as new health problems in cancer 
care and spawned the field of cancer survivorship which can be regarded as an extension of 
supportive cancer care.34,35  
 
The difference between PC and supportive care is primarily related to differences in the stage of 
disease to which they are applied, rather than to the treatment itself.36 This is reflected in the  similar 
defintions of the concepts by the US National Cancer Institute (NCI )and the WHO.37 According to the 
WHO definition, PC focuses on patients with a life-limiting disease, while supportive care is applicable 
irrespective of treatment intention and may also include rehabilitation of cured cancer survivors. 
Therefore, in our view, treatments of pain, fatigue, physical and psychological distress after curative 
treatment are best characterized as supportive care.  
 
The content and the professional competence needed to provide PC and supportive care are 
basically similar, both focusing on the host – the patient living with the cancer disease and/or with 
side effects after the treatment.  PC and supportive care are differently organized across locations, 
based upon resources and traditions. In some centres, the two are organized as one service, while in 
others they are totally separated. Independent of organizational structure, the focus on the host with 
a patient-centred focus is similar. Therefore, when resources permit, integration of PC and 
supportive care may be most effective in terms of treatment delivery and as a direction to 
strengthen the patient-centred culture in cancer care delivery. 
 
The latest definition of PC by the WHO (2002), revised from its 1989-definition points to integration 
of oncology and PC by stating: “PC is applicable early in the course of illness, in conjunction with other 
therapies that are intended to prolong life, such as chemotherapy or radiation therapy, and includes 
those investigations needed to better understand and manage distressing clinical complications”.38 
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The integrated care model has more recently also become a topic in cardiology, pulmonology and 
other specialties. The difference between an integrated model and PC as an end of life care is 
illustrated in Figures 1a and 1b. 
 
 
Figure 1a and 1 b. Traditional versus early palliative care 
 
Patients live longer with metastatic disease – need for coordination and planning 
The possibilities for tumour-directed treatments have increased exponentially during the past 
decade.  Multiple treatment lines have become the rule for common cancers, such as breast, lung, 
colorectal and prostate, and many more patients are now living with metastatic disease. New 
immune-therapies are being introduced into standard oncology care, with side-effects that differ 
from those of traditional chemotherapeutic agents. We lack systematic data on the impact of these 
new therapies upon the host and their clinical presentations. However, we do know that the increase 
in number of patients living with advanced disease necessarily will have implications on coordination 
and planning of care by combing the tumour- and the patient-centred approaches.  
 
This development has reshaped cancer into a chronic disease, and cancer was recognised as one of 
four major types of chronic diseases by the WHO in 2010.39 The development has also made the 
terms curative and palliative tumour-directed treatment even more vague and prone to be 
misunderstood by patients and possibly colleagues. We prefer terms related to treatment intention; 
curative, life-prolonging or palliative.40 Probably will an increasing number of patients with advanced 
cancer die from other comorbid diseases after a prolonged period of tumour-directed treatment. 
Thus, the chronic care model will become increasingly relevant for oncology-palliative care, but our 
impression is that the traditional disease model still is the dominating model within cancer care. The 
chronic care model was launched at the end of the 20th century and represents a shift of paradigm 
within health care.41 The model emphasises patient-centred elements such as patient empowerment, 
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patient preferences, and family and social support,41  and therefore has obvious similarities with 
patient-centredness although the two seem to have been developed in parallel. 
  
Integration in health care   
The availability of new tumour-directed treatments for advanced cancer points to a basic challenge in 
health care, in general, and in cancer care specifically: how to organize complex care pathways in a 
flexible and optimal structure involving multiple professionals working simultaneously or in parallel. 
Health care is currently most often organized in silos of primary, secondary and tertiary levels of 
care, with levels within each silo as well. Surgical oncology, medical oncology, radiation oncology and 
cancer PC within the cancer centre are examples of such silos, organized with separate leaders from 
different departments with individual budgets. Patients and their families may experience great 
difficulty navigating between and within each of these silos as well as to understand mixed messages 
about the main focus of care presented by two different cultures within the same department or 
hospital.  As exemplified in figure 2, these silos should be “connected” to provide the varying needs 
for care of each individual patient. SCP is a method to foresee, establish and administer such 
connections. 
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Figure 2. Health care includes silos at different levels 
 
In 2007, the WHO Director-General stated that “We need a comprehensive, integrated approach to 
service delivery. We need to fight fragmentation”.42 The current challenge is to specify the nature of 
integrated services in different settings and how integration can contribute to the intended aim of 
ensuring that cancer patients and their families receive the care they need. The WHO Technical brief 
on integration of health services aimed to show that integrated service delivery is best seen as a 
continuum involving technical discussions about tasks that need to be performed in order to provide 
good quality health.9  
 
Integration aims to coordinate the activities of professionals with the overall goal of improving 
patient care. Achieving such coordination requires change at the system level based upon a common 
understanding and acceptance of the two paradigms in this context. From an organizational 
perspective one need to take into account the flow of patients between levels (or silos) of the 
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organization; this refers to the units, sections, departments and/or hospitals. To reach the goal of 
integration a common understanding of a merging of the two paradigms are probably needed as well 
as budgetary reallocations and formal or informal changes in the organization may be required. 
These changes may allow more flexible allocation of human and treatment resources according to 
the needs defined in the SCPs.  
In an influential article, Leutz defined integration as: “the search to connect the health care system 
with other human service system in order to improve outcome (clinical, satisfaction and efficiency)”.43 
He proposed three levels of integration in the same article: linkage, coordination and full integration. 
In Table 1, examples and understanding of these three levels are provided from a general health care 
perspective and from an oncology/PC perspective.  
 
Linkage • Patients are cared for in a planned system  
• Based upon an understanding of special needs (formalized in an SCP) 
• Work in parallel or in series  
• Basic understanding of the various professional skills   
Coordination • Patients are cared for in a well-structured plan based upon patients’ needs 
and the content of the SCP 
• It operates in separate structures within a system (exemplified by pathology, 
imaging, surgery, radiation or tumour directed chemotherapy symptom 
management etc.)  
• It has been an implementation plan (of the SCP) and follow ups/monitoring 
of the plan 
 
Full 
integration 
• Resources (competence and skills) are pooled into one unit/section taking 
from existing systems 
• The silos are eliminated (partially or totally) and the organization is based 
upon the SCP 
• The MDT can as a dynamic structure be an example of full integration as 
they meet  
 
Table 1. Three levels of integration adapted and revised from Leutz.43 
The levels of integration as outlined in table 1 can be understood as both static and dynamic. 
Integration as outlined in Table 1 will also challenge the internal life and individual priorities in 
cultures and subcultures in both oncology- and palliative care. In order to reach achievable and 
practical solutions integration can be formalized and made routine in some situations, as with 
multidisciplinary team meetings (MDT) as one component in a planned structure (the SCPs), while in 
other situations may be added according to patient needs in order to optimize care. 
Integration of oncology and palliative care 
The term integration has been applied to the interplay between oncology and PC for some decades. 
It was used in an Editorial in JCO in 2004 that recommended efforts be made to bridge the gap 
between oncology and PC, in order to provide better care for those dying from cancer.44 The 
distinction between integration and early integration has not been clearly defined, but use of the 
latter term might help to counteract the commonly held belief that palliative care is equivalent to 
end-of-life care. The strong focus on integration in contemporary oncology and PC has also led to 
experts formulating consensus- based indicators of integration.45 
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The 2010 Temel et al 3 findings of improved survival and better quality of life with early palliative care  
paved the way for the integration of PC in oncology, as a means to provide better and more patient-
centred care for patients with a life-limiting cancer disease. PC has also been proposed as a means to 
offset the rapidly increasing costs in oncology, especially in the patients’ last year of life, and to 
address the anticipated shortage of resources due to increasing demands and costs. The findings of 
the Temel study led to the formulation of an ASCO provisional clinical opinion in 2012, which was 
revised into a clinical practice guideline in 2017.16,46 Without using the term early integration, the 
provisional clinical opinion clearly stated that PC is more than end-of-life care and that patients 
would benefit from receiving PC, while still receiving tumour-directed treatment, based on a low to 
medium level of evidence.46  
Randomized studies  
The current research on integration between oncology and PC primarily stems from studies of cancer 
patients in outpatient hospital settings and has recently been synthesized in a review 47. Other 
published reviews of the effectiveness of specialized palliative care have mainly been based on mixed 
populations, without separating the results for patients with cancer. The trials included in the 2017-
review have been published from the late 1990s with different designs and endpoints. Table 2 
presents the components of integration from the seven randomized trials included in the 2017-
review.47 The components vary considerably across the studies but are systemized in this table based 
upon components proposed in a recent study.48  
 
 
Jordhøy 
2000 49 
Temel 
20103 
Zimmer-
mann 
20145 
Bakitas 
201550 
Maltoni 
2016 51 
Temel 
201752 
Grønvold  
201753 
Clinical structure (*)       
 
Presence of palliative care 
inpatient consultation team  
      
 
Presence of palliative care 
outpatient clinic  
      
 
Presence of  community based 
/ home palliative care  
      
 
Clinical processes (*)       
 
Presence of multidisciplinary 
specialized palliative care team  
      
 
Routine symptom screening in 
the outpatient oncology clinic  
      
 
Administration of systemic 
cancer therapy (e.g. chemo 
and targeted agents) possible 
in patients admitted to PC 
service 
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Follow pre-specified palliative 
care guidelines  
      
 
Early referral to palliative care        
 
Availability of clinical care 
pathways (automatic triggers) 
for palliative care referral  
      
 
Palliative care team routinely 
involved in multidisciplinary 
tumour conference for patient 
case discussions 
      
 
Communication, cooperation 
and coordination between PC 
and oncology service 
      
 
Routine discussion of 
prognosis, advance care 
planning with  goals of care 
      
 
Table 2. Components of integration from 7 randomized trials (colored cell indicates presence of 
component in trial) (*) adapted from Hui. 45,48 
 
Jordhøy and colleagues published at the turn of this century the results of a cluster-randomized trial 
of PC.49 We are not aware of any randomized trials on the effects of PC-programs prior to this 
publication. Some trials in the 1980s and early 1990s had tried to evaluate the effects of elements 
included in PC, such as end-of-life care, with negative results.54-56 These early trials were hampered 
by methodological shortcomings, such as lack of well-defined primary endpoints, control 
contamination, recruitment, and problematic attrition and adherence. In their large study of mixed 
cancer diagnoses, using well-validated instruments, Jordhøy et al circumvented many of these 
limitations.49 However, the main focus of this comprehensive trial was integration of community and 
hospital care for patients with advanced cancer. More patients in the intervention group died at 
home, compared to the control group, and these patients also spent less time in hospitals and more 
time at home and in nursing homes. No effect on symptom burden was demonstrated, which was 
reported in a separate article.4  
 
Several years later, Bakitas and colleagues designed Enable II, an RCT to test a telephone-based 
psycho-educational PC-intervention delivered concurrent with oncological treatment.57 The program 
was found to significantly improve both mood and quality of life in a sample of 322 patients with 
mixed cancer diagnoses. However, a traditional PC-model was not applied, as the study did not 
systematically include the intervention of a (multidisciplinary) PC-team. 
The publication by Temel and colleagues in 2010 is usually referred to as the landmark trial of 
integration of oncology and PC.3 They demonstrated that, among newly diagnosed lung cancer 
patients, early PC not only reduced depression and symptom burden and improved quality of life, but 
also produced a survival benefit. Finally, the intervention group was found to report improved 
prognostic awareness and to receive less intensive cancer treatment at the end of life. However, the 
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study was carried out in a highly specialized institution and some researchers have raised doubt as to 
its generalizability to other care settings.58   
In a cluster-randomized trial in 2014, Zimmermann and colleagues investigated early involvement of 
specialized PC in the treatment of patients with a wide range of advanced cancers.5 This study 
provided evidence of benefits on quality of life and symptom burden. Further, it was the first study 
to explore clinician-patient interactions: a difference with satisfaction with care was found in favour 
of the intervention group, but no differences were found on other measures of patient/staff 
interactions.  
In the meantime, the initial model constituting the Enable II had been somewhat expanded, and in 
2015, Bakitas and colleagues published the findings of the Enable III trial.50 By applying a fast-track 
design, this trial was the first to evaluate the optimal timing for introducing PC concurrently with 
standard oncological care.50 The only difference between the groups that was identified was longer 
one year survival for the “early” group. This was a tele-health intervention with an advanced practice 
nurse, rather than a PC team, initiating and in charge of all patient contact. This raises the question of 
whether the Enable III is a sophisticated psycho-educational model, rather than a specialized PC-
intervention. 
In 2016, Maltoni and colleagues carried out a multi-centre randomized trial to evaluate early PC 
efficacy for patients with advanced pancreatic cancer on both patient-reported outcomes and health 
care utilization 51. They reported benefits on quality of life, symptom burden and less time spent in 
institutions. As such, this was the first European trial to confirm the results of the important North 
American trials. 
The most recent study by Temel and colleagues has again drawn attention to early palliative care, 
examining the impact of an integrated PC model on newly diagnosed GI (non-colorectal) and lung 
cancer patients.52 In addition to improved quality of life and decreased depression, they showed that 
an integrated PC-model improved the patients’ ability to cope with their prognosis and enhanced 
their communication with clinicians about end of-life preferences. They showed that these positive 
effects vary by cancer types, but the two sub-samples were too small to substantiate these 
differences. 
The Danish PC-trial (DanPaCT) from 2017 investigated the effect of a PC-intervention among patients 
with a range of cancer diagnosis.53 Patients were included if they scored above a predefined 
threshold for self-reported symptoms or reduced functioning. The primary outcome was defined as 
the individual patient’s main problem, as defined by a screening process. The sample was large with 
little loss to follow-up. No differences on either primary or secondary outcomes were reported. 
Grønvold and colleagues proposed several possible explanations for the lacking beneficial effects, 
including the lack of structure in the PC-visits and short observation time.53 
The most recent study relevant in this context confirmed the findings of Temel et al from 2010.59 
However, the intervention was not palliative care per se but consisted of monthly sessions with 
palliative nurse and inferred more usage of consultations with a psychologist. The study therefore 
adds to the variability in the content of the palliative services (i.e., the intervention) and of how 
palliative care and oncology care are delivered, in studies of integration of oncology and palliative 
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care.60 Still the added element was definitely patient-centred which is of particular relevance in this 
context. 
The growing literature on integration of oncology and PC has been synthesized in reviews, 
statements and guidelines, some of which focus specifically on integration, while others more 
generically on “specialized PC”.16,58,61-63 However, several issues complicate attempts to evaluate and 
compile this body of literature. Most of the reviews underline that the heterogeneity in settings, 
target populations, and study outcomes make it difficult to directly compare trials. Particularly 
cumbersome is the diversity in intervention content and the PC specific component (Table 2). In 
addition, the variability in methodological quality across trials was highlighted in a recent meta-
analysis.64 When considering only trials with low risk of bias, the authors concluded that the evidence 
for the effectiveness of specialized PC-interventions for improving quality of life and symptom 
burden is relatively weak.64  However, a 2017-Cochrane review concludes that early palliative care 
may have more beneficial effects on quality of life and symptom intensity among patients with 
advanced cancer than among those given usual/standard cancer care alone. The effects are of clinical 
relevance at an advanced disease stage with limited prognosis, when further decline in quality of life 
is the rule.65  
 
The heterogeneity in study outcomes and methodological quality of studies of the effectiveness of PC 
are obvious limitations in research on integration. However although the evidence supporting 
integration of oncology and palliative care might seem somewhat meagre, the recommendation to 
integrate is strong. This is explained by the overall picture, showing that early palliative care 
interventions of different sorts have a positive impact on various patient outcomes. 
  
Systematic symptom assessment 
In order to facilitate better patient involvement in cancer care and improved patient-centred 
outcomes, the patients’ “voice” must be heard, in terms of symptoms, functions, quality of life, and 
preferences for information provision and shared-decision making. The recognition of the patients’ 
perspectives as valuable or even decisive when choosing how to care, where to care and when to 
care, represents a major shift in medicine during the last 10-20 years. Patients’ perspectives have 
now been recognized as valid outcomes in clinical medicine, as endorsed by the National Institute of 
Health consensus conference.66 While systematic symptom assessment is an established core clinical 
activity in PC, directly derived from the definition of PC as stated by the WHO, symptom assessment 
is still rarely performed systematically and even rarely used actively in the patient decision making 
processes in present oncological and palliative care practices.    
 
The U.S. Food and Drug Administration (FDA) proposed in 2006 to use the term Patient Reported 
Outcomes Measures (PROMs) for all measures that can best or only be assessed by asking the 
patients themselves. By that, the FDA also formally recognized the importance and clinical utility of 
PROMs by releasing a new Guidance for Industry on these issues.67 PROMs are therefore an umbrella 
term covering the patient’s perspective on physical and psychological well-being, and symptoms and 
treatment effects 68. The recognition of PROMs as independent outcomes in cancer 69,70 is 
consolidated by the CONSORT-PRO Extension Statement developed to improve the reporting of 
PROMs on patients’ evaluation of symptoms, functioning and quality of life 70. As the patient is the 
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primary source of information, PROMs supplement clinical observations and objective findings with 
individual patient information.   
 
Symptom assessment tools are, for these reasons, presently grouped under the umbrella PROMs, 
which also encompasses other outcomes assessed similarly, such as quality of life and functional 
status. Symptom assessment is pivotal for palliative/supportive care efforts throughout the whole 
cancer disease trajectory, and increasingly so as life-prolonging tumour-directed treatment ceases. 
Still, the infrequent assessment of symptoms is a major factor explaining inadequate symptom relief, 
with undue suffering among cancer patients approaching end of life. A key symptom in health care is 
pain, and, according to the international definition by IASP,71 pain can only be assessed reliably and 
validly by self-report, not by observations. Several other symptoms, only assessable by patients’ 
report, i.e. as PROMS, are important to consider in the care of cancer patients. These include 
psychological symptoms such as anxiety and depression symptoms, somatic symptoms, such as 
anorexia, dyspnea, fatigue and overall quality of life.  
Traditionally, PROMs were collected on paper-based questionnaires. New advances in health 
information technology have promoted the development of electronic tools for the distribution of 
PROMs. Such new tools allow an effective integration of patient related data from various sources. 
Further, electronic tools permit distant follow-up of patients who are not hospitalized and can also 
promote data sharing between care teams at different care levels. Studies in oncology have shown 
that electronic assessments and rapid presentation of results facilitate communication, is well 
perceived by patients and clinicians, and may also result in a more efficient and focused use of 
time.72,73 A recent qualitative study showed that perceived usefulness may be more important than 
functional aspects.74 Still, immediate display of easily interpretable results to the HCP is a crucial 
factor for successful implementation of electronic registration of PROMs into the clinics.75  
On this background we find it pertinent to point to a recent study on the effects of systematic 
symptom assessment by tablet computers in patients with advanced solid tumours. The study 
demonstrated positive outcomes of systematic symptom assessment in oncology practice. The 
authors demonstrated that health-related quality of life improved among more in the intervention 
group and worsened in fewer than among those receiving usual care.76 In a separate letter the 
authors also demonstrated improved survival among those having their symptoms assessed 
systematically.77 The results of this trial are a strong reminder of the importance and positive effects 
of systematic symptom assessment in cancer care in general.  
  
Standardized care pathways 
Integrated care models can be understood as organizational methods to solve the challenges of 
management of complex care processes, and particularly so in the growing elderly population. In 
integrated care, professionals with different competencies and from distinct organizations work 
together in complex and formalized structures. This model challenges the traditional “vertical 
organization” of health care, as outlined previously, structured in pillars or silos.  
Patients often experience gaps between services when they must shift levels of care or between 
types of specialization.78  A different matrix is hypothesized to better meet patients’ needs, which are 
complex and shifting over time, and allow the patient’s flow in such complex movements to be more 
predictable and transparent to them and to their care providers. In order for this to occur, 
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communication and collaboration among the health care providers must also be predictable, clearly 
understood, with the roles of team members clarified and agreed upon.  
Achieving integration among the different services and levels of health care is by no means 
straightforward since two different cultures, each with different foci, the tumour-centred and the 
patient-centred, need to “join forces” and thereby solve the patients’ needs during the development 
and implementation of the SCPs. Indeed, the greater the number of actors that are involved in a 
patient’s care, the more difficult the communication and coordination becomes. The development of 
SCPs is a method for meeting these challenges.  
Having its roots in the automobile and production industries, multiple SCPs have been developed and 
published throughout the recent years, covering a wide area of health services ranging from surgical 
procedures to complex disease trajectories.79 Implementation of SCPs ensures that care is organized 
with the right people at the right time in the right place. Therefore, SCPs can work as a systematic 
way of organizing integration in the organization to improve patient care and resource utilization. 
This however, requires that seamless patient flow in a customized organizational model is possible.  
A wide range of methodologies have been used in the development of SCPs, mainly without a 
common framework or international consensus on how to develop them in a standardized and 
evidence-based way.80,81 The generalizability of findings is also limited by the plethora of study 
designs, settings, and proposed pathways. This makes the relevance of individual studies difficult to 
evaluate and apply to clinical settings that are different from the one in which the specific SCP was 
developed and tested.82 In their review, Rotter et al. assessed the effects of SCPs on professional 
practice, patient outcomes and hospital costs.78 They included 19 RCTs comparing SCPs to standard 
practice based on more than 3000 abstracts identified in their search, covering a wide range of 
medical conditions and surgical procedures. Among the RCTs included, nine gave some form of 
description on how the SCP was developed and implemented. In those nine studies, the 
methodology applied to develop an SCP was mainly described in general terms (such as «a protocol 
was developed by a multi-professional team»). Ten of the studies conducted a follow-up on how 
health care providers complied with the SCP protocol, but none were performed in a similar way. 
Only one RCT included described how relevant clinical outcomes were monitored in the SCP-group by 
the use of computer-technology.83 A main feature of the RCTs included was that the SCP was applied 
in a facility-specific manner for a defined period of time, disregarding other elements involved in 
patient care and follow-up. Further, since the SCPs tested were mainly paper-based, the potential 
utility of a common and flexible electronic SCP was not evaluated. There is also a high variability with 
respect to how different SCPs are audited.82 
Conclusions 
There is now a strong consensus in contemporary cancer care on integration of oncology and PC. In 
fact, the newly released ASCO guidelines on the topic were for months the most searched article in 
the Journal of Clinical Oncology.16 The published RCTs on the subject point to health gains by 
integration, but what, when and how to integrate is still not established facts. Despite very clear 
recommendations of integration, this commission has not identified any health care system where 
the content and the constructs of integration are implemented. This commission will hypothesize 
that broad implementation plans are needed, adapted to national, regional and local organizations of 
19 
 
oncology- and palliative care as well as their cultures.  Local variations in terms of resources and 
practices also probably play a role. 
By acknowledging integration of oncology and PC as a complex process including different parts of 
the health care system, both horizontally and vertically, and also involving the patient, we propose 
SCPs as a means for future efforts to promote integration. For the same reasons, this paper will 
address integration in different panels. Each panel will address different aspects of integration, 
ranging from how to focus on the patient, to societal changes and new research areas.  
Introduction of panels 
Policy – challenges and frameworks 
Societal challenges  
Prognostication 
Patient-centredness – content methodology and clinical implications 
Models of palliative care integration 
The role of education: challenges and recommendations 
Research 
 
The commission is an international collaboration between 30 experts in oncology, PC, public health 
and psycho-oncology. In October 2016 a kick-off meeting was held in Milan where panel leaders 
were appointed, the structure of the commission was decided, and a plan for the work was agreed 
upon. During the two following years each panel expanded with experts within the relevant field, 
conducted topical literature searches, and an interactive writing process was conducted. Both 
administrative and academic organization were run from Norway, by Stein Kaasa, Jon Håvard Loge 
and Tonje Lundeby.    
Policy - challenges and frameworks  
 
Questions to be addressed 
What type of recommendations is given for integration at the national 
and international level on policy and public health at present?  
What are the current examples of different practices in organization of 
palliative care in different national policies in European countries? 
What kind of policies and approaches are needed for integration of 
oncology and palliative care? 
 
Introduction 
Demographic data demonstrate the undeniable fact of a rapidly increasing cancer incidence and 
prevalence and an ageing population with multiple chronic comorbidities. A recent publication, 
presenting various models for extrapolation in high-income countries found that 69-82% of those 
who die need palliative care.84 Consequently, an augmented need for palliative care at all health care 
levels is expected.  
Palliative care has been clearly identified as an integrated part of the cancer care pathways by 
professional international organisations, such as ASCO, ESMO, and EAPC, but also by the European 
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Union projects, such as the European Partnership Against Cancer.85-88 In sum these statements clearly 
indicate that palliative care should be part of national cancer politics and national cancer plans.89 
How this is accomplished in present national politics in Europe will be addressed in the present 
panel. Further, examples of different practices in organization of palliative care in some European 
countries are presented and recommendations for future politics are given. 
 
Organization, development of health policies and health systems 
General aspects on health policies of relevance for palliative care 
Health care systems in Europe are generally classified with respect to the role of the state, the role of 
the health care providers and the role of the payers. This triad is furthermore amended by the closer 
or looser links with the social care sector. Countries with a strong National Health Service tend to 
have closer links between health care and other sectors including the social care sector. Health care 
systems based upon social health insurance systems have a looser link with social care sector and 
consequently, more often have gaps in the comprehensiveness and continuity of care. Type of 
system is very relevant for palliative care since the health and social sectors often need to interact, 
flexibly and fast in order to meet the needs of the patient and the families. 
Modern health care systems in Europe build on the experiences of the 20th century when the State’s 
responsibility for delivery of health care became a social and political issue. This responsibility was 
primarily approached in three different ways; the Bismarck system, the Beveridge system and the 
Semashko system.90-92 The oldest of these systems, the social health insurance (also called the 
Bismarck system), originated in 1883.90 The coverage was gradually extended from industrial workers 
to other categories of the workforce. In 1940s, Lord Beveridge lead the work on the development of 
the National Health Service,91 which became a more comprehensive response to the demands for full 
coverage, irrespective of employment status. Between the two, in 1928, Soviet Union developed the 
Semashko system,92 which was dealing with the organizational aspects of health care rather than the 
financing or entitlements. 
The main differences between the Beveridge and Bismarck systems are the degree of state control 
over health care and how this control is exerted. In the Beveridge system, the Ministry of Health 
(MoH) is typically the budget holder and therefore commissioning services through a network of 
health care providers. In the Bismarck-type of systems, budgets are predominantly with health 
insurance companies, regulated by the MoH and operating in public interest. The role of the different 
partners has significantly more weight in Bismarck systems. Although the Beveridge systems seem to 
perform better in terms of care coordination as health and social care are integrated in a common, 
welfare stem, this may only be the case at the governmental level. In the Bismarck system, social 
care and other types of care (related to health but not necessarily inherent in health care) show a 
large degree of fragmentation as they are financed from different sources, often as cash benefits or 
entitlements.  
An OECD conference in 2011,93 pointed out that the sharp distinction between these two systems are 
mainly of historical interest, and that the "pure" Bismarckian era was more or less over, because 
policies emphasized universal coverage rather than a right of labour. Further, little if any scientific 
evidence exists on the superiority of one system over the other, specifically regarding coordination of 
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care, for which no universal definition presently exists.94 
On the global arena, the resolution by The World Health Assembly (WHA) (governing body of the 
WHO), 95 on “Strengthening palliative care as a component of comprehensive care throughout the 
life course” led to a presentation in the WHO on the progress of implementing the resolution. A civil 
society report requesting e.g. that palliative care should be covered under National Universal Health 
Coverage plans, and national strategies for palliative care implementation, including universal health 
professional training, followed the resolution. As much as the systemic approach to organising and 
financing palliative care is in societal interest and pertinent to population approaches, palliative care 
is in essence to meet individuals’ needs and therefore must be planned and designed to address 
those needs. In that sense, palliative care needs to be patient-centred as the primary driver for its 
planning, assessment of needs, organisation and delivery are patient needs, which should steer the 
development of adequate services. 
European over-riding policies and recommendations on palliative cancer care 
In Europe, the European Association for Palliative Care (EAPC) 96 has since its foundation been 
influential in the promotion, advocacy and development of palliative care in Europe, scientifically, 
clinically, socially and politically. In 2010, EAPC launched the Prague charter, stating that access to 
palliative care is a legal obligation and a human right, and thus beyond the established palliative care 
community.85 This was followed by the Lisbon challenge, identifying four major objectives related to 
access to essential medicines, development of health policies that address the needs of patients with 
life-limiting or terminal illnesses, adequate palliative care training also at undergraduate levels for 
health care providers and a structured implementation of palliative care.97 In 2013, the Budapest 
commitments presented frameworks for palliative care development as a joint initiative by EAPC, 
International Association for Hospice and Palliative Care (IAHPC) 98 and Worldwide Palliative Care 
Alliance (WPCA).98 Key elements were policy, availability, education, and quality.99,100  
In 2006, the European Palliative Care Research Collaborative (EPCRC) was the first palliative care 
research project that received funding from the European Commission (EU) under the 6th framework 
program for research. The promotion and financing of palliative care research within the EU 
framework represented a major step forward for European palliative care research. Since then, 
several high-quality projects on oncology and palliative care have received funding, e.g. the IMPACT 
project developing and testing quality indicators for dementia and cancer palliative care,101 
EUROIMPACT 102 a multi-professional research training program, the ATOME project on access to 
opioid medication in Europe, and the International Place of Death Study.103 
The objectives of the EU-funded PRISMA project (7th Framework Programme) conducted in nine 
countries were to co-ordinate research priorities, measurement and practice in end-of-life (EOL) care 
in Europe, resulting from an identified need for high quality palliative and EOL care and research. The 
research agenda and subsequent guidance should reflect the European cultural diversity and be 
informed by public and clinical priorities.104 Consensus was reached on the following priorities for 
EOL cancer care research in Europe: symptomatology, issues related to care of the dying, policy and 
organization of services, and moving from descriptive to interventional studies.105 
Two EU-funded projects also addressing European cancer politics have now come to an end; the 
EPAAC (European Partnership on Action Against Cancer) 106 and the European Guide for Quality 
National Cancer Control Programs (CANCON) (Cancer Control).89 The EPAAC report on National 
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Cancer Plans (NCPs) is based on a survey running from December 2011 to April 2012 in the EU 
Member States, Iceland and Norway.86 An NCP was defined as a public health programme designed 
to reduce the number of cancer cases and deaths, with strategies for key areas such as prevention, 
early detection, diagnosis, treatment, rehabilitation, palliation and research. The survey aimed to 
map the current level of integration in cancer care, including palliative care, and to develop 
indicators to monitor the actions of NCPs across countries prior to developing guidelines for 
preparing or evaluating cancer plans. 
The final EPAAC report points to significant variations in cancer control and care within and between 
EU Member States across the key areas of cancer care mentioned above. The report identified a lack 
of a comprehensive approach from policy documents addressing the rising needs of cancer patients, 
especially due to the increasing incidence and prevalence of cancer. Finland specifically prioritized 
palliative care in its national cancer plan, whereas e.g. Estonia, Greece and Portugal were lacking an 
appropriate infrastructure to carry out the NCPs adequately, especially with respect to home care 
and palliative care services. This means that the awareness of the need for palliative care is rising but 
the political willingness to dedicate adequate resources may be lacking.  
The identified inadequacies in policy mentioned above were included in the CANCON project in 
which the primary objective was to improve overall cancer control throughout the EU.89 The final 
guide covers the areas of quality-based cancer screening programmes, better integration of cancer 
care, community-based cancer care approaches and survivorship. 
The main target group for dissemination of CANCON deliverables were policy- and decision-makers 
at EU and national levels.107 Palliative care issues were promoted as part of an overall disease 
trajectory, also pertaining to the primary care level.108 
In summary, the findings and resolutions presented above represent major assets for the recognition 
of palliative care as an inherent part of oncology, thereby justifying integration of palliative care and 
oncology, politically and organizationally. Still, the findings also illustrate a huge divergence across 
Europe regarding the recognition of palliative care as an integrated part of cancer care at the political 
level. This contrasts tumour-directed treatments which to a much higher degree are based upon 
commonly agreed-upon guidelines and treatment algorithms which are accepted as premises for 
organisation and resource allocation at the political level. By learning from oncology care and its 
successes, the development of clinical relevant guidelines for organization and implementation of 
palliative care integrated into “main stream” oncology is rapidly needed and may be a success factor 
for high quality cancer care in the future. 
European examples of organisation of palliative care 
The report by the European Parliament on Palliative Care in the European Union found a pronounced 
heterogeneity in the way in which national health systems care for their dying, as well as the quality 
and access of the care provided, not only between countries, but also within them.109 Countries 
involved in the CANCON project have various policies on palliative care. These policies are often 
nationally developed and highly influenced by local opinions leaders in palliative care. However it is 
often referred to recommendations for palliative care published by international organizations, such 
as the WHO, the European Union or the Council of Europe.2  
Policies vary on horizontal and vertical integration of services and structures for palliative care. 
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Palliative care in Belgium, Bulgaria, Denmark, France, the Netherlands, Norway, Slovenia and Spain is 
provided in various providers’ organizations and across all levels of care (Table 3).  
        Providers 
 
 
Countries 
Hospitals Out-
patient 
clinic / 
Day-care 
centres 
Nursing 
homes (and 
homes for 
the elderly) 
Hospices Home care 
Belgium 110  + (PCU*) + +  + 
Bulgaria 111 + (including 
CCC** and 
PCU*) 
 + + + 
Denmark 112 + (including 
PCU*) 
 + + + 
France 113 + (including 
PCU*) 
+   + (including 
HAD - 
Hospital at 
home 
programme) 
Netherlands 114 + + + (including 
PCU*) 
+ + 
Norway 115,116 + + +  + 
Slovenia 117,118 + +  + + 
Spain 119,120 + +   + 
Table 3. Providers of palliative care in some European countries. (+) indicates availability of 
providers. *PCU - palliative care units, **CCC - comprehensive cancer centres.  
Hospitals are mostly either specialised cancer centres or general hospitals authorised to participate 
in some or all parts of oncological care. Out-patient clinics might be organized as part of departments 
or as special clinics for patients in need of palliative care. In many countries, nursing homes take over 
the care for those patients who for various reasons are not capable of living in their homes.   
In Belgium, France, the Netherlands, Norway and Spain different types of networks and 
multidisciplinary teams provide coordination and/or care at patients’ homes, out-patient clinics and 
in in-patient departments in hospitals and nursing homes. The level of institutionalisation seems to 
depend strongly on the specific organisation of health care. Thus, in some countries, such as Bulgaria 
and Belgium, there is strong dependence on institutional care, whereas in the Netherlands palliative 
care is often primarily delivered in home settings by GPs and specially trained nurses. 
The compositions of the teams that deliver palliative care vary across European countries. In the 
Netherlands, a large proportion of palliative care is put on the shoulders of GPs, who - among others 
- run in-patient palliative care units in nursing homes. On the other hand, in many countries palliative 
care remains a function carried out in hospital settings or in day hospital departments as part of 
hospitals. The latter policies are likely to become unsustainable for some reasons: 
1. Patient preferences, which indicate that patients prefer to be treated close to home when 
they need palliative care 
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2. Demographic changes with an increasing number of patients needing palliative care, which 
cannot realistically all be organized in hospital settings alone 
As pointed out already, palliative care in European countries is delivered in different settings, but it is 
difficult to identify a systematic pattern based upon the health care system in the country. This 
observation confirms the hypothesis that palliative care is underdeveloped in the health care system 
and still is too much dependent upon individual initiatives. From the project meetings and interviews 
on the CANCON, it was identified that in the Netherlands, a patient with a condition that requires 
only palliative and/or end-of-life care is discharged from in-patient oncological facility and his/her GP 
and district nurse are informed. Some of the patients who cannot stay and be cared for at home are 
placed in nursing homes with palliative care units, which are run by additionally trained GPs. In many 
countries, this would not meet the patient’s and/or family’s expectations. This is in contrast to the 
Bulgarian system, where cancer care is exclusively delivered by the so-called Comprehensive Cancer 
Centres, which exist in all regions. 
There is no ‘one-size-fits-all’ policy in developing different models in palliative and end-of-life care. 
Still, we observe a significant heterogeneity of services within and between countries. These partly 
reflect the organisation of health care services but very often, and even more importantly, different 
societal and political attitudes with respect to palliative care. It seems as if the “mature” systems 
place palliative care in a more central position than systems with a shorter history.  .  
When comparing the two analyses of EU and EEA countries’ cancer plans in 2011 and 2016, we 
observe a trend towards more frequently including palliative care as an element of the cancer plans. 
Still, in most cases palliative care is regarded as an add-on service, receiving less attention than the 
traditional diagnostic and therapeutic elements of cancer care. 
Barriers for integration of palliative care into a comprehensive planning seem to fall in two clusters. 
One is the fact mentioned above that health systems have different traditional and current attitudes 
with respect to palliative care. This impedes a more open debate on how to organize, place and staff 
palliative care as an element of a continuous cancer care. The other cluster seems to be a lack of 
dedication to secure financial resources and organisation capacity that make palliative care 
accessible to all patients who need it irrespective of their financial ability to pay for care.  
US policies on palliative cancer care 
Palliative care was introduced to United States (US) in 1963.121 It first started as a hospice movement 
focusing on the provision of home-based care to patients in the last weeks/days of life.  In 1973, the 
first hospice was established in Connecticut.  In 1978, the National Hospice Organization was 
founded. The Hospice Medicare Benefit Program was established by the Tax Equity and Fiscal 
Responsibility Act in 1982, defining the payment and policies for hospice care in the US.  By 2015, 
there were over 5800 hospice programs across the US. 
In contrast to hospice programs that are community-based, palliative care programs reside in acute 
care facilities. The first palliative care unit in US was established in Cleveland Clinic in 1988.  Over 
time, other cancer centres have developed models of excellence for integrated palliative cancer care, 
such as the MD Anderson Cancer Center.8 Since the 1990s, there has been a growing proportion of 
cancer centres with outpatient clinics to facilitate timely palliative care.122,123 In 2006, the American 
Board of Medical Specialities recognized hospice and palliative medicine as a medical specialty, 
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further promoting the growth of this discipline.   
Australian policies on palliative cancer care 
Palliative care has had growing recognition in Australia over the last three decades. The sub-specialty 
was first recognised within the College of Physicians in 1988 and training from that time was 
available. Specific national policies allowing reimbursement for clinical care were introduced in the 
year 2000. 
There has been a national strategy endorsed by all states and territories since the year 2000. This 
sought to address access and equity, models of care and the relationship between specialist services 
and the rest of the health sector including primary care. It has been revised twice since its initial 
genesis, and has had comprehensive evaluations for its first two iterations. This process enabled 
conversations that were far more broad-ranging both within the health sector and the community 
more broadly.124  
 
Approaches for integration of cancer and palliative care 
Coordination of care, regardless of definition, is demanding, involves a vast number of professionals 
and multiple transitions from one care level to another during a disease trajectory, which makes 
collaboration and integration of services paramount. One response to this complex process is the 
introduction of standardized care pathways, which have been adopted and adapted to cancer care in 
several countries (e.g. Belgium, France, the Netherlands, Norway and Spain).  
Another organisation principle at an even more micro-level is MDTs. This was proposed by one of the 
EPAAC’s working groups as a core element for an effective cancer care policy. A Policy Statement on 
multidisciplinary cancer care was formulated for implementation by all tumour-based MDTs, to 
provide patients with the care they need.125 The MDTs may be a place for integration of palliative 
care through an assessment and discussion about patient-centred needs at any stage of the disease 
trajectory. The policy statement is intended to serve as a reference for policymakers and healthcare 
providers to improve coordination. 
The ASCO recommendations 126 of early referrals to specialist palliative care teams and the other 
listed policy statements on integration of cancer care and palliative care, conflicts with the 
documented workforce shortage in palliative care.127 Thus, it is necessary to define the level of 
palliative care expertise at all health care levels, be it in tertiary specialist centres or home care (see 
Models and Education). Oncologists, palliative care specialists and other relevant health care 
professions should be part of all hospital SCPs, whereas primary care workers must possess basic 
palliative care skills to meet patients’ needs. However, an Australian survey reported that a 
significant number of GPs (31%) felt they had inadequate training and insufficient resources to 
provide home-based care to advanced cancer patients,128 which represents a challenge for the 
educational programs (see Education).  
The gap between hospital-based SCPs and the primary care level is well-known but challenging to fill 
due to different funding and administrative allocation. In practice this gap is often compensated for 
by informal networks. Bainbridge et al.129 explored the horizontal integration among professionals in 
informal palliative care networks. They found that the informal care networks often produce positive 
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results and that they were well accepted. What was commonly perceived as insufficient was inter-
professional communication and evaluative activities. Han and Rayson 130 explored the collaboration 
between oncological specialists and primary care doctors and their roles in the end-of-life care. They 
concluded that the following requires further elaboration, reflection and research (Box 1). 
Box 1. Required for collaboration between oncological specialists and primary care doctors 
• Defining when end-of-life care begins 
• Assessing the patterns and specific components of end-of-life care as provided by 
different types of oncologists and primary care physicians 
• Understanding patient and caregiver preferences for the relative involvement of 
oncology vs primary care medical specialists at the end of life 
• Designing appropriate and validated assessment tools to further understand how 
end-of-life care should best be managed 
• Evaluating the impact, in terms of quality of care and other endpoints, of different 
models of end-of-life care and understanding how these different models might be 
implemented in different health-care delivery systems 
• Ascertaining best practices and methodologies for integrating primary and oncology 
specialty care in patients dying of advanced cancer 
 
The disease trajectory of an advanced cancer patient consists of several sub pathways and many 
patients will be in an incurable state for many years, with large variations in the need of palliative 
care. During these years several transitions of life expectancy will occur all of which represents 
multiple challenges and complaints related to lack of communication across care levels, fragmented 
care, unclear responsibilities etc. Thus, we recommend that assessing patient preferences, and 
planning the transitions should be focused in early palliative care consultations, use of shared 
decision making (SDM) as part of the SCPs. This seems pertinent given the fact that 82% of the late 
palliative care was for end-of-life hospitalization 131 or that only 8% of lung cancer patients in the 
United States see a palliative care specialist, often to address end-of-life issues.132 As a rule, patient 
needs should be assessed as a continuous process since the diagnosis onwards and palliative care 
needs should not be an exception to this rule. 
The work in CANCON therefore did not focus on one particular aspect of cancer care in isolation but 
rather on (re)-defining the care pathways of cancer patients in order to map all services required to 
meet patient needs throughout the disease trajectory and beyond.  
A recent study from Canada showed that citizens’ expectations are high with respect of integrating 
palliative care standards into the Canada Health Act and thus into the basic processes of care. 
Importantly, the survey showed that there are strong concerns around the financial accessibility of 
such care but this is regarded as a condition for successful implementation of such a programme. 
Furthermore, the majority of Canadians agree that surveys should be conducted among family 
members (84%), caregivers (82%) and patients (79%) regarding the care received, and 72% of 
Canadians agree that annual surveys should be conducted to measure and track Canadians’ 
awareness levels of palliative care.133 For the political level, these findings also support the obligation 
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for politicians and health authorities at the uppermost level to put palliative on the agenda as an 
integrated part of the health care system and not as a »hidden« service for the dying patients.  
 
Costs and cost-effectiveness of palliative care 
Major concerns in oncology today are the rapidly increasing complexity of treatment and costs of 
care, which threaten the sustainability of the present services.23,134 As pointed out by Isenberg et 
al,126 increased delivery of palliative care as recommended by the updated ASCO guidelines,16 must 
be accompanied by changes in the health care financing.  
An editorial from ASCO-pubs 135 concludes that determining cost-effective methods to care for 
patients with advanced cancer should be given high priority, based on the rapidly increasing demand 
for palliative care in an ageing population. However, there is a need to establish valid methods for 
cost estimates that consider both cost-effectiveness and cost-benefit analyses (outcomes translated 
to monetary units/dollars). Although studies have shown that palliative care interventions improve 
both patient-reported outcomes 3,5,57,136-139 and cut costs for second party payers and hospitals,140-142 
most studies are relatively small-sized, and conducted from the health services perspective, not the 
societal perspective.135 Thus, they often do not include patient, caregiver and societal costs in the 
calculations.  
Intensive end-of-life care is expensive, but studies fully illuminating the costs associated with 
integration or not integration of oncology and palliative care are lacking. However, there are findings 
that indicate that integration is more cost-effective than “treatment as usual”. Early palliative 
referrals improves end-of-life care in terms of earlier hospice referrals,143,144 lower readmission 
rates,145 shorter length of stay;146 all contributing to significant reductions in cost. According to Cassel 
et al. early palliative care is an excellent example of how to improve or maintain quality of health 
care delivery for patients and caregivers at a lower cost.147 Further, studies demonstrate that the vast 
majority of costs in late-stage cancer results from advanced therapy with marginal effects, ICU and 
emergency admissions, and protracted hospital stays, and not to direct personnel costs.148 Estimates 
from the United States and UK indicate 25% of health-care expenditure is related to patients in their 
last year of life, while end-of-life care takes up 20% of hospital beds.149,150 In sum these figures and 
findings indicate expenditures that can be reduced and that integration can serve this function. 
 The present evidence of better care at lower costs associated with early access to palliative care, 
makes it necessary to evaluate the policy on subsidies, revenues, payment for patients, 
reimbursement practice and organization of services to promote integration of oncology and 
palliative care. Co-payment for patients may be one option but may be unacceptable from a societal 
point of view, as underserved populations may refrain from using the service. Compulsory palliative 
care consultations at a certain stage of advanced disease alongside tumour-directed treatment; the 
time-based model, as opposed to a patient-centric, need-based model as defined by Hui et al,151 adds 
cost to the already substantial costs in this group of patients. This is primarily in relation to personnel 
costs at the tertiary level; e.g. consultations with both oncologists and palliative care specialists, and 
more time allocated to the consultations. Another option is to make reimbursement conditional on 
palliative care involvement at a certain stage in the disease trajectory.126  
However, it must be demonstrated in larger and sufficiently powered cost studies that these 
additional costs offset savings in other domains of oncology and end-of-life care. Greer et al 152 
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analysed cost-data from the Temel study 3 and found that patients in the early palliative care group 
had higher hospice costs in the 30 days of life, but less costs related to chemotherapy than patients 
in the control group. Some studies have examined the cost-effectiveness of specialized palliative 
care, and report diverging results. This is mainly related to differences in financial incentives and 
reimbursement issues, whether patients are seen on an out-patient basis exclusively, if the unit is 
located together with other highly specialized teams providing palliative care services and referral 
and follow-up practice. The latter is an important and political issue in the years to come, as an 
increasing amount of palliative care must be delivered by the primary health care services. As 
pointed out previously, this has implications for the education of personnel at the primary health 
care (see also Education). Systematic palliative care interventions initiated on the specialist levels, 
but also followed by multidisciplinary palliative care teams, have improved patients reported 
outcomes and proven cost-effective.153-155 The recent book by Gomez 156 concludes that home and 
community-based services are emphasized over building in-patient palliative services.  
Researchers have since recently started researching a quantifiable or at least a qualitatively 
comparable contribution of the different models in palliative care. An example of such a study is by 
Siouta et al. 157 from 2016. The authors performed a qualitative systematic literature review of 
empirically tested models in cancer and in other chronic diseases. They included 14 studies, seven 
models for chronic disease, four for integrated care in oncology, two for both cancer and chronic 
disease and two for end-of-life pathways. The benefits of the involvement of a palliative care (PC) 
multidisciplinary team showed: better symptom control, less caregiver burden, improvement in 
continuity and coordination of care, fewer admissions, cost effectiveness and patients dying in their 
preferred place. The authors proposed a generic framework for integrated PC in cancer and chronic 
disease. This framework fosters integration of PC in the disease trajectory concurrently with disease-
oriented treatment and identified the importance of employing a PC-trained multidisciplinary team 
with a threefold focus: treatment, consulting and training.  
Limited resources, pressures on cost containment, cost-effectiveness and overall cost control are 
present in cancer care as well. Consequently, it is necessary to look at the best performing types of 
care in the whole cancer care trajectory. A study that looked into the evidence on the cost and the 
cost-effectiveness of PC is a literature review by Smith et al.158 They carried out a comprehensive 
review of available international evidence on the cost and cost-effectiveness of palliative care in any 
setting (hospital-based, home care or hospice-based). Quality of retrieved papers was assessed 
against 31 indicators, which they had developed for the purpose of this review. The authors 
identified 46 papers, meeting the inclusion criteria. They found that palliative care is very often less 
costly relative to the comparator groups and, in most cases, the difference was statistically 
significant.  
 
Final reflections 
Barriers Solutions 
Palliative care not being perceived as a needed 
integral part of the cancer care continuum 
Setting up SCPs that cover all cancer care 
services (envisaged also by National Cancer 
Control Programs (NCCPs)) 
Deficient planning of palliative care at the Adherence to the European Guide for Quality of 
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national and regional levels  National Cancer Control Programs 
Insufficient organizational and infrastructural 
capacity of palliative care 
The need to invest in palliative care 
infrastructure – partly related to the workforce  
Limiting palliative care to respite care and 
supportive care and often leaving it to the 
family 
Building on infrastructure for palliative care also 
in outpatient and home settings in order to 
address the needs of cancer patients 
Inadequate assessment of costs and benefits of 
palliative care 
Transparency of direct and indirect costs – and 
also performing HTA for palliative care 
procedures 
 
Standards, guidelines and guidance are meant to standardize procedures and SCPs can be used as an 
implementation tool in order to equalize quality and enable comparative analysis in health care. As 
much as SCPs are helpful, they might also cause tensions and frustrations at the political level related 
to struggles to secure an adequate level of human and financial resources. However if high quality 
cancer care is the goal in a country these tensions and frustrations need to be solved and directions 
need to be given by the governments based upon a sustainable health policy independent upon who 
is in position. This approach is strongly supported by all international statements that access to 
palliative care is a human right. 
Given the challenges facing the patients, the care providers and the system as a whole, the bulk of 
financing should be carried by public funds or at least, the share of public financing of palliative care 
should not be different from the financing of other health care services in a given system.  
In brief, this panel gives reasons to formulate political arguments that can be raised in order to 
enhance palliative care at the political level: 
1. The needs for palliative care are rising and many present needs are unmet 
2. Palliative care is part of the cancer care continuum 
3. Palliative care is patient-centred and should be delivered systematically  
4. SCPs can secure availability of palliative care but presupposes relevant professionalism at all 
levels and willingness and resources for the implementation 
5. The population is fragile, does not demand expensive treatments but lacks public 
spokesmen.  
6. The industry or other strong stakeholders with easy access to the political decision-making 
processes are focused on other treatment alternatives than palliative care  
7. The fragility of patients and their relatives in need of palliative care incapacitates them in the 
public debate on resource allocation. Public funding is therefore necessary 
Still, the main question is – how to ensure that policies on palliative care are effectively 
implemented? There needs to be a concerted action of cancer care professionals and patients 
through advocacy efforts making a case especially with respect to the currently unmet needs, which 
represent a significant burden for the individual, family, health care and, ultimately, on the society as 
a whole. 
 
30 
 
Recommendations  
• Convergent policies in all continents on integration of oncology and palliative care need to be 
developed 
o How to do: The WHO and professional organizations (EAPC, WPCA, IAHPC, IONS, ESTRO 
and ASCO among others) should establish guides to policy makers based upon present best 
knowledge 
o Timeline: Now 
• Organizational structures of early integration of oncology and palliative care in hospitals need to be 
developed on a global level 
o How to do: Professional organizations EAPC, WPCA, IAHPC, IONS, ESTRO and ASCO among 
others shall establish consensus on structure and implementation plans.  
o Timeline: Now    
• Organizational structure of early integration and collaboration between hospitals and community 
care in oncology/palliative care at global level need to be developed 
o How to do: Professional organizations ESMO, ESTRO, EONS, ASCO, EAPC, WPCA and IAHPC 
among others shall establish consensus on structure and implementation plans. 
o Timeline: Now 
 
Societal challenges  
 
Questions to be addressed 
What are the societal challenges that may hamper 
integration of oncology and palliative care? 
What are the societal challenges at following levels 
• Professional? 
• Patient? 
• Public? 
• Media? 
 
Introduction  
Despite the growing evidence of the benefit for patients and those close to them, and to health care 
systems, many challenges remain in the better integration of palliative care and oncology. Some of 
the challenges can be considered as societal, i.e. problems in the interactions and structures within 
society and the normal patterns of practice. Any people from a community can be considered to 
make up a society, and anything connected to that group can be described as societal.  In this section 
we consider the challenges at ‘societal’ levels, professional, patient, public, the media, medical 
education, which may hamper the better integration of palliative care and oncology.    
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Professional: oncologists, palliative care, surgeons, general medicine, primary care 
Although much practice by oncologists involves people with advanced cancer, the liaison and 
integration with palliative care varies considerably. This is despite recommendations by the European 
Society of Medical Oncology (ESMO) and the Organisation of European Cancer Institutes (OECI) that 
to be designated, a cancer centre must have integrated oncology and palliative care.159,160 
A survey of 895 members of ESMO regarding their involvement in and attitudes toward the palliative 
care of patients with advanced cancer found that although the importance of palliative care was 
recognized, actual participation levels commonly are suboptimal.161 43% of respondents reported 
that they directly administered end-of-life care often, and 74% reported that they derived 
satisfaction from their involvement in end-of-life care. Only around a third of respondents 
collaborated often with a PC care specialist (35%), a palliative home care service (38%), an in-patient 
hospice (26%), or a psychologist (33%). Yet respondents were involved more commonly in treating 
physical symptoms, such as pain (93%), fatigue (84%), and nausea/emesis (84%), than in managing 
psychological symptoms and end-of-life care issues, such as depression/anxiety (65%), existential 
distress (29%), or delirium (12%). Most respondents, 88%, endorsed the belief that medical 
oncologists should coordinate the end-of-life care for their cancer patients, but almost half, 42%, felt 
that they were trained inadequately for this task. Although most of the responding medical 
oncologists expressed positive views regarding their involvement in the PC of patients with advanced 
cancer and dying patients, 15% of respondents had pervasively negative views.161 Similar challenges 
have been more recently reported among oncologists in other countries, including China, Thailand, 
the USA and many others.162-172 
Oncologists' end of life care attitudes can influence their timely palliative care referral and end of life 
cancer treatment decisions. There is evidence that oncologists often refer patients late in the course 
of illness, 166,167,173-176 despite believing, as found in recent surveys, that integration of early specialist 
palliative care in cancer improves symptom control, end-of-life care, health-related communication, 
and continuity of care.173,176 A survey of 182 oncologists in the USA from a major cancer centre, found 
that comfort with the concepts of end of life care was associated with higher rates of specialist 
palliative care referral and self-reported primary palliative care delivery.177 A recent systematic 
review found that the concepts of integration were varyingly defined.45 
However in many instances decisions against intensive treatments are often made only when death 
is imminent. A study interviewing Belgium oncologists identified seven categories of barriers which 
discouraged them from discussing palliative care: oncologist-related barriers, patient-related 
barriers, family-related barriers, barriers relating to the physician referring the patient to the medical 
oncologist, barriers relating to disease or treatment, institutional/organizational barriers and 
societal/policy barriers.178 Communication, approaches to the management of uncertainty in illness, 
as well as broader cultures and the focus of research in oncology may have a role here. Sympathetic 
yet honest communication about the irreversible nature of advanced cancer is important to improve 
patients' prognostic understanding and, thereby, to allow for adjustment of treatment intensity to 
realistic goals, to overcome some of patient- and family-related barriers.  A qualitative in-depth 
interview study in Germany found that oncologists reported patients with unrealistic expectations to 
be a challenge for end of life communication, especially in comprehensive cancer centres. 
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Oncologists responded to this challenge quite differently, by either proactively trying to facilitate 
advance care planning or passively leaving the initiative to address preferences for care at the end of 
life to the patient. A major impediment to the proactive approach was uncertainty about the right 
timing for end of life discussions and about the balancing the medical evidence against the 
physician's own subjective emotional involvement and the patient's wishes. These findings may help 
to explain why end of life communication is often started rather late with cancer patients.179  
Uncertainty in prognosis and likely treatment outcomes is inevitable in complex illnesses with 
evolving treatments, like cancer in modern times. With increasingly intensive treatments and 
population ageing, more people face more complex treatment, care decisions and uncertainty.180   
Yet uncertainty can become a major barrier to effective care, because clinicians delay raising issues 
or making decisions in an attempt to reassure in the face of uncertainty.181 A study of decision-
making processes during critical care found that decisions were made serially over the whole 
trajectory, usually several days or weeks. There were four trajectories with distinct patterns: curative 
care from admission; oscillating curative and comfort care; shift to comfort care; comfort care from 
admission. Conflict occurred most commonly in the trajectories with oscillating curative and comfort 
care, and conflict also occurred inside clinical teams. This complex web of discussions means that 
there is a need for early communication, especially around the values and preferred care outcomes 
from care of patients and their families. The study also suggested that there should be clearer 
discussions of a 'trial of treatment', rather than waiting until the 'end of life'.180   
A further issue impeding integration may be the research focus of oncology, versus that in palliative 
care. Only a tiny proportion of research spending in cancer is allocated to palliative or end of life 
care, in contrast to that spent on perusing oncological treatment. Data on research funding by 
National Cancer Research Institute partners in the UK, based on studies included in the national 
Cancer Research Data Base for 2015/6 found that, of the £579·79 million awarded for research into 
cancer, just 0·33% (£1 925 909) was allocated to palliative and end-of-life care research. In contrast, 
£207·28 million (36%) was allocated to research into treatment, and £163·11 million (28%) to 
research into the biology of cancer.182 This small amount is often spent across multiple projects, 
meaning that there is insufficient support for evaluative trials, or new palliative treatments.  
These figures are similar to those reported for 2010, when only 0·24% of cancer research spending 
went to palliative or end of life care, although the overall funding for research in cancer increased 
slightly (from £508 million in 2010).183 Similarly, in the USA, of the National Cancer Institute's total 
appropriation for 2010 of US$5 billion, only 1% was awarded to palliative care research.183 Data in 
Australia mirror these findings although, on a positive note, the Australasian Clinical Oncology 
Research Development program (ACORD) specifically seeks to attract young clinical palliative care 
researchers to develop their clinical trial protocols alongside young oncology trainees. This focus on 
research on treatment may further drive oncologists towards tumour-directed treatment, and in 
valuing cure, over improving quality of life and palliative care. Opportunities for oncologists to 
develop in teaching hospitals, with a combined career in research and practice, are therefore almost 
exclusively in the area of cancer biology or cancer treatments, and almost never in palliative care 
where the funding for individual projects appears to be insufficient to support a substantial 
fellowship for a PhD or MD. Investment in research into palliative and end-of-life care is urgently 
required to inform the transition from tumour-directed to palliative care, to improve symptom 
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control, to deliver cost effective care, and to ensure that choices at the end of life are offered and 
met, and in turn this will also help to further the integration of palliative and oncological care.  
There are some proposals that palliative care would be more acceptable to oncologists if it were 
renamed supportive care. Surveys among haemato-oncologists and other medical oncologists have 
reported that these would be more likely to refer to services called supportive, rather than palliative, 
care.184,185 However, others have argued that any proposed renaming clouds the more nuanced 
issues, such as attitudes, resources, and the issues raised above, that together hamper referrals.186 
Supportive care is something that all oncologists should do, and the term is much linked to cancer. 
Others have proposed renaming the palliative care as ‘enhanced supportive care’. The important 
questions, however, should be around what patients and families feel are appropriate services, not 
what professionals feel they would like to refer to.  
A further consideration is the attitudes of palliative care to oncology. Palliative care services are 
overstretched, with staff shortages, and insufficient resources to treat all patients. They are often 
supported by the charitable sector, and in many countries, are not included in mainstream health 
care funding. These can lead to services being limiting. The US hospice benefit, which reimbursed the 
provision of hospice care under Medicare, specifically included that patients should have a less than 
six month prognosis, and that patients in hospice should agree to withdraw from all treatment of 
potential curative intent.187  While this definition does not exist in most countries outside the USA, 
the earlier focus on palliative care on the end of life, can limit referrals. Palliative and oncology 
clinicians have to recognize the change in the needs of cancer patients, for earlier, more integrated 
care as a consequent of changes in treatment and disease trajectory. This was clearly expressed at 
the 67th World Health Assembly, when the World Health Organisation (WHO) passed the first ever 
resolution on palliative care, recommending national health systems to provide palliative care in 
conjunction with potentially curative treatment, and not just as an “optional extra”. 188 The 
resolution urged member states to develop and implement policies which support the integration of 
cost-effective and equitable palliative care services in the continuum of care, across all levels.189 A 
modern approach to palliative care can also include an integration with oncology and relevant 
community and hospital services.190 
Patients, families, the public and the role of the media 
Public priorities when faced with a terminal illness, such as an advanced cancer, would suggest that 
better integration of oncology and palliative care is important for care and would be preferred. A 
population based survey of people's priorities for treatment, care and information across seven 
European countries asked respondents their priorities if 'faced with a serious illness, like cancer, with 
limited time to live'. Of the 9344 individuals interviewed most people would choose to 'improve 
quality of life for the time they had left', ranging from 57% (Italy) to 81% (Spain). Only 2% (England) 
to 6% (Flanders) said extending life was most important. An important minority, from 15% (Spain) to 
40% (Italy) said quality and extension were equally important. Prioritizing quality of life was 
associated with higher education in all countries. The survey included people with different health 
statuses, but these did not affect priorities.191 Further components of this survey in the open-ended 
questions identified a public perception of needs for improved quality of end-of-life and palliative 
care and access to this care for patients and families, and a recognition of the importance of death 
and dying, the cessation of treatments to extend life unnecessarily and the need for holistic care to 
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include comfort and support.192 Most people in fact would want to know if they had a terminal 
illness, and factors associated with this wish have been identified.193  
However, public awareness of palliative care and related services among oncology patients is often 
limited. One survey in London found that only 19% patients recognized the term 'palliative care', 
although 68% understood the role of the hospice, and 67% understood the role of Macmillan nurses 
(specialist nurses providing an advisory palliative care service in the UK). Age-adjusted multiple 
logistic regression found that the most socially and materially affluent patients had eight times 
higher odds of recognizing the term 'palliative care' compared with those who were the poorest.194 A 
survey in Japan found similar challenges in awareness of palliative care.195 More recently, an internet 
search query in the USA, has found that public awareness of the term palliative care is growing 
month by month.196   
Uncertainty and communication for cancer patients is also likely to have a role during treatment. In a 
qualitative study in intensive care, uncertainty was a pervading feature over the trajectory of care. 
Families were most often involved in decision-making regarding care outcomes and seemed to find it 
easier when patients switched definitively from curative to comfort care. Some families considered 
decision-making a negative concept and preferred uncertainty. We found eight categories of 
decision-making; three related to the care outcomes (aim, place, response to needs) and five to the 
care processes (resuscitation, decision support, medications/fluids, monitoring/interventions, other 
specialty involvement). The study suggests a need to support early communication, especially around 
values and preferred care outcomes, from which other decisions follow, including Do Not Attempt to 
Resuscitate.180 Simple tools to understand patients and families priorities and aid communication 
have been developed, and undergone preliminary testing and many be promising to improve this 
situation.197   
Stigmas about cancer are common and present significant challenges to treatment and care,198-200 
including to palliative care and its integration with oncology. Stigma can have a silencing effect. The 
social, emotional, and financial devastation that all too often accompanies a diagnosis of cancer is, in 
large part, due to the cultural myths and taboos surrounding the disease.198-200 There are several 
reasons that cancer and within this palliative care may be stigmatized.201,202  Symptoms or body parts 
affected by cancer can cultivate stigma. Beliefs about treatment can also fuel stigma.203 Pain, other 
symptoms or the cancer itself can be seen as a ‘test’ or punishment, affecting the willingness to use 
therapies or to be referred to palliative care.204  Breathlessness and cough are common symptoms 
but are associated with social withdrawal, non-response of services, and invisibility.205,206 Depression 
is a stigmatising symptom in many countries.207 Negative illness perceptions can increase 
depression.208 Some cancers or their treatment cause changes in appearance, which can also be 
distressing and result in stigma.209 Fear of dying and the stigma associated with terminal events may 
also hamper access to palliative care.210 While it is common that many people report how they grow 
despite cancer, treatment and through stigma, appropriate support systems and resilience are 
needed.209  
News reports about cancer frequently discuss intensive treatment and survival but rarely discuss 
treatment failure, adverse events, end-of-life care, or death.211,212 These portrayals of cancer care in 
the news media may give patients an inappropriately optimistic view of cancer treatment, outcomes, 
and prognosis, Language in the media likening cancer to a battle or war and frequently conflating 
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cancer and fear 213 may lead people whose disease is continuing despite treatment, may to feel a 
failure (losing the war) and reluctant to seek or discuss any alternative. All of these factors may in 
turn result in difficulty in communication, and a stigma against accepting anything not directed 
towards cure. 
Public communication is probably critical to decreasing cancer-related and palliative care-related 
stigmas, raising awareness, disseminating education and importantly also in direct patient and family 
care.214,215 Wide ranging public education, links into schools, use of modern forms of media, such as 
social media, twitter and web based for a,216 and well as more traditional health education are 
needed.217 Cultural differences in beliefs in and response to cancer, palliative care, information 
needs, and end of life care need to be respected and accounted for in this.218  
Despite the fact that cancer is a major and increasing health problem widespread in older people, 
paradoxically, older people with cancer are often undertreated when compared to younger patients 
and excluded from clinical trials.219 The inequalities do not only pervade new therapies, but also 
reconstruction surgery, nursing, primary and palliative care. For example, immunotherapy, breast 
reconstruction, and chemotherapy rates are lower for older patients than for younger patients. In 
one study, nurses' vision of aging influenced lower support for breast reconstruction: nurses with a 
negative view of age discriminated more between a 75-year-old patient and a 35-year-old patient 
(less encouragement for the older patient).220 Older patients have lower access to in-patient hospice 
and palliative care services, although this appears to be improving slightly.221 Older people are more 
likely to die in hospital and less likely to die at home, often their preferred place of death, when 
compared with younger patients.222 A large population based studies found that older lung cancer 
patients (age > 60 years) had significantly lower chances of receiving opioids than their younger (age 
< 50 years) peers (prevalence ratio [PR] range, 0·14 to 0·78), even adjusted for comorbidity.223  
Barriers and challenges related to death and dying  
Despite the fact that everyone eventually dies, death and dying are often taboo subjects, with 
considerable stigma for people who are dying and those close to them. This is a challenge at a 
professional level, patient and caregiver level and a societal level. A study of 233 college students 
used a range of semantic differential adjectives to explore their attitudes toward young and old 
people who were healthy, ill, or terminally ill.  The results identified negative attitudes toward dying 
people in both young and older age groups, their role was conceptualised as disvalued, indicating a 
stigma towards those who are terminally ill.224 Saunders wrote on the need to change these stigma’s 
and focus on living and dying well.225 Writing in the Lancet in 1984, Wilkes, drew attention to the 
challenges that these stigmas bring.226 
Yet stigma’s and taboos still pervade society, leading some countries, such as the UK, to launch a 
‘Dying Matters’ initiative in response.227 As death has become less common in our daily lives, it 
possibly has become harder to consider our own mortality or that of those close to us. Some have 
said that there is neglect within oncology with regards to those patients who are dying. Indeed, this 
may be is a particular problem in oncology and sometimes in cancer nursing, where the focus is on 
more treatment, on cure, on “fighting the illness”, rather than on living and dying well.228 The 
emphasis on cure may be helpful when encouraging patients to come forward for screening or early 
treatment.229,230 But there are many examples of patients receiving chemotherapy in the last 30 days 
of life, in many instances when it is not through to be effective.231  Death often remains a taboo 
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subject in the clinical encounter.232 A lack of openness about death has negative consequences for 
the quality of care provided to the dying and bereaved, with missed opportunities for symptom 
management and psychosocial support.225 A lack of transparency can be very hurtful for patients.233  
A lack of openness often pervades undergraduate and postgraduate education, including in 
oncology, where many doctors and others feel unprepared to discuss death and dying, deteriorating 
illness or even to be able to break the news of a death to family members and friends.234,235 Failing to 
have those conversations can deny patients and families from making important decisions.233 These 
are difficult conversations and not everyone will want to talk about the end of their life, or will want 
to talk but at different times and stages. This often takes time and it is often difficult to know how to 
open the conversation. But there is clear evidence that through training and continued support it can 
be done even in the context of offering further treatment.236-238 Tools have been developed to help 
clinicians to ask about and understand patient priorities and these could be a starting point for 
dialogue.197   
Implications 
Cancer is one of the most common health issues in society. Worldwide, there were 14·1 million new 
cases and 8·2 million deaths from cancer in 2012. The most commonly diagnosed cancers were lung 
(1·82 million), breast (1·67 million), and colorectal (1·36 million); the most common causes of cancer 
death were lung cancer (1·6 million deaths), liver cancer (745 000 deaths), and stomach cancer (723 
000 deaths).239 An estimated 169·3 million years of healthy life are lost because of cancer. Colorectal, 
lung, breast, and prostate cancers are the main contributors to total years of life lost in most world 
regions and caused 18-50% of the total cancer burden.240 Cancer will increase in all parts of the 
globe. Currently around 44% of cancer cases and 53% of cancer deaths occur in countries at a low or 
medium level of the Human Development Index (HDI).239 Projections to 2030 suggest that if recent 
trends in major cancers are seen globally in the future, the burden of cancer will increase to 23·6 
million new cases each year by 2030. This affects all countries, with an increase of 68% compared 
with 2012 overall, and 66% in low and medium HDI countries and 56% in high and very high HDI 
countries.241  
Although early resolutions regarding palliative care mainly focused on the more advanced stages of 
disease and the end of life,30 the WHO mandate on palliative care has evolved and currently extends 
to include patients in the early phase of all diseases. This evolution of the WHO mandate reflects the 
evolution of the concept of palliative care as a whole,242 which consists of: extending care beyond 
cancer and into more general chronic conditions; promoting early palliative interventions in the 
clinical evolution of the disease; applying palliative care measures in all settings of the healthcare 
system; and identifying complexity versus prognosis as criteria for specialist interventions. In other 
words, the focus of palliative care has shifted from the concept of terminal illness to ‘advanced 
chronic illness with a limited prognosis’; and from a specialty approach, to a national health care 
system approach.30,243 
 
Recommendations   
• Public actions focusing on death as a part of being human 
o How to do: Develop international and national consensus programs (campaigns) on 
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being mortal. Engage in the international and national parliaments, patient 
organizations and professional organizations campaigns. 
o Timeline: Now 
• Destigmatize palliative care – it is more than end of life care – it is patient-centred care 
o How to do: Develop international and national consensus programs and engage 
parliaments, patient organizations and professional organizations in the campaigns.   
o Timeline: Now 
• Economical resources to palliative care and palliative care research must reflect the needs and 
the volume of the patients in oncology practice  
o How to do: Establish an international expert panel in developing multinational 
estimations of needs reflecting the complexity of the patient population. 
o Timeline:  1-2 years 
• Raising public awareness of the goals of tumor directed treatment (life prolonging, symptomatic 
and end of life care)  
o How to do: International and national discussions on information policies and 
communication in the public domains aiming to raise awareness of the marketing by the 
medical industry and health care providers 
o Timeline: Now 
 
Prognostication  
 
Questions to be addressed 
Why is prognostication important in advanced cancer? 
What objective prognostic tools are available? 
How should prognostic information be communicated? 
 
The importance of prognosticating in oncology and palliative care 
Prognostication is the skill of predicting future outcomes. Most commonly the outcome that is being 
predicted is the length of survival of the patient, although one can also prognosticate about other 
clinically relevant outcomes such as symptomatic response to palliative treatment, discharge from 
hospital or recovery of function. Once patients have received an accurate diagnosis of cancer, 
frequently the next question is about the likely prognosis.244  
Oncologists are thus routinely required to prognosticate. At diagnosis prognostication primarily relies 
on an accurate staging of the extent of disease. All cancer staging systems are based upon the 
premise that the severity and extent of disease is associated with different outcomes (particularly 
the risk of death).  At diagnosis the stage of disease frequently dictates the preferred course of 
treatment. Detailed prognostic information about survival associated with each stage of disease can 
help patients and clinicians to make informed decisions about the best course of treatment.  
 
In palliative care practice the issue of prognosis is also very important, although in these 
circumstances the question is more specifically about how long patients are expected to live, rather 
than on predicting their response to further treatment.245 In routine practice, issues of prognosis are 
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pertinent to decisions and discussions about place of care, advance care planning and determining 
ceilings of care.246-248   
At the interface between oncology and palliative care prognostic questions are most relevant to the 
decision about whether or not to proceed with palliative chemotherapy. Deaths occurring within 30-
days of chemotherapy are increasingly recognised as an indicator of the quality of oncological care.249 
When used appropriately palliative chemotherapy can improve quality of life and survival in patients 
with advanced cancer.250 However, when given to patients who are near the end of life, even to 
those with a relatively good performance status, chemotherapy seldom has benefits and may 
adversely affect the “quality of death”.251 Early involvement of palliative care services can reduce the 
frequency of chemotherapy administration close to death, without any adverse consequences for 
survival.3,252   
In 2008 the UK National Confidential Enquiry into Patient Outcome and Death (NCEPOD) conducted a 
review of deaths occurring within 30 days of systemic anti-cancer chemotherapy treatment (SACT).253  
External review of the notes suggested that the decision to give palliative SACT was “inappropriate” 
in 19% of cases (due to factors such as poor performance status, lack of realistic prospect of benefit, 
or end-stage disease). In 27% of patients receiving palliative chemotherapy, external advisors 
considered that the treatment may actually have caused or hastened the patient’s death.  The 
authors recommended that prior to administering SACT oncologists should fully discuss with patients 
the aims and likely outcomes of treatment and that this should include a discussion of the option of 
no treatment.  Moreover, for patients with ECOG performance status 3 or 4, they recommended that 
palliative chemotherapy should only be embarked on with caution and after consideration by a 
multi-disciplinary team. 
There is frequent discordance between patients’ and clinicians’ perceptions about the intended 
purpose of chemotherapy.254-256 In one study only 51·9% of 216 patients correctly recognised 
whether the treatment that they were receiving was either curative or palliative in intent.256 Similarly 
it was reported that 64% of patients with incurable lung cancer did not report understanding that 
their radiotherapy was unlikely to cure them.257 This mismatch between clinicians’ and patients’ 
understanding about the indications for their treatment is not confined to oncologists. In once recent 
study 258 it was reported that 57·4% of patients with metastatic lung, and 79·8% of patients with 
metastatic colorectal cancer believed that their surgery was likely to have been curative. Moreover 
there is also evidence that patients with advanced cancer are subject to increasing numbers of 
radiological investigations 259 and to a higher frequency of artificial nutritional support even in the 
context of decreased SACT.260  
Predicting survival in advanced cancer using prognostic tools 
Accurate staging can provide valuable prognostic information; can guide decision making about 
treatments at the individual patients level; allows for a common international terminology so that 
different centres can accurately describe the case-mix of their patients and can compare outcomes; 
and is essential for identifying homogenous populations for entry into clinical trials.261 However, in 
the context of palliative care, when nearly all patients have metastatic disease, the usefulness of 
current staging systems is more limited. In advanced disease “traditional” prognostic factors (e.g. site 
of primary cancer, number and sites of metastases) may be less relevant as many patients follow a 
common disease trajectory of increasing debility, anorexia, cachexia, fatigue and decreased mobility; 
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leading ultimately in many cases to confusion, drowsiness, coma and death.262 In these 
circumstances simply knowing that a patient has Stage 4 disease does not help clearly distinguish 
between those patients with prognoses of days, weeks, months or years. Clinicians frequently rely on 
their own clinical judgment or intuition to arrive at prognostic estimates. However, systematic 
reviews consistently show that such estimates are frequently inaccurate and over-optimistic.263,264 
The most commonly used “qualitative” method of predicting survival in patients with advanced 
disease is the so-called “Surprise Question (SQ)”. The SQ (“Would you be surprised if this patient died 
within the next x months?”) used either alone, or as part of the Gold Standard Framework (GSF) 
proactive identification guidance tool,265  has been recommended as a way to identify patients who 
may benefit from referral to specialist palliative care services. A recent systematic review 266 reported 
that, overall, the SQ was accurate on 74·8% of occasions. Although the positive predictive value of 
the SQ was low (30%), it performed better at screening out those patients who were not expected to 
die within a specified time frame (negative predictive value 90%).  
In response to the inaccuracy of clinicians’ predictions an increasing number of prognostic tools have 
been developed specifically for use in palliative care patients with advanced cancer.245,267-269 There is 
no consensus about the most accurate or practical tool for clinical use. However, a few of the better 
validated tools are shown in Table 4 and are discussed below. 
Name of tool Variables included in score Type of prognostic estimate 
Palliative 
Prognostic Score 
(PaP) 270,271 
Dyspnoea; Anorexia; Karnofsky 
performance Status 272; Total white cell 
count; Lymphocyte percentage and 
Clinician Prediction of Survival 
Scores divide patients into three risk 
groups: A >70% probability of surviving 30 
days; B 30-70% probability of surviving 30 
days; C <30% probability of surviving 30 
days 
Delirium PaP (D-
PaP) 273 
Delirium; Dyspnoea; Anorexia; Karnofsky 
performance Status 272; Total white cell 
count; Lymphocyte percentage and 
Clinician Prediction of Survival 
Scores divide patients into three risk 
groups: A >70% probability of surviving 30 
days; B 30-70% probability of surviving 30 
days; C <30% probability of surviving 30 
days 
Palliative 
Performance 
Scale (PPS) 274 
Ambulation; Physical activity and extent of 
disease; Self-care abilities; Oral intake; 
Conscious level 
Patients can be divided into risk groups 
according to PPS score 10% -100%. Life 
tables can be used to predict probability of 
surviving to defined time periods. 
Palliative 
Prognostic Index 
(PPI) 275 
PPS score; Oral intake; Dyspnoea; Oedema 
and delirium 
Patients are stratified into three groups; 
survival shorter than three weeks; shorter 
than six weeks; or more than six weeks 
Modified 
Glasgow 
Prognostic Score 
(mGPS) 276-278 
Serum C-Reactive Protein and Albumin Patients are stratified into three groups 
with good, intermediate and poor 
prognoses. 
Feliu Prognostic 
Nomogram (FPN) 
279 
ECOG performance status; Serum albumin; 
Lactate Dehydrogenase;  Lymphocyte count 
and time from initial diagnosis to diagnosis 
of terminal disease 
Using the nomogram a probabilistic 
estimate can be calculated for  survival at 
15, 30 and 60 days 
Prognosis in 
palliative care 
scale – A (PiPS-A) 
280 
Performance status; Anorexia; Dyspnoea; 
Global Health; Breast cancer; Male genital 
organ cancer; distant metastases; bone 
metastases; liver metastases; Mental test 
score; Heart rate; Dysphagia; Weight loss 
Categorical survival prediction; “Days”, 
fewer than 14 days; “Weeks”, between 14-
56 days; “”Months+”, more than 56 days 
Prognosis in Performance status; Anorexia; Global Categorical survival prediction; “Days”, 
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palliative care 
scale – B (PiPS-B) 
280 
Health; Male genital organ cancer; distant 
metastases; bone metastases; Mental test 
score; Heart rate; Fatigue; Lymphocyte 
count; White cell count; Neutrophil count; 
C-Reactive Protein; Albumin; Platelets; 
Urea; Alanine Transaminase; Alkaline 
phosphatase 
fewer than 14 days; “Weeks”, between 14-
56 days; “”Months+”, more than 56 days 
Table 4. Summary of characteristics of palliative prognostic tools 
The Palliative Prognostic (PaP) score 270,271 consists of six variables. Partial scores are allocated to 
each variable and the total score determines whether the patient is in a high, intermediate or low 
risk group for death within 30 days. The PaP score has been externally validated in a number of 
studies 268 and the original performance of the tool has been broadly replicated. The total PaP score 
is more accurate than a simple clinician prediction of survival although somewhat paradoxically, its 
accuracy may be improved by removing the clinician prediction of survival from the scoring 
algorithm.281 A modified version of the PaP (including delirium as an additional prognostic factor), the 
D-PAP, has also been developed 273 and has been found to be more accurate than the original PaP. 
One criticism of both the PaP and the D-PaP is that they are heavily reliant on a clinician prediction of 
survival to generate the overall score. The Palliative Performance Scale (PPS) 274 was developed as a 
modification of the Karnofsky Performance Status 272 with a focus on those patients with poorer 
mobility / self-care abilities and the inclusion of other potentially relevant prognostic indicators. A 
recent systematic review 268 reported that the scale had been evaluated in 18 studies (n = 21 082) in 
numerous countries and multiple tumour types. In these studies the PPS has demonstrated that it is 
able to distinguish between patients with differing survival outcomes.282,283 Prognostic accuracy has 
not been directly compared to clinician predictions of survival. The Palliative Prognostic Index (PPI) 
275 is calculated using five clinical variables. The model stratifies patients into three groups; survival 
shorter than three weeks, shorter than six weeks, or more than six weeks. It has been validated in a 
number of studies 284,285 and it has the advantage of not relying on either the clinician prediction of 
survival nor on laboratory measures (which can be challenging to obtain in palliative care patients). 
Prognostic accuracy improves if used between 3-5 days after admission to a palliative care unit rather 
than on admission.286 It is more accurate than clinician predictions of 30 day, but not 100 day, 
survival.287 Perhaps the simplest measure is the modified Glasgow Prognostic Score (mGPS) 276-278 
which is calculated from the serum CRP and Albumin levels. The mGPS has been shown in previous 
studies to distinguish patients with good, intermediate and poor prognoses.268,288 The scale is simple 
to calculate and has been widely used in a variety of different cancer types. Its prognostic value is 
based on its association with the severity of the cachexia syndrome.289 Feliu and colleagues 279 
developed a prognostic nomogram consisting of five variables (ECOG performance status, serum 
albumin, Lactate Dehydrogenase, lymphocyte counts and time from initial diagnosis to diagnosis of 
terminal disease) to predict survival at 15, 30 and 60 days. Most recently Gwilliam and colleagues 
reported the development of the Prognosis in Palliative care Predictor models (PiPS).280 Two scales, 
PiPS-A and PiPS-B, have been created so that a prognostic score can be calculated regardless of 
whether or not blood test results are available. Both scores have subsequently been validated by 
external groups.290,291 The PiPS scales produce a categorical output such that patients are stratified 
according to whether they are likely to live for “Days”, “Weeks” or “Months+”.  
Only a few studies have directly compared the performance of the different prognostic tools and no 
clear pattern emerges. The PiPS tools have been directly evaluated against clinician predictions of 
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survival. Gwilliam et al 280 reported that the PiPS-B tool was significantly more accurate than a 
doctor’s or a nurse’s estimate of survival (but was not statistically significantly more accurate than a 
combined multi-disciplinary team estimate). The PiPS-A and PiPS-B were also reported to be better at 
predicting short-term prognoses than the PaP, D-PaP or PPI; but less good than the D-PaP at 
predicting longer-term prognoses.291 The same study reported that the PiPS-A and the PPI were the 
most feasible tools to use in clinical practice (routine data available for >90% of patients). The PaP 
has been shown to perform better than, or as well as, the PPI 292,293 or the PPS 294 but less well than 
the Feliu Prognostic Nomogram.279 Chou and colleagues 295 reported that the PPI performed better 
than the mGPS in patients with hematologic malignancies under palliative care. A large (n = 1 778) 
prospective comparative study is currently underway in the UK 296 comparing the accuracy of the 
PiPS-A and PiPS-B tools with the PaP, the PPS, the Feliu Prognostic Nomogram, the PPI and the 
Glasgow prognostic score. Importantly this study also includes several clinician predictions of survival 
(probabilistic and temporal) to act as comparators. The study is due to report in 2019. 
Although accuracy is clearly an important factor when weighing the relative merits of different 
prognostic tools there are also other issues to be taken into consideration. Steyerberg and colleagues 
have emphasised the importance of conducting studies to assess the impact of prognostic tools on 
clinical practice and outcomes.297 The best method of undertaking such studies is a cluster 
randomised controlled trial but no such studies have been undertaken in the context of palliative 
care. Impact studies are required to determine whether more accurate prognostication would lead to 
(for instance); earlier referral to palliative care services; more advance care plans being prepared; 
more home deaths; less intensive treatment in the last weeks of life; and/or greater satisfaction with 
communication and with care.   
In conclusion, the current state of the knowledge is insufficient to make a definitive recommendation 
about the best prognostic tool to use. Nonetheless there is good evidence that clinicians’ estimates 
alone are inaccurate and are generally over-optimistic. Therefore they should be complemented by 
use of “objective” prognostic tools wherever possible.  
Communicating prognosis 
For prognostic tools to provide benefits for patients, the estimates that they produce (including the 
associated uncertainty) and the implications for treatment must be communicated clearly and with 
empathy so that the information is understood and can be used by the patients. Doing a proper 
prognostic evaluation and sharing the results with the patient are core clinical skills in an integrated 
oncology-palliative care. Communicating prognostic information is one of the fundamental 
communicative tasks in the provision of patient-centred care. For a broader presentation of 
communication tasks see panel on Patient-Centredness. 
Clinicians have a duty to fully inform patients about treatment intent and its risks and benefits, and 
this is particularly important for SACT as patients often have unrealistic expectations about its 
potential benefits.254,298 Although most patients are told that their cancer is incurable, physicians 
have been found to steer the conversation towards treatment, engage in ‘collusion’ with patients’ 
false optimism, and sometimes fail to check that their patients have understood the purpose of 
SACT.299-302 Studies have shown that 50% or fewer patients were offered alternatives to SACT in 
consultations and that palliative care was often described by clinicians as “doing nothing” rather than 
having a more extensive discussion of its potential benefits.302,303 The increasing number of 
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chemotherapy lines and novel therapies further adds to the uncertainty facing the informing 
physician. This points to the need to adhere to one of the basic prinsicples of prognostication; it is 
not an event but a process.304 Further, the patients’ and the relatives’ wishes for prognostic 
information vary over time.247 Generally, the patients’ wishes for exact information decreases as 
death approaches but is in general ambivalent.247 Involving the patients in a continuous discussion on 
their prognosis might influence on their alternative future goal settings, to be other than survival.  
 
There are a range of patient, physician and institutional barriers to clear communication about 
prognosis and palliative care in oncology. Oncologists describe a cure culture in which they are 
‘trained to treat’ and so can feel that stopping SACT is a sign of failure, often resulting in discussions 
about hospice being delayed until all treatment options have been exhausted.305 Physicians report a 
lack of confidence in this communication, particularly related to uncertainty about prognosis, leading 
to concerns that an inaccurate prediction could reduce patient trust.306 They also express concerns 
that breaking bad news could lead to depression and a loss of hope in patients.307  
Despite these perceived barriers, clear communication about prognosis early in the disease trajectory 
must be the aim within oncology. Contrary to the concerns of many physicians, it is possible for 
patients to maintain hope following the disclosure of a poor prognosis.308 Mack and Smith 309 argue 
that this is a common misconception and point to evidence that, honest discussions, even where the 
news is bad, contribute to better physician-patient relationships that foster hope. A narrative review 
found that avoidance of prognostic discussions can lead to mistrust, anxiety, poorer quality of life, 
and family distress.310  
Perhaps not surprisingly given the focus on quality of life in palliative care, satisfaction with 
communication is higher for bereaved relatives in hospice settings than hospitals.311 Earlier 
integration of palliative care specialists may therefore increase patient prognostic awareness and 
improve patient and caregiver satisfaction. In RCTs integrating palliative care from diagnosis, 
including regular appointments with a palliative care specialist, Temel and colleagues found that 
early palliative care interventions could improve quality of life, prognostic awareness and 
communication about end-of-life preferences.3,52,312  
In addition to the involvement of palliative care specialists early in the disease trajectory, oncologists 
need practical advice on communication strategies to integrate early and honest discussions about 
prognosis and palliative care into their own practice as part of a standardised care pathway. There is 
some guidance available on strategies that can be employed during conversations about prognosis 
and other end-of-life issues, see Box 2.  
Box 2. Australian clinical practice guidelines for communicating about prognosis and end-
of-life issues include the following:313 
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• Assess what the patient already knows and the level of detail they want  
• Tailor the information to the individual and their family: pace provision of the 
information depending on the individual, use non-technical language, consider the 
family’s individual needs 
• Acknowledge uncertainty and avoid giving exact timeframes. Be honest without being 
blunt 
• Explore and acknowledge emotions 
• Encourage questions, check understanding and emphasise continuing care 
 
In a review and synthesis of best practices, Bernacki and Block 310 suggest using a conversation guide 
to ensure key topics such as goals, fears and trade-offs (i.e. prolonging life through intensive 
treatment vs quality of life) are covered. Several discussions may be needed to allow a staged 
disclosure that develops prognostic awareness,314 and to adapt information provision as the disease 
progresses and the patient’s communication preferences change.27,315 Raising these issues early in 
the disease trajectory allow the time needed for such staged disclosure. From the patient 
perspective, adjusting their hopes and expectations for the future from where they are to the factual 
situation is for most a process that takes time. The type of conversation guide suggested by Bernacki 
and Block 310 may be particularly useful as a starting point for clinicians with little experience of 
prognostic conversations. For those who will be having regular prognostic discussions, more focused 
communication training about cultivating prognostic awareness may be appropriate. 
Systematic reviews of training to improve clinicians’ end-of-life communication and communication 
with cancer patients have shown some positive results, such as increasing expressions of empathy, 
increased us of open ended questions and improved clinicians’ self-efficacy and comfort with these 
conversations.316,317 However more evidence is needed about the impact of training on patient 
satisfaction, whether positive impacts are sustained over time and on other outcomes such as quality 
of patient death.316,317  
Barriers and solutions 
Accurate prognostic information is needed by patients and clinicians to help inform treatment 
decisions. Clinicians’ survival predictions are frequently inaccurate and over-optimistic. Moreover, 
professionals working in oncology often lack confidence in communicating poor prognoses and 
related uncertainty, resulting in these conversations being delayed or omitted and in patients having 
unrealistic treatment expectations. Some of these barriers could be overcome by the use of objective 
prognostic tools to complement clinical intuition, although further research will be required before 
definitive recommendations can be made. Earlier integration and increased joint-working between 
oncology and palliative care may improve the quality of communication and reduce the frequency of 
futile treatments in patients approaching the ends of their lives. Evidence based communication 
guidance and training (as part of a wider integration of palliative care and oncology education, see 
Education) to provide practical strategies for communicating prognosis and uncertainty would reduce 
barriers to prognostic awareness amongst patients. 
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Recommendations  
• Prognostic communication about life expectancy should occur early in the disease trajectory as a 
part of early integration of palliative care.  
o How to do: Teach oncologists and palliative care physicians how to convey prognostic 
information, establish national and international indicators of patient involvement in the 
prognostic process 
o Timeline: 1-2 years 
• Develop new prognostic tools to predict survival, symptom control and maintenance of functions 
(physical, mental and social) during cancer palliative care.  
o How to do: Allocate research resources and establish international collaboratives to 
develop the prognostic tools Timeline: 1-2 years 
 
Patient-centredness – content, methodology and clinical implications  
Questions to be addressed 
What is patient-centredness? 
What are the main elements of patient-centred care in practice? 
How do we involve the family? 
Communication – a necessary tool for patient-centred care  
What are the barriers and solutions to succeed? 
Introduction 
Patient-centredness has been defined by the Institute of Medicine (IOM) as “care that is respectful 
of, and responsive to, individual patient preferences, needs and values, and ensuring that patient 
values guide all clinical decisions”.318 This approach is recommended in all areas of medicine but its 
content and methods have been considered particularly appropriate in cancer care.319 Central to this 
approach is patient-centred communication that aims  to 1. foster healing relationships, 2. exchange 
information, 3. respond to emotions, 4. manage uncertainty   5. make decisions  6. enable self-
management.320 Patient-centred care is dynamic and should address the patients’ physical, 
psychological, social and spiritual needs at all stages of the disease.318 These needs must be 
documented dynamically as they may change over time and shall be used in the decision-making 
process in consultations, MDT meetings or other clinical decision points. 
 
There has been increasing attention to the concept of value-based care in cancer, which refers to the 
quality of care achieved modified by the cost.321 However, until recently patient-reported outcomes 
were not included in the evaluation of the quality of cancer care and the clinical focus tended to be 
disease-centred rather than patient-centred. This has contributed, at least in high-income countries, 
to the overutilization of some cancer treatments, including those that are futile, and to the rising cost 
of cancer care.322 The utilization of patient-reported outcome measures (PROMs) in both clinical 
trials and in clinical care has facilitated the shift to greater patient-centredness in cancer care. 
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Systematic symptom assessment is an important component of patient-centred care since many 
symptoms are overlooked unless they are assessed systematically. The positive effects of systematic 
symptom assessment on the patients’ quality of life and possibly also survival, have been 
demonstrated in recent publications.76,77 However, in spite of the overwhelming evidence of the 
benefits of systematic symptom assessment, implementing such  assessments in routine cancer care 
has been slow, due to concerns about its feasibility, benefit, cost, and the lack of a strong enough 
system of implementation without economic and/or professional incentives and a patient-centred 
focus.73,77,323-325   
Adequate communication skills are necessary in order to provide patient-centred care. Patient-
centred communication can be learned 326 and must be regarded as a professional skill, rather than 
merely as a personal attribute. This competence is needed in order to assess symptoms, provide 
information about diagnosis and disease progression and to discuss options and  patients’ 
preferences for treatment and care.320 Such skills are of importance throughout the entire cancer 
trajectory but may be particularly relevant when the treatment intention is non- curative and/or 
when the biological effects of tumour-directed treatments may be minimal and the adverse effects 
on quality of life may be substantial. Recent evidence suggests that there may be significant deficits 
or shortcomings in the emotional engagement and communicative skills of oncologists with their 
patients.327 Evidence also suggest that both empathy and communication skills can be improved with 
training.326,328 
 
Patient-centredness has been central to contemporary palliative care since its emergence in the 
1960s. At that time, the patients did not receive palliative care until near the end of life, when it was 
clear that symptoms, needs, concerns and relationships would be the primary targets for 
interventions. It is now recognized that palliative care may be of value from the time of diagnosis, 
but the focus on patients and families has remained central to palliative care. Quality of life and 
symptom alleviation are primary targets of treatment in palliative care, and communication and 
shared decision-making (SDM) are considered essential methods of practice.  
 
SDM has been defined as: “an approach where clinicians and patients share the best available 
evidence when faced with the task of making decisions, and where patients are supported to consider 
options, to achieve informed preferences”.329 SDM is a process that involves both the patient and the 
physicians and helps to ensure that there is informed consent and patient autonomy in decision-
making. SDM presupposes that the patient has knowledge of the disease, of the intended effects and 
toxicity of treatments, of the expected survival and of the symptom burden, with and without the 
proposed treatment. SDM requires a trusting relationship between the patient and the health care 
providers, as well as communication skills on part of the health care providers. Such skills are needed 
to facilitate the appropriate, timely and sensitive sharing of relevant information and to support 
patients in expressing their preferences and views and in making truly informed choices.330 
 
Advance Care Planning (ACP), a special variant of SDM, focuses on the patients’ priorities for the 
future including being able to die in accordance with their personal values and wishes. ACP is an 
important aspect of contemporary cancer palliative care,330 recommended to take place early in the 
course of treatment when cure is not an option. Engaging patients and families in ACP can help them 
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to reflect on and to manage the transitions that lie ahead and to set treatment goals that are 
consistent with their values and preferences.331  
 
The integration of palliative care and oncology highlights the importance of patient-centredness 
including skills in communication, SDM and ACP. Although there should be some division of 
responsibilities between oncologists and specialists in palliative and supportive care, communication 
and interaction between them is important to support a common understanding of the disease and 
the treatment. The “back-feeding” of the observations of palliative medicine specialists to 
oncologists may help to ensure that patients are truly informed and without unrealistic expectations 
about the goals and results of the tumour-directed treatment and therefore they can meaningfully 
participate in SDM.332  
This panel builds on the IOM definition of patient-centredness in which a central component is to “…. 
ensure that patient values guide all clinical decisions”. Symptom assessment, SDM with its special 
variant, ACP, and care for the caregivers are key elements of patient-centred practice. 
Communication skills are central in order to practice patient-centredness. These skills and barriers to 
and solutions to patient-centred practice barriers will be discussed. 
 
Patient-centredness in the oncology setting 
Cicely Saunders established modern palliative care, highlighting the importance of active listening to 
patients’ needs, and making patients’ views visible and recognizable in the care processes.32 She also 
introduced the concept of total pain 333,334 which infers a broad understanding of the patients’ needs 
during a life limiting disease. In these ways, she was a pioneer in patient-centred care, although this 
term had not yet entered the medical lexicon. With the advancement of modern surgery, 
chemotherapy, and radiotherapy, targeted therapies and, more recently, immune therapies, cancer 
treatments have often become combinations of modalities administered by different specialists, 
each with its own risks and benefits. Navigating such complex systems and participating in SDM 
requires ongoing communication and support of the patient and the family by oncologists and the 
other participants in the treatment teams. 
 
Contemporary cancer care has some characteristics of special relevance for promoting patient-
centredness as a means to improve care. Cancer is no acute disease and most patients experience 
cancer as a chronic disease although the public perception of cancer is probably close to the acute 
disease model.335 The chronicity of cancer stems from the fact that many patients undergo life-
prolonging treatments for years or are cancer survivors with manifest or latent late effects. The 
chronic disease model has become even more relevant during the last decades with the 
advancement of modern surgery, chemo- and radiotherapy, targeted therapies and recently various 
types of immune therapies. Cancer treatments are often combinations of different treatment 
modalities administered by different specialists, and each treatment carries its own risks and 
benefits. Navigating through such complex systems therefore become a core task in itself, which the 
patient cannot be expected to solve by himself.  
 
The patient and eventually his family, in order to be actively involved in the care planning, must 
understand and accept the reality of the situation and the different options at hand. Many patients’ 
disease understanding is far from their medical reality when their cancer journey starts or even when 
they come to breaking points such as tumour progression at a later stage. Combined with the distress 
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accompanying the cancer disease trajectory demonstrated repeatedly,336 the physicians meet 
patients who are often misinformed or under-informed with compromised decision capabilities due 
to distress. They are therefore at high risk of accepting treatment proposals with uncertainties which 
they are not aware of. This places a special responsibility upon the physicians as they can start 
treatments in patients who are not truly informed about the treatments’ risks and benefits. The high 
percentages of patients misinterpreting palliative radio- or chemotherapy as curative support this 
understandin.337 
 
 
Patient-centred care is a broad approach that must take into account both the person and the 
disease, with attention to individual values, needs, resources, needs and preferences. The health 
literacy of the patient 338 i.e. the ability to obtain, read, understand, and use healthcare information, 
may vary widely across patients and must be taken into account in communication and SDM. A 
variety of factors, including anxiety related to the life-threatening circumstance, language, culture, 
and recent immigration all may affect health literacy and the ability of patients to participate in 
decisions about their care.  The fragmented nature of the cancer care system, with multiple levels of 
care, providers and locations also presents major challenges to coordinated care and the 
development of comprehensive treatment plans.339  
 
Shared decision-making (SDM)  
SDM is a central component of patient-centred care. It is highly relevant in all phases of cancer 
treatment, but becomes increasingly important as the disease progresses. At such times, decisions 
often become more complex, with trade-offs between life quantity and life quality.  SDM is an active 
process, requiring the exchange of information and opinions in order for patients to make decisions 
based on their values and preferences and on their understanding of the best available medical 
evidence.340 This means combining the tumour-directed and the patient-centred approach to care 
and weighing the benefits and risks of starting, changing, continuing or stopping tumour-directed 
treatment. Decisions about selecting one treatment option over another may also be difficult, since 
there is often little or no empirical data that indicate greater value for one regimen over another. 
341,342 
 
A variety of factors unrelated to the value of care may affect SDM, including those highlighted by the 
fields of behavioural economics and the psychology of decision-making.343  Decisions about starting, 
continuing or discontinuing chemotherapy or other cancer treatment may be difficult to make 
because of insufficient, uncertain or even conflicting empirical data and because they are made  
under circumstances of emotional strain. In this situation, available statistical and clinical data may 
Box 3. Main elements of patient-centred care 
• Respect for patients’ values, preferences, and expressed needs 
• Coordination and integration of care 
• Information, communication and education 
• Physical comfort – relieving bothersome symptoms 
• Emotional support – relieving fear and anxiety 
• Involvement of family and friends 
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not be used 344 and some clinicians may find it easier to prescribe another round of chemotherapy 
than to engage in a conversation about futile treatment.322 Further, the “last-case bias” may operate 
in which decision-makers are more influenced by recent experiences than by remote events. 
Reimbursement practices may also directly or indirectly influence institutions and providers toward 
“grey zone” chemotherapy that is costly, but of uncertain benefit. Patients and providers may both 
tend to be “treatment focused” in such situations of uncertainty,345 hoping that treatment will 
prolong survival and/or because physicians are uncomfortable having conversations regarding 
prognosis.345 Correcting misbeliefs about quantity of life and introducing alternative treatment goals, 
such as preserving quality of life, require communication skills and are most appropriate within the 
framework of SDM.  
Physicians are legally and ethically obligated to provide information in a way that enables patients to 
be active and informed partners in the decision-making process and to promote their participation in 
decision-making.346  A process to accomplish such  SDM can be described in four steps; 1) awareness 
of equipoise, 2) discussion of the  benefits and harms of options and their probabilities, 3) elicitation 
of  patients’ concerns and expectations, 4) partnership and participation.347 Only the second step 
seems to be common in cancer clinics,348 where most attention is typically paid to the “objective“ 
biological aspects, consistent with the  tumour-directed approach.  Little attention is often paid to 
the host, i.e. patient’s preferences, symptoms, quality of life and care, and to the option of no 
tumour-directed treatment.  
Despite being a central element of patient-centred care, SDM is not explicitly included as an 
integrated part of oncology guidelines.16,22,348 A premise of SDM is that the oncologist and the 
palliative medicine specialist must both be aware of the patients’ prognosis and the risks and 
benefits of treatment choices in patients with advanced cancer.349,350 Patients may have 
unrealistically positive perceptions of their prognosis and effects of tumour-directed treatments and 
be willing to continue or to start therapy with minimal or no likelihood of therapeutic effect and a 
high risk of side-effects.337 The use of intensive and non-beneficial treatment at the end of life is both 
extensive and expensive,25,260 although such treatments often reduce quality of life and time spent at 
home.254 Paradoxically, physicians tend to choose less intensive treatment for themselves at end-of-
life than they offer their patients.351  
A common misunderstanding is that SDM implies leaving decisions to the patient. As demonstrated 
in Table 5, there are different degrees of SDM, partly depending on the different choices at stake. 
The process, the making, is the main component of SDM. 
 Physician’s premises Patient's premises 
Physician makes the 
decision 
Physician makes the decision 
without access to patient’s 
preferences 
Patient lacks competence to 
give informed consent 
Physician limits the 
patient’s preferences 
Physician clarifies available 
treatment options 
Patient wants a treatment 
that is not available 
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Physician makes decision in 
collaboration with the 
patient 
Physician recommends a defined 
treatment 
Preferences and wishes for 
shared decision-making might 
vary 
Patient makes the decision 
during the consultation 
with their physician 
Physician presents 
equivalent/similar treatment 
alternatives 
Preferences and wishes for 
shared decision-making might 
vary 
Table 5. Examples of different degrees of SDM 
 
To promote SDM, the doctor must encourage patients and caregivers to participate in consultations 
and decisions regarding the care, determine situations where this is critical, and inform patients 
about the benefits and disadvantages of available treatment options. This must include balanced 
prognostic information about best and worst case scenarios, responding to patients’ concerns and 
their understanding of the information, which helps to reach an agreed-upon treatment plan.352 This 
approach largely corresponds with the 5-steps presented in Table 6. Patients’ and caregivers’ 
assertive behaviours and physicians’ facilitative behaviours interact to promote patient participation 
over time.353 This complexity explains why a single, unidimensional intervention is less likely to 
work.354 
 
1 Determine situations in which SDM is critical  Complexity depends on treatment intent 
and options  
2 Acknowledge that decisions are to be made 
to the patient 
Increasingly important with sensitive issues 
3 Describe treatment options, including risks, 
benefits and uncertainty associated with 
options 
Avoid hastened decisions, make sure 
patients are fully informed 
4 Elicit patient preferences and values, and 
make sure the patient understands the 
information in her/his perspective 
Listen carefully and convey information in 
a language that matches the patient’s 
cognitive level  
5 Agree on a plan for the next steps in the 
decision-making process 
Agree that the plan may be revised 
depending on the disease development 
Table 6. Five steps in shared decision-making, Adapted from Politi et al 340 
 
The literature on outcomes of SDM in palliative care remains scarce and findings are inconclusive.355 
However, in a range of studies in different groups, SDM has been associated with better quality of 
life and treatment and consultation satisfaction, better affective-cognitive outcomes, and decisions 
that are more in line with the patient’s pre-consultation treatment preference. A recent study 356 
showed that 49% of 102 cancer patients preferred shared treatment decision responsibility, whereas 
29% preferred to leave the decision to the physician, the latter significantly associated with more 
advanced age and greater distress. This corresponds to another study reporting that about 50% of 
patients with advanced cancer preferred to be involved in SDM, whereas the remaining 50% were 
almost equally divided between active (making the decisions by themselves) and passive (the 
physician making the decision for them) approach.357 Such attitudes may change over time in either 
direction, pointing to a need for individualization and flexibility in communication and in care 
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planning.  More research has been conducted on the use of decision aids finding increased 
knowledge, greater patient engagement and decisions more consistent with patients’ preferences.358 
 
There is little evidence about patient preferences concerning communication and information as an 
aid to shared decision-making in palliative oncology.359 Most patients (90-95%) are more willing to 
obtain information about diagnosis, prognosis and treatment options than about palliative care 
(63%).360 However, about 50% wish to participate in treatment decision-making as time passes, and 
patients with more pain are more likely to change their preference towards being more involved.361 
Most patients with advanced cancer say they want honest, sensitive communication about end-of 
life issues. This helps patients and their families to prepare, make informed decisions, and also to 
avoid potentially burdensome medical treatments near death.362 
 
The role of family and caregivers is important in the SDM process through the disease trajectory. Two 
thirds of patients with advanced cancer want family members to participate in the communication 
and the decision-making.360 However, caregiver preferences may not be concordant with those of 
patients 363,364, especially regarding information when death comes closer.349 Some cancer patients 
may want to “spare” family members from the emotional strain of receiving bad news and it has 
been found that distress in caregivers of patients with advanced cancer is greater than in patients 
themselves.365 
 
A successful implementation of SDM in clinical practice relies on training physicians to engage with 
the patients and to provide the right information at the right time. Several decision aids exist to 
facilitate this process,22,340 and the stepwise approach presented here, represents a systematic 
approach. Further, specifically defining SDM as a part of the standardized care pathways, may 
promote its implementation in clinical practice at the organizational as well as the individual patient 
care level.  
 
Advance care planning (ACP)  
ACP can be considered a special variant of SDM, focusing on the patients’ voluntary participation in 
discussing their future care with their care providers.   ACP should be an integral part of the care and 
communication process and of the regular care plan review. ACP differs from regular care planning 
by focusing an anticipated deterioration in the individual’s condition approaching death. ACP 
developed from advance directives, which have been used in the USA and other countries since the 
mid-1970s.366 From the mid-1990s there was a shift from standardized legal forms to an ongoing and 
flexible process and from the focus on refusal of treatments to promoting statements of preferences 
and wishes, paving the way for ACP.366,367 ACP has received growing attention since that time and is 
currently an important issue in palliative care internationally.330,368 In Europe, efforts to promote ACP 
have been focused on patients with life-limiting illnesses, rather than on the general public.369,370 
While advance directives are specifically directed at refusing treatment when individuals are no 
longer able to express their wishes, ACP concerns also future care in a broader sense.368,370 
 
A recently published consensus definition of ACP describes it as “a process that supports adults at 
any age or stage of health in understanding and sharing their personal values, life goals, and 
preferences regarding future medical care. The goal of ACP is to help to ensure that people receive 
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medical care that is consistent with their values, goals and preferences during serious and chronic 
illness”.371 The word ‘process’ underlines that the planning is not a one-time event, but usually 
evolves over time through a series of conversations, and therefore that ACP documents should be 
updated regularly.368,370,372 Although the definition does not specify who should take part in the ACP 
process, ACP discussions commonly involve the patient, family, informal caregivers and health care 
professionals. This discussion can be conducted by the primary care or oncology team or by the 
palliative care team, depending on the skills and resources that are available.  
The ACP process starts by exploring the patient’s health-related experiences, concerns, and personal 
values, and his/her understanding of ACP and readiness to engage in it. Not all patients want such a 
plan or are able to formulate their wishes for future care, which is, in itself, is valuable information 
for planning of care. Next, the current disease situation should be discussed in order to obtain a 
common understanding of treatment and care options and their advantages and disadvantages.  ACP 
may also include discussion and completion of an advance directive or living will, depending on the 
national legislation. The advance directive will typically address specific interventions, such as cardio-
pulmonary resuscitation or tube feeding, in a future scenario of incapacity. Finally, encouraging the 
individual to share thoughts and preferences with family and friends is an important part of the 
process.368,370,372  
Different forms and templates for ACP documents have been proposed and many are freely available 
on the internet.373 There is an ongoing debate about whether ACP should be based on open or 
scripted conversations.330 The use of a template may ensure that most relevant areas are presented 
to the patient, although strict adherence to a guide may restrict the free exchange of thoughts, and 
reduce ACP activity to a tick-box exercise.370 A semi-structured interview guide may avoid these 
dangers.374 ACP ensures that the care is more likely to be in accordance with the patient’s 
preferences than if it is not performed.375 It has also been shown to decrease life-sustaining 
treatment at the end of life and to increase the use of hospice and palliative care and to prevent 
unwanted hospital admissions.362 Comprehensive ACP programs seem to be more effective in making 
end of life care coherent with patients’ preferences than just completing a written advance 
directive.376  
Although there are still unresolved questions as to the optimal ACP system and how to assess its 
impact and effectiveness, ACP is coherent with patient-centred care and therefore relevant for the 
early integration of palliative care and oncology although many countries presently do not have any 
legislation regarding ACP. 
  
Assessing the patients’ perspective systematically 
Symptoms, preferences and patient-reported outcomes have been labelled differently in recent 
decades. The U.S. Food and Drug Administration (FDA) has proposed the term Patient Reported 
Outcomes Measures (PROMs) for all measures that can best be assessed by patient self-report.67 
PROMs is an umbrella term covering the patient’s perspective on well-being, symptoms, subjective 
treatment effects and side effects.68 The CONSORT-PRO Extension Statement, aiming to improve the 
reporting of PROMs on symptoms, functioning and quality of life,70 further consolidates PROMs as 
independent outcomes in cancer.69,70  
 
The patient perspective and experience cannot be replaced by clinical observations and examinations 
performed by the oncologist or by the palliative medicine specialist. In ordinary consultations, many 
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bothersome symptoms are not identified or addressed.377 However, PROMs can be used to highlight 
the patient’s experience and to bring the “patients’ voice” into the clinical consultations. The benefits 
of routine PROM assessment in clinical practice are well documented. These include improved 
patient–physician communication,378-380 increased physicians’ awareness of patients’ physical and 
psychosocial functioning,381-383 improved patient well-being,76,379 and a more efficient and focused 
use of time.382 Regular use of PROMs makes the physicians aware of symptoms they did not know 
bothered their patients.383  
 
Symptoms are essential information for the primary cancer diagnosis and for follow up care during 
curative and life prolonging treatments. Still, systematic symptom assessment is not part of routine 
oncological care,381,384-386 even though this is frequently employed in clinical trials.387 For patients 
with advanced cancer, for whom symptom management is a central goal of care, systematic use of 
PROMs is even more important and is a prerequisite for optimal symptom management.318 Relieving 
burdensome symptoms is therefore a core task within patient-centredness and a special obligation 
on part of the physicians.   
 
Insufficient and unsystematic assessment of symptoms is a major factor explaining inadequate 
symptom relief in cancer patients. Inadequate pain control has been documented in up to 50% of the 
cases, despite strong efforts to improve pain treatment.388,389 Clinical studies of patients with cancer 
have found systematic use of PROMs to improve a range of symptoms.382 The discrepancy between 
research outcomes and those in clinical care is probably explained by the rigorous diagnosis, 
documentation, treatment and follow-up in clinical studies, which are often not conducted in regular 
care.  
 
For patients with limited life expectancy, the balance between treatment effect and tolerance of 
therapy, based on toxicity and adverse effects, is crucial in the treatment decision-making. Toxicities 
and adverse effects are mandatory to report in clinical trials by such systems as the Common 
Terminology Criteria for Adverse Events (CTCAE) developed by the National Cancer Institute.390 These 
criteria have, until recently, been rated by the physicians, although many are symptoms that are best 
reported by the patients. This recognition has led to the development of a PROMs-version of the 
CTCAE, the PRO-CTCAE.  
  
The most feasible and reliable form of PROMs is via standardized and methodologically sound self-
report questionnaires, traditionally paper-based. New advances in health information technology 
have led to the development of electronic tools (e-tools) for the collection of PROMs. Electronic data 
collection permits dynamic assessment i.e. automatically tailored questions for individual patients 
based on the patients’ previous scores on given symptoms. This results in fewer repetitive and 
irrelevant questions, thereby reducing patient burden. Several electronic questionnaires (e-PROMs) 
now exist, with a user-friendly interface and immediate aggregation, storage and transfer of patient 
scores, for direct use in the clinical encounter and possibly integration with other clinical data in the 
electronic patient record.391 In the oncological setting, electronic assessment and rapid presentation 
of results to the clinician facilitate communication, are well accepted by patients and clinicians, and 
may result in more efficient and focused use of time.72 A recent qualitative study showed that 
perceived usefulness might be more important than functional aspects regarding applicability.74 Still, 
immediate display of easily interpretable results to the physician is a crucial factor for successful 
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implementation of electronic registration of PROMs into the clinics.75 Nevertheless, the most 
important obligation on the part of health care providers is to actively use PROMs tools, discuss the 
scores with the patient, explain potential interventions and make the patient an active partner in the 
decision-making process.  
 
Systematic symptom assessment by either paper-based or electronic assessment tools (PROMs) 
ensures registrations of burdensome symptoms, also such symptoms patients do not report 
spontaneously unless asked, specifically anxiety and depression. These may not be spontaneously 
reported by patients, particularly if they perceive that they will not be regarded as relevant to their 
cancer care. Still, the symptoms reported by the patients with PROMS must be addressed in the 
clinical encounter and used in the decision-making processes. Often symptom intensity, the most 
common symptom assessed in the assessment tools, must be supplemented with other symptom 
characteristics in order to decide about intervention. The duration of the symptom, its meaning and 
the distress associated with it may best be elucidated in a follow-up clinical interview.  This may be 
initially conducted in an oncology clinic but may also be assessed by the specialized palliative care or 
psychosocial oncology team. The latter may be able to conduct a more in-depth assessment and 
provide more specialized care  
 
Caregiver involvement  
Patient-centred care and SDM aims also to involve the family members. It should be routine in 
clinical care for patients to be asked to identify their significant others, and to provide information 
about the nature of their relationship with them,  strengths and limitations in their ability to take on 
complex cancer caregiving, and how much information about the medical situation they can and 
should and can receive.  Further, caregiver problems, such as serious illness or emotional or 
economic problems need to be assessed.  
  
Caregivers are often actively involved by cancer patients in decisions about their care and treatment, 
particularly those focusing on the end of life. Patients choosing to participate in SDM have been 
found to prefer to share this experience with their family members.392 Caregivers, including family or 
friends, often provide care for cancer patients, although many may not be well-prepared to do so.  
The burden of such caregiving on caregivers may also be substantial and reduced quality of life, 
distressing symptoms such as insomnia, fatigue, anxiety and depression, and financial stress have 
been shown to be common among them.393,394 The strain on caregivers may have increased in recent 
years, as cancer care has shifted towards more outpatient and home-based care. Moreover, with 
cancer being more prevalent in the elderly, many caregivers of advanced age and may suffer from 
substantial health problems of their own. Therefore, involvement, training and support of caregivers 
are key components of modern cancer care.  
 
Caregiver resources and the quality of the support for the patient and the caregiver support may be 
decisive in determinations about the place of care, when the disease progresses, and the location of 
death.395 The family as informal caregivers of patients is often the patients’ main source of emotional 
and practical support, although the burden and challenges of disease may create or intensify family 
conflict. Such conflict, which can obstruct or complicate treatment planning, may benefit from 
intervention. These disagreements and tensions may be easily recognizable, but can be challenging 
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and time-consuming to resolve. Palliative care physicians and teams can help to support caregivers in 
addressing these conflicts though engagement of specialized psychosocial oncology may also be of 
value. The updated ASCO Clinical Practice Guideline on integration of palliative care and oncology 
emphasizes that services by multidisciplinary palliative care teams complement existing programs, 
and that “Providers may refer family and friend caregivers of patients with early or advanced cancer 
to palliative care services”.16  
  
Studies of the effects of early provision of palliative care on caregiver satisfaction with care, quality 
of life and emotional distress have produced conflicting results. One Norwegian study 396 showed an 
overall positive impact on quality of life, in line with a study using specialty trained PC clinicians in 
patients with a poor prognosis.397-399 The ENABLE-III study by Dionne-Odom, is probably the first RCT 
examining a specific palliative care intervention for family caregivers of patients with advanced 
cancer.400 The intervention group received three structured weekly telephone coaching sessions, 
monthly follow-up, and bereavement calls compared with usual care in the control arm. The results 
showed lower depression scores at 3 months in the intervention group.   
 
Two consecutive meta-analyses have examined the effect of different interventions on various 
caregiver outcomes in a total of 79 RCTs with family caregivers of cancer patients.393,394 Results from 
the first analysis indicated that these interventions had small to medium effects on caregiver burden, 
caregivers’ ability to cope, their self-efficacy, and aspects of their quality of life.394 In the period 
covered by the second analysis (2010-2016), the number of trials had increased substantially 
corresponding to a huge variety of formats and types of interventions. This make comparisons and 
conclusions about efficacy thereby difficult but indicate that caregiver interventions can vary and 
probably should be flexible.393 What should be remembered is that caregiver satisfaction in most 
RCTs of early introduction of PC is at best defined as a secondary outcome, and therefore can be 
interpreted as a complementary effect of improved patient care, and not the result of specific 
interventions directed at the caregivers. 
  
Qualitative data from trials of early palliative care have identified certain aspects of palliative care 
that may influence the caregiver satisfaction; e.g. building rapport, establishing a relationship with 
patients and family, focusing coping and providing realistic information about prognosis.332,401 The 
content of the early and subsequent palliative care visits, identification of key issues and timing of 
when to address these, were regarded as reasons for favourable outcomes in one study.332 
Statements expressed in another study gave important clues to how incurable cancer affects the 
family and ways that helped them cope.401 Statements like:” It is the family that’s going through it” 
and “Talking with the palliative care physician was immensely advantageous” clearly illustrate these 
points.  
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Communication – a key to patient-centredness  
Oncologists and palliative care specialists face difficult communication situations through the 
trajectory of cancer, including breaking news about disease progression and non-response to 
tumour-directed treatments. A strong focus on better communication as part of early palliative care 
promotes patient-centred care, and results in better prognostic awareness and higher patient 
satisfaction.5,312 
 
Patient-centred communication is a key asset for implementing SDM in oncology practice. As 
mentioned the main characteristics of patient-centred communication are attention to patient’s 
affective states, values, needs and preferences.346 Patient-centred communication aims to create a 
dialog between the physician and the patient and therefore the clinician must be able to monitor and 
consciously adapt the communication to meet the patient’s needs. When this does not occur, the 
communication easily takes the form of a monologue which is provider-centred and not patient-
centred. 
 
 
Box 4. Communication in the cancer care setting shall help the patients to:  
(Adapted from Epstein RM, Street RL, Jr.) 320  
• Receive bad news  
• Handle the emotional impact of a life-threatening illness  
• Understand and remember complex information  
• Communicate with multiple health professionals  
• Understand statistics related to prognosis  
• Deal with uncertainty while maintaining hope  
• Build trust that will sustain long-term clinical relationships  
• Make decisions about treatment, possibly including participation in clinical trials  
• Adopt health-promoting behaviour  
 
The key tasks to be solved by patient-centred communication span the whole cancer trajectory, but 
common features to all phases are exchanging information, responding to emotions, fostering 
healing relationships, managing uncertainty, making decisions and enabling patient self-
management.352 Patient-centred communication transcends medical issues and also includes 
practical issues such as clarifications of responsibilities and who to contact.310 Key communicative 
tasks to be solved in advanced cancer are presented in Table 7. 
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Key communicative tasks 
• Eliciting the patient’s report of symptoms 
• Communicating prognosis while maintaining hope 
• Making decisions about tumour-directed and intensive medical treatments – 
particularly about starting and stopping criteria 
• Making decisions about future care including hospice care 
• Responding to the emotions of the patient, the family and caregivers 
• Helping the patient navigate the transition to end-of-life care 
Table 7. Advanced cancer - key communication tasks to be solved  
 
Communication includes both sending and receiving information with both verbal and non-verbal 
elements. Both parties must repeatedly change roles from sender to receiver; being the receiver, i.e. 
performing active listening, is challenging for many physicians. Indeed, one of the most-cited studies 
of physicians’ communication demonstrated that GPs interrupted the patient on average 18 seconds 
after the patient had started talking.402  Physicians must be willing to “see” patients as whole persons 
and providing them with information that is understandable and useful from their perspective. They 
must also be prepared to discuss the end of life,  although the words “die” and “ death” are generally 
avoided by oncologists, who may be uncomfortable engaging in meaningful discussions about the 
end of life.403 A common belief is that honesty undermines hope, although there is evidence that 
honest but empathic communication may actually help to preserve morale and psychological well-
being.233 Finally, both parties also need to share knowledge and understanding and must have 
suitable perceptual and linguistic skills to produce effective communication behaviours that are 
appropriate to the situation. 
For patients, good enough communication with their physicians can help to make them feel 
understood, participate actively in the interaction, improve their understanding of the disease and 
treatment options, cope better and to experience trust in their physicians and in the health care 
system.  Patient-centred communication can also result in a treatment plan that is concordant with 
patient preferences and values. It is essential that the physician and the patient establish a common 
understanding of the current situation as the starting point for patient involvement. A prerequisite is 
that the information and answers are communicated in a way and in a language that match the 
patient’s cognitive and intellectual abilities and that it take into account the patient’s emotional state 
at the time of the consultation. Hence, provision of sufficient information requires knowledge about 
how to convey the information in an understandable manner at the right time.  
With more complex clinical conditions and therapeutic opportunities, patient-centred 
communication is especially salient.404,405 Nevertheless, inadequate communication about prognosis 
and treatment choices is common,349,350,406 although listed as a key dimension of patient-centred 
communication.318 Moreover, critical information about prognosis and treatment options is often not 
discussed during life-prolonging treatment, and may lead to unrealistic patient expectations 
regarding cure.3,312,352 Much too often, these discussions typically take place late in the disease 
trajectory, often in the last month, which is too late for patient and family to benefit from referral to 
palliative care.407  
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The tendency of physicians to avoid honest communication is not supported by empirical research.  
Parker et al found that up to 90% of patients with advanced cancer want information about the 
disease, treatment options, symptom management and life expectancy.349 There is accumulating 
evidence showing that early discussions about care goals in advanced disease improve end-of-life 
outcomes.310 Further, patients who have discussed the future with their doctor before the disease is 
too far advanced, report greater well-being and have fewer unwanted intensive interventions in the 
last weeks of life, with no detrimental effect on survival.3,362 An earlier integration of oncology and 
palliative care with patient-centred communication also enhances patient and family involvement, 
guides the decision-making and promotes realistic expectations for the future, and is therefore an 
important improvement of general oncology care.401 
 
Communication skills can be taught to medical undergraduates and postgraduates, but discussion of  
prognosis and at relevant time-points must be part of oncology and palliative care training. Such 
discussions presuppose detailed knowledge about prognosis, including the uncertainty inherent in a 
prognostic evaluation. Empathic communication about prognosis and about uncertainty are 
communicative skills that should be mandatory in the curriculum for oncologists and other clinical 
specialities treating cancer patients (see Prognostication and Education). 
 
As outlined in the scheme for SDM, treatment options should be explained simply and clearly. Most 
topics are emotionally loaded for the patients and family members. Learning how to elicit and 
respond to the emotions during and still carry the consultation forward is a skill that physicians must  
acquire. Very few learn these skills by themselves, some improve by an open professional culture 
focusing treatment of the patients, and most probably need specific training like an athlete that 
needs training to improve.  
 
Training in SDM as a method in clinical practice and on how to maintain, develop and share 
fundamental communication skills is needed at regular intervals for oncologists, palliative care 
specialists and other health care providers to foster patient-centred communication 332,408. Empathic 
listening, flexible and attuned responsiveness to the shifting needs of the individual patient and to 
patients’ and caregivers’ emotions are important skills that can be improved through 
learning.310,314,401,409,410 The best methods for improving communication skills are not yet 
established.411 However, interventions such as communication skills training with role play and 
feedback, e-learning, group discussions, modelling, case evaluations and coaching are some of the 
most commonly used strategies. Overall, strategies that involve activity and practice are most 
efficient.411 Although less common, interventions aimed to influence the patients’ behaviour include 
encouraging them to use prompt lists which can be combined with patient and oncologist 
coaching.412,413 Although evidence about their usefulness in palliative care patients is limited, they 
could help to engage patients and physicians in more active and deep interaction.340,414,415  
 
Psychosocial Care 
The prevention and alleviation of psychological and social distress in patients with cancer and in their 
families and support for their personhood has been a central goal of palliative care from the time of 
its inception.416 Indeed, palliative care emerged, in part, to the neglect in modern medicine of the 
human dimensions of suffering.417,418 Nevertheless,  there has been much less attention in palliative 
care to training and the systematic delivery of psychological and spiritual care, compared to physical 
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interventions, for which there are well developed protocols and guidelines. This contrasts recent 
findings on depression being the main factor associated with poor QOL in patients with advanced 
cancer.419 
 
Symptoms of depression,336 demoralization,420 and spiritual distress 421 are common in patients with 
advanced cancer and longitudinal research has shown that, without intervention, these symptoms 
tend to worsen with greater proximity to death.422 There is a growing evidence base for the 
effectiveness of psychological interventions to alleviate depression and other manifestations of 
distress in patients with advanced disease. These interventions include supportive-expressive group 
therapy,423 Meaning Centred Psychotherapy, 424 Problem-Solving Therapy and behavioural activation 
425 and Dignity Therapy.426 However, psychosocial interventions and skills are not well integrated at 
present into either oncology or palliative care. 
 
A recently developed approach to psychological care of the patient with advanced disease that is 
integrated with cancer care and with palliative care is referred to as Managing Cancer and Living 
Meaningfully (CALM).427 This intervention is intended to provide patients and their caregivers with 
reflective space to communicate their experience and to address the major decisions, burdens and 
adaptive challenges of advanced and progressive disease. Palliative care, oncology and psychosocial 
care providers can be trained to deliver this intervention and such training has the potential to 
enhance their ability to engage empathically in sensitive conversations and to create reflective space. 
An international training program for health care providers is now underway 428 for this intervention 
which has been shown to alleviate and  prevent depressive symptoms, to reduce death-related 
distress and to enhance the capacity of patients to communicate with their family and their health 
care providers.429 This program infers training of members of the multidisciplinary palliative team. 
The palliative care multidiciplinary team is set up in order to adress the complexity of problems 
facing the patients and their families. Patients’ problems are often complex and cannot be solved by 
a single profession alone. Some problems are best adressed by specific members of the team, such as 
financial problems that often needs the competence of a social worker. The  effects of a 
multidicplinary approach have been demonstrated but perhaps not fully utilised.430 Although a 
broader patient-centred approach on part of the physicians seems pertinent, other members of the 
team are often in better positions to provide the care.  The CALM approach is therefore promising in 
terms of its focus on skills needed to provide patient-centred care. 
 
Box 5. Psychological domains - content  
Treatment decisions and communication with health care providers 
Renegotiation of personal  relationships and self-concept 
Reframing priorities and the sense of meaning in life 
Fears, hopes and plans related to impending mortality   
 
Barriers and solutions  
At present the delivery of cancer care is more provider-centred than patient-centred.431 This applies 
to the system as a whole, including institutions, payment systems, infra-structure and professional 
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cultures. In sum, these factors represent substantial barriers towards making care more patient-
centred.  
 
On the macro-level, the focus on promising new cancer therapies is prominent. This focus can be 
traced in present research priorities (see Societal Challenges) and also mirrors the priorities and 
marketing activities of the drug companies. It has been stated that the ultimate goal of contemporary 
science is immortality,432 and, if correct, this represents a strong driver for further strengthening the 
focus on the tumour. These factors also create expectations both within and outside the medical 
community and effects priorities at all levels within health care and in politics. The public opinion and 
thereby the expectations of patients, are also influenced and contrasts the reality facing a substantial 
proportion of them and their families, namely that their cancer is incurable. In our view, these factors 
with their unilateral focus on the tumour, represent barriers against a focus that includes both the 
tumour and the patient. 
  
Oncology as a medical specialty has its roots in internal medicine while palliative care has its roots 
outside mainstream medicine. This has created different cultures with different foci; the tumour and 
the host.  A culture is characterized by sharing the same values including taboos, and acts as an 
“invisible” but commonly shared guidance for social interactions for those sharing it.433 Cultures also 
create borders. This contrasts legislation which is open and explicit, making legislations easier to 
discuss and change.  Bridging the two cultures in oncology and palliative care is therefore a challenge 
which is traceable at all levels in health care including daily activities at wards, departments and 
hospitals. 
 
One prominent characteristic of the medical culture is the perception of the paternalistic doctor 
deciding over life and death. This is communicated at medical schools, and also fulfils the 
expectations of the students. The majority of them start at medical school with an “inner picture” of 
the physician as the person who is in power over life and death. The most challenging parts of 
teaching communication skills to medical students are to motivate them for the training and to teach 
them to systematically explore the perspective of the other, the patient. 
 
The tabooing of death is another observable trait of the medical culture. The word is seldom used,403 
and many medical schools do not teach palliative care or end-of life care at all. The lack of exposure 
to these topics during the formative years as students or freshmen have consequences for 
performing clinical tasks such as discussing tumour-directed treatments with a patient who has 
limited life expectancy or providing care which includes death as the endpoint. Euphemisms are 
commonly used by the physicians when topics are perceived as challenging, often without checking if 
the information is understood by the patient. This protects the physician from challenging 
communicative tasks in which he often lacks or does not have the correct answer but when open 
negotiations with the patient would have been preferable.  
 
Even if most patients with advanced cancer express a preference for realistic information and 
realistic discussions about treatment options and prognosis,362,434 it must be acknowledged that 
barriers for high-quality conversations exist on the patient side as well. Patients may be reluctant to 
ask questions, express their feelings, do not want to admit that they are unsecure or that they do not 
quite understand the options and the implications. Two tongues – one towards the oncologist the 
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other towards other health care providers is documented in qualitative studies in patients 
approaching the end of tumour-directed treatments.435 This points to a very important and common 
trait among patients with advanced cancer; they are ambivalent both wishing to live and wanting to 
live a good a life as possible. This ambivalence is also commonly observed in relation to wanting 
information about prognosis when this is poor.  
 
There are examples of how the medical culture has changed in response to new dogma. The best 
described is probably the change from hiding to disclosing the cancer diagnosis described earlier. In 
an editorial commenting upon the study of Novack 436 which confirmed disclosure to be the preferred 
practice, informed consent as a prerequisite or inclusion of patients into trials was pointed to as the 
most possible explanation for the change of attitude.437  
 
When asked, doctors are generally positive to use PROMs, but this is still much more common in 
palliative care units compared to general oncology units, primarily because of the enhanced focus on 
symptom management in palliative care. Frequently cited barriers towards the use of PROMs are 
time-constraints, cumbersome use, difficulties related to interpretation and logistical problems.385,438 
Other factors including resistance to change of an established system, lack of strong enough 
implementation, no economical and/or professional incentives and absence of patient-centred focus 
also play a role. These factors are basically the same for all organizational changes, and represent a 
challenge when implementing all types of new practices. Paradoxically, introducing new drugs or new 
technologies do not seem to meet the same resistance to change. It is reasonable to assume that the 
economic strength of the producers of drugs and new technologies therefore plays a role.  
 
To enhance a patient-centred approach, the following factors apply on the organizational, 
professional and personal, levels: a) implementation of a patient-centred approach and 
communication plan into the SCPs, b) willingness to change behaviour and incorporate this into 
clinical practice and c) a mutual understanding and internalization of the content and values of a 
patient-centred approach among all health care providers involved in the care  
 
The problems of sharing information within and between health care organizations have been 
recognized as a barrier to the implementation of ACP. Other barriers include competing demands of 
other work for health care professionals, and the emotional nature of these types of conversations. 
Specially trained staff using a structured approach has been shown to facilitate implementation.439 
Also, prompts in the electronic health record can increase the rates of documentation.440 At the 
patient level, factors influencing the uptake of ACP are complex, including previous illness 
experiences, preferences and attitudes. Generally, cancer patients are more open to ACP than 
patients with non-malignant diagnoses.441 However, one systematic review suggested that cancer 
patients value more the shared decision-making and communication elements of ACP than the 
avoidance of excessive medical treatment at the end of life.392  
 
Other strategies to enhance patient-centredness are elaborated upon in other panels and include 
economic incentives, organization, and education.  
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Recommendations  
• Patient-centred care (focusing on the host) must be an integrated part of all cancer guidelines and 
all treatment/care plans early in the disease trajectory until end of life care 
o How to do: Societal and political demands at national and international levels initiated by 
WHO and professional organizations and patient advocacy groups  
o Timeline: Now 
• Implementation of routine use of PROMs in all settings of patient care 
o How to do: Develop PROMs for use in electronic patient record systems and assure that 
the information is used in the decision making processes. Implement incentive driven 
indicators for the use of PROMs 
o Timeline: Now  
• Shared decision-making (SDM) and advanced care planning (ACP) must be integrated as a 
mandatory part of all standardized care pathways (SCP) 
o How to do: Refine the methods for SDM and ACP internationally and adapt to national 
needs and norms. Implement incentive driven indicators for the use of SDM and ACP 
o Timeline: 1-2 years 
• Involvement and assessment of the family as a part of early integration of cancer palliative care 
o How to do: Develop methods (tools) for involvement and assessment internationally, and 
adapt nationally and implement indicators to monitor implementation 
o Timeline: Now 
• Develop the content and the basic method of SCP for use as a tool for early integration of palliative 
care into oncology care in hospitals and community care 
o How to do: International research on method development, complementary intervention 
strategies/plans, training of health care personnel and resource set with continuous 
funding  
o Timeline: Now 
• Mandatory training of oncology and palliative care specialist in patient-centred care including 
patient-centred communication  
o How to do: Refine (and further develop) methods for training to be supplemented by 
international and national accreditations   
o Timeline: 1-2 years 
 
Models of Palliative Care Integration  
Questions to be addressed 
What current models exist to describe how palliative care can be 
successfully and comprehensively integrated into oncology care? 
Which model is best placed to reach patients across all areas of the 
cancer care trajectory (community, outpatient and inpatient settings)? 
What is the role of the primary care/community team in the delivery of 
palliative care for patients with advanced cancer (Primary Palliative 
Care)? 
What is the role of the oncology team in the delivery of palliative care 
(Secondary Palliative Care)? 
How can we best utilize the skillset of specialist palliative care teams for 
patients with advanced cancer (Tertiary Palliative Care)? 
How can we optimize communication and standardise transitions 
between Primary, Secondary and Tertiary palliative care services? 
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Introduction  
The overall aim of integration of health care services is to coordinate care among providers and 
across settings, so that patients and their families have access to the care that they need when they 
need it, resulting in improved health outcomes.43 Thus a key question is: how should integration or 
collaboration occur between the two disciplines, oncology and palliative care? Internationally, a 
series of different organizational models have been developed, some of which have been tested in 
clinical studies. Although the content, structure (internally as well as externally) and professional 
competence within these models varies considerably, there are also important common themes. The 
aim of this panel is to present and discuss models of care and propose future organizational models.  
Over the last decade, several studies and models of care have addressed how palliative care can be 
moved from a focus exclusively on end-of-life, to a focus on early integration within the cancer care 
trajectory. As previously highlighted early integration of palliative care has been shown to improve 
quality of life, satisfaction with care, symptom control, mood, and illness understanding.3,5,49-53 As a 
result, early palliative care is now widely endorsed by a number of influential international 
organisations as the standard practice of care for patients with advanced, incurable illness.16,88,442 The 
question is no longer whether and why integration of palliative care is worthwhile, but how this can 
best be accomplished to optimize the goal of better patient-centred care.  
Although integration is important for all aspects of health care, it is of particular importance for 
patients with advanced cancer, who have complex problems that are best managed by MDT.443 
Within the hospital setting, MDTs can span a variety of providers including physicians (such as 
surgeons, pathologists, radiologists, medical and radiation oncologists and palliative care physicians) 
as well as other healthcare providers (including pharmacists, social workers, occupational and 
physical therapists, spiritual care providers, music and art therapists). In addition, over the last few 
decades, cancer care is increasingly delivered in outpatient rather than inpatient settings.444 For this 
reason, it is increasingly recognized that primary care, including GPs and community nurses, has an 
important role to play in cancer control, and that communication between MDT providers across all 
settings and disciplines is necessary to improve patient care.445 The MDT approach should ideally link 
oncology and palliative care services in the hospitals and also involve and communicate with primary 
health care providers as needed. Consideration of how to optimally plan and collaborate between 
oncology and palliative care services should form an essential component of patient-centred care.  
 
Models of integration – the broad picture 
Existing models of palliative care integration into oncology care can be broadly classified as 
conceptual or empirical. Conceptual models outline broad theoretical principles, while empirical 
models depict how these can be put into action in specific settings.  
 
The conceptual models can be classified broadly into time-based, provider-based, and setting-based 
models.151,446 The most well-known conceptual model of palliative care integration is time-based. 
This model contrasts the traditional provision of palliative care only at the end of life with a 
contemporary model where palliative care is introduced at diagnosis, and gradually increases over 
time until the time of death and bereavement (Figure 1a and 1b)). Non-integrated care, where care is 
“handed over” to palliative care teams when the patient’s disease no longer responds to tumour-
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directed treatment, is counterpoised with integrated care, where palliative care teams provide 
advice throughout the course of the illness. Other conceptual models are provider-based. These 
classify palliative care conceptually as primary/secondary,447 or primary/secondary/tertiary,448 based 
on level of complexity, and propose the involvement of different care providers at each level (Figure 
3). While tertiary palliative care is consistently depicted as being provided by specialized palliative 
care physicians, there are variations in the classification of primary and secondary palliative care. 
Primary palliative care is provided by family physicians in some models 449 and oncologists in others 
447. Similarly, some models specify that SPC is provided by oncologists 450 and others classifying SPC as 
care provided by palliative care specialists in non-tertiary settings.449 These models emphasize 
differential competence of providers in palliative care, with increasing levels of competence required 
to deal with more complex issues. 
 
 
Figure 3: Conceptual model of palliative care delivery based on provider expertise  
 
The third conceptual model of palliative care integration is setting-based, where delivery of care is 
based upon the setting where care is provided. The main setting for care in these models is ideally 
proposed to be in the community, with palliative care being provided primarily in the patient’s home, 
rather than in the hospital (Figure 4).446 This community-based care may be provided either by the 
patient’s family physician, with support from a palliative care team,446 or by a specialist, community-
based palliative care team.451 There is an emphasis on facilitating smooth transitions in care between 
inpatient, outpatient, home and community hospice settings. 
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Figure 4: Conceptual model of community-based palliative care provision. Kamal AH, et al. 446 
 
These conceptual models identify important factors related to organization, professional 
competence and timing as a part of the care pathway, which should be considered when describing 
and defining integrated oncology and palliative care across all settings. However, none of the existing 
models specifically describe the detailed mechanics of how patients move among primary and 
specialized levels of care or among care settings and how communication occurs among providers. 
Furthermore, none of these models outlines how care is provided within the organizational 
structures of the oncology health care system. Full integration requires defined processes such as 
clinical care pathways, referral guidelines or pooled resources, to provide truly integrated care.43 
The remainder of this section will focus in greater detail on a provider-based conceptual model of 
primary (PPC), secondary (SPC) and tertiary palliative care (TPC) provision, delivered by generalists, 
oncology teams, and specialized palliative care teams, respectively (Figure 5).  
This model crosses settings and is not time-specific, but emphasises the need for oncology and 
palliative care to be fully integrated across all settings and levels. Through the use of standardized 
care pathways and referral guidelines, it is more likely that patients can access the right care is 
provided at the right place at the right time. It is grounded in the concept that the majority of 
palliative care can, when the treatment goals are cure or life prolongation, be provided by 
oncologists with basic competence in palliative care. Palliative care specialists should provide 
consultation for complex problems.8  Within this larger model, we review some examples of empirical 
models of palliative care within each level of care. 
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Figure 5: Proposed model of optimal oncology palliative care provision based on integration across 
providers and settings  
Primary Palliative Care: community-based care provided by GPs  
Secondary Palliative Care: more complex care provided by oncologists 
Tertiary Palliative Care: complex care provided by multidisciplinary specialist palliative care teams 
 
 
 
Primary, secondary and tertiary palliative care integration 
Primary palliative care 
Primary palliative care (PPC) has been defined as the core skills and competencies that all clinicians 
should feel comfortable providing to patients with advanced cancer and their families. These include 
basic assessment and management of physical, psychological, social, spiritual and practical problems; 
communication related to prognosis and advance care planning; appropriate referral to available 
community-based supports; and bereavement care for the family.8 While primary palliative care can 
occur at any clinical setting, it is best provided in the community, both in outpatient settings for 
those patients well enough to attend appointments, and in the home setting. Home-based care is 
particularly important in this context, as it prevents unnecessary visits to the emergency department 
and hospital admissions, and enables a home death.452  
 
PPC is best provided by multidisciplinary teams that may include general practitioners, home care 
nurses, personal support workers, and case managers.453 Whilst PPC in some countries is delivered by 
palliative care or hospice specialists, family physicians and general practitioners are well-placed to 
provide PPC. Their therapeutic relationship with their patients and families may span many years, 
giving them a unique perspective into their patients’ values and priorities, potentially including 
preferences for end-of-life care and advance care planning.454 Since a large proportion of cancer 
patients have uncontrolled symptoms from the time of diagnosis,455 it is imperative that family 
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physicians are sufficiently competent to embark on an initial symptom management plan. As cancer 
progresses, patients often express a preference to receive care at home and to die at home, if 
possible,456 which may be facilitated by PPC providers.457 In addition, these physicians support 
families during bereavement, offering excellent continuity of care that is highly valued by patients 
and their families.458 There is wide variability internationally in the engagement of family physicians 
and general practitioners in palliative care from less than 50% in some countries such as Canada and 
Japan,459,460 to up to 85% in the United Kingdom, the Netherlands and Australia.461-463  
 
The literature around the integration of PPC into oncology is limited.  As cancer care becomes more 
specialised, many family physicians lose contact with their patients for the duration of their cancer 
treatment; this is often compounded by poor communication between cancer specialists and family 
physicians, making it challenging for family physicians to re-engage with patients at the end-of-life, or 
to recognise when patients are entering the final stages of their illness.445,464,465 Other barriers to the 
provision of PPC include time constraints,174,466,467 insufficient reimbursement,467 and limited 
palliative care training or expertise.63,468 Out-of-hours support for community-based patients can be 
particularly challenging.469 Home-based palliative care is often seen as labour-intensive, poorly 
remunerated and difficult to coordinate, especially outside of regular office hours, or when family 
physician offices are far from their patients’ homes.445,454,461 
 
Multiple initiatives have enabled the provision of PPC, both among family physicians and in 
collaboration with SPC and TPC providers. In some European countries (such as Ireland, the 
Netherlands, UK and Denmark), out-of-hours cooperatives have been set up to lessen the burden on 
individual family physicians to provide round-the-clock care for their patients;469,470 these are 
generally well-received by patients and practitioners alike.471 Educational initiatives around the core 
skills of PPC at the medical student and postgraduate learner level are vital, as are Continuing 
Medical Education programs, as discussed in Education panel. The development of collaborative 
partnerships between primary and tertiary palliative care providers is recognised as a vital 
component of promoting and supporting PPC, as further discussed below.454   
In the Netherlands, the general practitioner (GP) and home care nurse are the main providers for 
community-dwelling patients with cancer and palliative care needs. Nurse case managers have 
recently been introduced in some areas. To ensure continuity of care, the case manager collaborates 
with the patient, their informal carers, and the medical professionals involved in the care of the 
patient (GP, oncologist). The case manager provides advice to patients and their informal carers and 
refers them to other care providers as necessary. As well, the case manager may offer palliative care 
advice to other healthcare providers, including the GP and the home care nurse.472  
 
Secondary palliative care  
Secondary palliative care (SPC) refers to the care provided by the oncology team in the specialist 
health care system to both inpatients and outpatients. Because oncology teams are based for the 
most part in hospitals and cancer centres, these are the main settings for secondary palliative care. 
Cancer care itself is multidisciplinary, and involves medical specialists from medical, radiation and 
surgical oncology, as well as specialized nurses, social workers, psychologists, psychiatrists, dieticians, 
physiotherapists and occupational therapists, among others.473 All of these require core clinical 
competencies in palliative care, as described below. 
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Important strides have been made in promoting SPC as a part of oncology care programs. ASCO has 
formally endorsed early palliative care 16 and has published a number of clinical guidelines for 
palliative care in oncology.8,474 Several other international bodies have made efforts to formalise the 
role of oncologists in providing SPC. Among these, a partnership between ASCO and the American 
Academy of Hospice and Palliative Medicine (AAHPM) has produced a consensus statement using a 
Delphi process on high-quality palliative care delivery in US medical oncology practices 475 (Table 8). 
In this statement, they recommend that oncologists should provide regular systematic symptom 
assessment at least monthly, as well as conducting a basic assessment of psychosocial wellbeing and 
of faith group, and assessing caregivers for distress if they accompany patients to the 
appointment.475 SPC also includes assessment of prognostic understanding and communication of 
prognosis to the patient and primary care provider. Patients with complex or uncontrolled symptoms 
should be referred to TPC services as available.475  
Palliative Care 
Domain 
Endorsed elements of secondary palliative care in oncology practices 
Symptom 
Assessment/ 
Management 
• Monthly symptom assessment using a validated quantitative instrument  
• Educate patients about the cause and management of existing symptoms 
• Instruct patients how and when to contact the clinic during and after hours 
for new or worsening/poorly controlled symptoms 
• Assess the effectiveness of adjusted medication by the next clinical 
encounter  
Psychosocial 
Assessment/ 
Management 
• Conduct an initial, basic psychosocial assessment 
• Assess distress with a validated quantitative instrument initially and after any 
clinical change (e.g. cancer progression) 
• Manage distress at a basic level with supportive, empathetic statements and 
validation of the patient’s experience. Otherwise, patients should be referred  
Spiritual and Cultural 
Assessment/ 
Management 
• Document patient’s faith  
• Provide patients with a framework to consider their goals and hopes along 
with the likely medical outcome(s) of their illnesses and support those goals 
• Assess and document preferences for communication and language  
• Provide translation services  
Communication and 
Shared Decision 
Making 
• Assess patients and families for preferences regarding (1) how they want to 
receive information regarding the patient’s cancer, prognosis, treatment 
risks/benefits, treatment plan, and bad news; and (2) who participates in the 
decision making and to what extent  
• Provide oral and written documentation of the treatment plan to the patient 
and family with specific details regarding expectations for (1) disease control, 
(2) effects on symptoms and quality of life, (3) length and frequency of 
treatment, and (4) the frequency of and rationale for disease reassessment.  
• Assess the patient’s and family’s understanding of the patient’s illness, 
prognosis, and goals of care at diagnosis, disease progression, and with 
changes in the treatment plan 
• Openly acknowledge and address mistakes as soon as they are noticed  
Advance Care 
Planning 
• Begin advance care planning at the diagnosis of advanced cancer, starting 
with assessing the patient’s and family’s readiness to discuss advance care 
planning and any concerns they might have 
• Code status, living wills, advanced directives, health care surrogate, and out 
of hospital “do not resuscitate” orders should be discussed, completed and 
documented as soon as possible 
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Coordination and 
Continuity of Care 
• Coordinate care with primary care, hospice, hospital, and nursing home 
Appropriate Palliative 
Care and Hospice 
Referral 
• Describe the difference between hospice and palliative care to patients and 
families as soon as possible after an advanced cancer diagnosis 
• Conduct routine patient assessments to determine need for palliative care or 
hospice referral 
• Refer patients with a prognosis of 3 months or less and/or an Eastern 
Cooperative Oncology Group performance status of 3-4 to hospice 
• Collaboratively agree upon referrals with the patient/family  
Carer Support • Obtain permission to speak with primary caregiver(s) and to include them in 
conversations about the patient’s care 
• Assess caregivers attending clinic visits with patients for distress at least once 
• Inform caregivers how to contact the clinic in routine and emergency 
situations 
• Provide information about local and online caregiver resources 
• Provide bereavement follow-up in the form of a phone call and/or 
condolence card and information regarding local bereavement resources 
End-of-Life Care • Have processes to evaluate patient symptoms, advise medication changes to 
patients and family, and provide on-call coverage 24 hours per day, 7 days 
per week  
Table 8. Essential elements of secondary palliative care. Adapted from Bickel et al 475 
Despite these guidelines, oncologists continue to vary in their perceptions of their role in providing 
SPC. Some provide no palliative care and refer all patients to tertiary services; others see themselves 
as solo providers of simultaneous oncology and palliative care, and do not refer to TPC; still others 
refer to tertiary services only in complex clinical situations.174 At the SPC level, patients may associate 
cancer treatment directly with hope, and a singular interest in pursuing active anticancer treatments 
can impact on the delivery of appropriate palliative care.179  An additional complicating factor may be 
that some patients prefer to receive more positive messages from their oncologist regarding their 
cancer, linking this with a greater compassion on the part of the physician.476 
In an effort to improve integration and promote both secondary and tertiary palliative care provision, 
ESMO has developed designated centres of integrated oncology and palliative care based on 13 
rigorous criteria across clinical, research and educational domains.88 A recent survey of all active 
ESMO designated centres identified high levels of routine symptom screening and goals of care 
discussions among oncologists, although less attention was paid to advance care planning and end-
of-life discussions, which were more likely to be addressed by the palliative care services.159  
Tertiary palliative care 
Tertiary palliative care (TPC) is provided by physicians and other multidisciplinary team members 
with specialist palliative care training. These teams may include specialized palliative care physicians, 
nurses, social workers, spiritual care providers, occupational and physical therapists, and 
pharmacists, among others. Clinical guidelines recommend that inpatients and outpatients with 
advanced cancer and/or high symptom burden should receive dedicated palliative care services early 
in the disease course concurrent with cancer treatment.16 However, with shortages of TPC specialists 
worldwide, it is more practicable to limit the provision of TPC to the subset of patients whose care 
needs are the most complex and are not adequately met by primary or secondary level providers. It 
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is therefore important to have mechanisms of determining which patients would benefit most from 
consultation by TPC services.477  
 
TPC should be available to all patients with cancer, regardless of prognosis, and available to PPC and 
SPC providers on a consultant basis in all settings, including for inpatients, outpatients, and in the 
community. Where resources are limited, palliative care services provide care mainly as consultation 
services for inpatients.122 Acute palliative care units for the specialized management of complex 
symptoms and psychosocial concerns are limited to a minority of tertiary care hospitals and 
hospices.443 In the community, longer term palliative care units, hospices and palliative care home 
consultation services provide valuable support to patients at the end of life. More recently, it has 
been recognized that full integration, especially for patients at earlier stages of their illness, is only 
possible through an outpatient palliative care program.174,444,478 Development or expansion of TPC 
services should consider the unique needs, philosophy and culture of the broader institution, with 
input sought from key stakeholders across clinical and managerial levels.479 
How to integrate tertiary palliative care? 
Availability of TPC for outpatients is of paramount importance for integration into standard oncology 
care, as most of oncology care, including for patients with advanced disease, occurs on an outpatient 
basis. Several models of outpatient TPC care have been proposed, including mobile teams, 
freestanding palliative care clinics, and embedded clinics.480,481 A mobile team, where outpatient 
palliative care consultations in oncology clinics are performed by the inpatient consultation service 
on a same-day bases, is feasible if there are few consultations. However, outpatient palliative care 
clinics are more efficient on a larger scale, and allow patients to be seen by a number of 
multidisciplinary team members working together in the clinic.478,482,483 The most robust evidence for 
early palliative care is for palliative care clinic interventions, and has shown that these clinics improve 
quality of life, symptom control and mood.3,5,64 Embedded clinics offer opportunities for oncologists 
and palliative care clinicians to collaborate and coordinate care, and allow rapid access to palliative 
care teams. However, there are also challenges with this model, including finding adequate clinic 
space, fatigue on the part of patients with longer clinic visits, and involvement of only one discipline 
– usually a single physician or nurse.151  
 
Several models of integrated TPC programs have been described. In 1995, the palliative care program 
in Edmonton, Canada, was one of the first to report their practice, which consisted of an inpatient 
palliative care unit housed within an acute hospital setting, as well as a consultation service and an 
outpatient clinic. From the outset, a strong emphasis was placed on the use of standardised 
assessment tools, wide-ranging education and research initiatives, and close integration with family 
physicians to enhance PPC provision.484,485 These elements of care were similarly emphasized in 
subsequent reports of successful TPC programs in Lausanne,486 Milan,487 Cleveland,488 Houston,489 
Trondheim,49 and Toronto,490 with the latter two also publishing successful randomized controlled 
trials illustrating the effectiveness of this model of care.5,49 The model of palliative care at Princess 
Margaret Cancer Centre serves as one empirical example and is described in Figure 6. 
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Figure 6: Tertiary palliative care based on referral to a palliative care clinic 
Hannon B et al. 478 Referrals are made by the patient’s oncologist. Care is integrated and 
collaborative across acute and community care settings. Ultimately, care is transferred to home, 
hospice or a palliative care unit. 
 
Barriers to integration of tertiary palliative care 
Several areas are identified consistently within the literature as barriers to fully integrated oncology 
and palliative care services, across system, organisational, and clinical levels. Lack of institutional 
recognition of the value of TPC services has limited the development of new services. Palliative care 
services are infrequently afforded the same priority as other areas of cancer detection and treatment 
at executive or managerial levels. A new initiative from the Union for International Cancer Control 
aims to address this issue, identifying palliative and supportive care as one of the four essential 
pillars of cancer treatment and care (along with cancer data for public health, early detection and 
diagnosis, and timely and accurate treatment).491 ESMO designated centres also strive to boost the 
status of integrating high quality palliative care services within oncology.492 
 
Closely connected to this is the problem of adequate funding to support integration. Although 
oncology leadership tends to agree that integration is beneficial, funding to support program 
expansion often lags behind. A survey of members of the Multinational Association of Supportive 
Care in Cancer, the European Assocation  of Palliative Care, and ESMO found that only 17% of 
respondents felt their institution was likely to increase palliative care funding; 49% felt it was unlikely 
their institution would increase inpatient palliative care beds; and respondents were neutral 
regarding future palliative care team hiring plans.443 Despite several studies demonstrating the cost-
effectiveness of palliative care teams,158 this does not seem to factor into budgetary considerations 
at the oncology level.  
 
71 
 
Lack of trained medical and nursing personnel and poor reimbursement for palliative care physicians 
have also been cited as barriers to the access and development of TPC, even within cancer centres 
and ESMO designated centres of integrated oncology and palliative care.443 At the individual 
oncologist level, there remains significant heterogeneity in referral practices to TPC teams due to 
factors ranging from personal opinions to structural issues. For example, for some oncologists 
practicing secondary palliative care, especially in community practice, the additional reimbursement 
afforded by this may limit their willingness to fully integrate with palliative care teams or refer to TPC 
services.443 In an effort to standardise referral practices, the use of specific criteria to trigger 
automatic referral to palliative care teams alongside concurrent oncology care have recently been 
proposed; the success of these criteria has yet to be explored.151,493 
 
Ongoing stigma and misconceptions about the term palliative care are frequently quoted as barriers 
to integrated services.494 Because of its historical association with end-of-life care and medical 
futility, the name itself is often cited by oncologists and patients as an obstacle to early referral 167 
(see Societal Challenges). In one centre, the outpatient palliative care service has been renamed 
“supportive care”, which has been associated with earlier referrals.495   
 
Human resources & clinical competencies 
In order to deliver high-quality, integrated palliative care, an inter-disciplinary approach is required. 
The competence of PC needs to be placed into context in the cancer plans, such as participating as 
active and integrated partners of the MDTs.  As mentioned previously, this includes not only 
physicians and nurses but also social workers, spiritual care providers, physiotherapists, occupational 
therapists, psychologists, psychiatrists, and pharmacists, amongst others. Inclusion of these can be 
provided by the PC specialist physician based upon the needs addressed in the MDTs. Access to and 
close links with community-based nursing and allied healthcare providers is also essential to ensure 
seamless transitions between care settings.  
In terms of clinical competencies, PPC providers should have core skills in assessing and managing 
physical and psychological symptoms, as well as knowledge to use SDM in daily clinical practice 
which also includes ACP for patients with short life expectancy and planning, coordinating and 
providing end-of-life care in patients’ homes when feasible.  
Core teaching on pain and symptom management as well as end-of-life care has been recommended 
for medical students in the UK and the US;496,497 initiatives such as the Canadian LEAP program 
Learning Essential Approaches to Palliative and End-of-Life Care) 498 provide multidisciplinary PPC 
training for all healthcare providers (see Education).  
For SPC, wide variations exist in terms of the training and competencies of individual oncologists, 
often based on the clinical setting within which they work. Many physicians working within 
designated centres of integrated oncology and palliative care are dual-certified in both oncology and 
palliative care (65% in a recent study).159 These centres were also more likely to have access to a 
broad range of multidisciplinary clinicians.159 Mandatory rotations in palliative care and modules in 
symptom management, communication skills and up-dated skills in SDM and ACP have been 
recommended to improve SPC competencies. At minimum, competencies should include basic 
assessment of pain and other symptoms; assessment of psychosocial, spiritual and cultural needs for 
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the patient and family; appropriate goal-based communication; skills in using SDM/ACP; and 
coordination of end of life care (See Education).  
TPC services should be led by clinicians with specialist palliative care training and certification where 
available. As of today most countries with such a certification have organized it as a dual 
certification. For cancer centres that mean specialist certification in both oncology and palliative 
medicine (see Education). As consultants, these clinicians should have appropriate training in the 
management of complex symptoms and problems throughout the disease course and bereavement. 
Palliative Care is now recognised as a medical specialty or subspecialty across 18 European countries 
as well as the USA, Canada and Australia 499 (Also see Education.) 
 
Care Transitions and Collaboration: moving among levels of care 
A number of common facilitators to successful integration across primary, secondary and tertiary 
palliative care have emerged. These include structures and tools for transitions between levels of 
care as well as for collaboration among disciplines. Although there may be some overlap of roles, 
clarity and clear division of each team’s respective responsibilities is necessary to ensure a consistent 
message for patients.174,500,501 
  
Referral guidelines or other types of predefined structures such as PC incorporated in detail in the 
SCP can clarify which patients and when they are likely to benefit from referral to TPC services. In a 
recent study using a Delphi process, international palliative care experts reached consensus on 11 
major criteria for outpatient palliative care referral in cancer centres, based on stage of disease, 
prognosis, and clinical problems. These criteria can also be used as guides when detailed SCPs are 
developed in oncology. These criteria were categorized into needs-based and time-based criteria 
(Table 9).477  As well, consensus was reached that referral should be based on both automatic referral 
and clinician-based referral, with only 7% agreeing that referral should be based on automatic 
referral alone.502 
 
Needs-based criteria 
• Severe physical symptoms (e.g., pain, dyspnoea or nausea scored 7–10 on a 
ten-point scale) 
• Severe emotional symptoms (e.g., depression or anxiety scored 7–10 on a 
ten-point scale) 
• Request for hastened death 
• Spiritual or existential crisis 
• Assistance with decision making or care planning 
• Patient request 
• Delirium 
• Brain or leptomeningeal metastases 
• Spinal cord or cauda equina compression 
 
Time-based Criteria 
• Within 3 months of diagnosis of advanced or incurable cancer for patients 
with median survival of 1 year or less 
• Diagnosis of advanced cancer with progressive disease despite second-line 
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systemic therapy (incurable) 
Table 9. Needs based and time-based criteria for referral to tertiary palliative care. Adapted from 
Hui et al.477 
SCPs have been suggested as a potential means of recognising transition points in care, and of 
ensuring high-quality care regardless of the clinical setting. For example in Canada, Cancer Care 
Ontario has developed collaborative care plans based on Palliative Performance Status (PPS) for 
“stable” (PPS 70-100), “transitional” (PPS 40-60) and “end-of-life” (PPS 0-30) stages. Lessons learned 
from the use of SCPs in end-of-life settings indicate that these pathways should be detailed while 
also flexible in addressing individual needs; should not be a substitute for empathic care of the 
patient; and need to be coupled with ACP, comprehensive education and training in palliative 
care.503,504 Further research is needed to assess their effectiveness in earlier stages of disease.190,505  
The development of strong, collaborative relationships among primary, secondary and tertiary 
providers are essential for truly integrated care. Among PPC and TPC providers, these may include 
mentorship and advisory programs facilitating ready access to TPC teams, including out-of-hours 
support; inviting PPC providers to engage in discharge planning discussions or family meetings for 
shared patients prior to home discharge; and maintaining excellent communication between 
community- and hospital-based teams through shared electronic records. These partnerships may 
help to improve family physicians’ confidence in providing PPC and in recognising transitions in 
care.454 
Collaboration between SPC and TPC providers in cancer centres should be a part of the MDTs and/or 
be encouraged by joint rounds and tumour boards, as well as by combined palliative care and 
oncology educational activities for trainees.48  Sharing support staff (such as allied health 
professionals or nursing staff) can act as a bridge between services.174,501 Joint patient consultations, 
proximity of palliative care clinics to oncology clinics (or palliative care clinics embedded into 
oncology clinics), and the involvement of palliative care teams in tumour boards or cancer committee 
meetings may be superior to communication via email or phone.174,500 In addition to the clinical 
advantages offered by such collaborative models, there are also potential financial advantages 
associated with pooling resources, especially in the early stages of palliative care program 
development.  
Collaboration can also be facilitated by technology and clinical tools. Symptom screening has been 
established as a standard of care in all cancer centres in Ontario, Canada,506 is proven to be effective 
in routine oncology practice 76,507 as well as in pilot projects in primary care practices.508 This can 
serve to encourage systematic assessment and management of symptoms by oncologists, and trigger 
timely referral to TPC programs. Joint electronic patient records or mutual access to patient records, 
among all levels of care providers can improve information transfer among care providers in the 
hospital and in the community.509 Telehealth is also being explored as an intervention to improve 
communication in palliative care, particularly for those living in rural regions.510 
 
Conclusion 
We have presented conceptual models of palliative care integration as well as principles, 
competencies and resources necessary to achieve integration in various settings. There is no single l 
model of palliative care integration that is tested in clinical studies or used in any health care system. 
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This heterogeneity can indicate that palliative care integrated in oncology is in its infancy. It is an 
urgent need to, based upon the high quality studies to agree upon models that fit the different 
health care systems in high and middle income countries . The overall goals are that these novel 
organizational models will meet the needs of all patients in all settings and circumstances. However, 
a successful model of integration needs to incorporate primary, secondary and tertiary providers, 
span settings (inpatient, outpatient, community), and specify how movement between these levels 
occurs in a systematic fashion. Although there is now sound evidence for early TPC involvement for 
patients with advanced cancer, evidence is lacking for models of PPC and SPC provision, as well as for 
care pathways bridging levels of palliative care. Research in these areas should be prioritised. 
 
Recommendations  
• Establish integrated specialized palliative care/oncology services at cancer centers according to 
figure 5 
o How to do: Develop integrated models, train personnel, make palliative care mandatory at 
the MDT, and give economic incentives 
o Timeline:  1-2 years 
•  Establish multidisciplinary community teams for early integration 
o How to do: Develop models for community teams and evaluate the models in research 
projects 
o Timeline: 2-5 years  
• Community and hospital based services must be integrated.  
o How to do: Establish formal contracts on integration and payment plans (resource setting) 
o Timeline: 1-2 years 
• Basic early palliative care must be embedded into the oncology programs  
o How to do: Palliative Care must be a mandatory part of oncology training. Revise national 
content of oncology training programs and give international recommendations  
o Timeline: Now  
 
 
The role of education: challenges and recommendations 
Questions to be addressed 
What are the main international educational strategies that can promote integration of 
oncology and palliative care?  
What should the curricula include to promote integration of oncology and palliative care? 
What are the educational barriers and facilitators for integration of oncology and 
palliative care? 
How can educational activities be further developed to promote the integration of 
oncology and palliative care?  
75 
 
 
Introduction 
Several of the previous panels have pointed to education of health care providers as a key factor for 
promoting integration of oncology and palliative care both on the clinical and the organizational 
levels. This is in line with recommendations from authors, stakeholders and bodies.45,511,512 There is at 
present an unmet need for basic and specialist competence in palliative care at all levels of health 
care; tertiary, secondary and primary, which calls for increased educational efforts.  
Integration of oncology and palliative care requires close collaboration and exchange of information 
between primary, secondary, and tertiary palliative care providers (see Models). The tertiary 
palliative care (TPC) specialists are often located in comprehensive cancer centres and/or university 
hospitals, and are commonly also engaged in academic activities as research and education. The 
skillset of TPC specialists is essential to support primary and secondary providers. These premises 
expand the responsibilities of TPC beyond the cancer centre setting through education and 
mentorship programs aiming to upskill primary and secondary health care providers. 
The heterogeneity of the organizational models described in Models does not allow for drawing 
conclusions on what kind of competence and skills that best promote integration. Further, we were 
not able to identify reports, policy statements or articles at an international level specifically 
addressing how education programs can promote integration of oncology and palliative care or what 
they should include except for general statements about palliative care.  
In this panel we therefore describe available international educational strategies and 
recommendations in palliative care, contents of oncology and palliative care curricula, educational 
barriers and facilitators. We also discuss how education can promote integrational models. Medical 
education from undergraduate to post-graduate levels is the primary focus being aware of the fact 
that palliative care shall be delivered by multidisciplinary teams including health care providers with 
qualifications in other disciplines than medicine. Still, expanding the panel to education for all the 
other important health care providers in the multidisciplinary team would definitely exceed the limits 
for this panel. With a focus on medical education, principles and content is also considered of value 
for education of other health care providers as well. 
This panel is based upon available information regarding palliative care education (specialization and 
post-graduation programs) such as the EAPC Atlas of Palliative Care in Europe,499 EAPC Atlas of 
Palliative Care in Latin America 513 and the website Global Directory of Education in Palliative Care of 
The International Association for Hospice and Palliative Care.514 Further information was gathered 
from medical societies’ papers, websites supplemented by a systematic review of literature using the 
MESH terms palliative or palliation, oncology or cancer, education and the words integration or 
integrative in the title/abstract. The search yielded 23 articles considered of relevance for this panel. 
Of those, 12 were informative articles 
(consensus/panels/indicators/recommendations/discussion/debate/state-of-art) regarding 
integration of palliative care and oncology), four were descriptions/evaluations of multidisciplinary 
curriculum/specialist education, four presented professional perspectives/opinions, two surveys 
focused on guidelines and service management, and one was a systematic review about early 
integration. 
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Educational strategies  
International agencies and professional associations have developed and promoted policies and 
projects including educational strategies and recommendations to improve palliative cancer care. 
WHO has recognized that national actions are necessary to strengthen palliative care education and 
that it includes “ensuring that education about palliative care (including ethical aspects) is offered to 
students in undergraduate medical and nursing schools and health care providers at all levels, in 
accordance with their roles and responsibilities and as part of human resource development. 2  
The European Association for Palliative Care (EAPC) 96 has launched a recommendation of three 
levels of palliative care education that can serve as a basis for integration,515,516 (see Table 10). 
 
Table 10. Three levels of palliative care education*PC=palliative care 
Another example of an integrative approach is originating from the European Society for Medical 
Oncology (ESMO), which has developed designated centres of integrated oncology and palliative care 
based on rigorous criteria across clinical, research and educational domains promoting both 
secondary and tertiary palliative care provision. To date, close to 200 centres from 41 countries have 
achieved this designation.517 
Accreditation of palliative medicine 
In general, certification in palliative medicine falls into three categories, depending on the post-
graduate educational system of the different countries: specialty, subspecialty and general 
competence in the field. All three categories require a basic medical degree; however, subspecialty in 
palliative medicine also requires a clinical specialty degree in another medical area. Certificate of 
competence refers to formal educational courses in the field of palliative medicine approved by 
national health authorities and medical societies, but not necessarily a recognized new specialty in 
some countries.499 The supplement of the EAPC Atlas of Palliative Care in Europe collected 
information on education and certification in palliative care from 18 European countries, Australia, 
Canada and the United States.499 As expected, variations were demonstrated in type of certificates, 
demand for clinical practice, theoretical content and length and whether research was a mandatory 
component (Table 11).  
The integration of palliative care into oncology may be highly dependent on the level of 
accreditation. Thus, the different models of integration generally originate from countries with some 
kind of accreditation of palliative medicine and availability of TPC. Palliative medicine achieved 
specialty/subspecialty status in the UK in 1987, USA in 2006, and Canada in 2016.518,519 Palliative 
medicine has also been established as a specialty in multiple countries in the Asia-Pacific region, 
including Australia, New Zealand, China, Japan, Taiwan, Malaysia, Singapore and India.520 Other 
• PC* approach at a basic level (level A; undergraduate and postgraduate) 
➢ integrate PC methods and procedures in general care, for all health care professionals 
• General palliative care at an advanced level (level B; postgraduate) 
➢ for professionals involved with PC, but not as their main occupation; e.g. oncologists 
• Specialist PC (level C; postgraduate) 
➢ for professionals working solely in PC whose main activity is complex problems requiring 
specialized skills and competencies 
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countries in Europe, Asia, Latin America and Africa are actively working toward some kind of 
accreditation. In some countries, such as the UK, Ireland, New Zealand and Australia, palliative care is 
a full medical specialty requiring a minimum of three to four years of postgraduate training to 
achieve certification. In other countries; e.g. Canada, the United States, France and Germany, 
palliative care is organized as a medical subspecialty.521,522 Other educational programs are directed 
towards medical specialists associated with some kind of accreditation, which include the Japanese 
Palliative Care Emphasis Program on Symptom Management and Assessment for Continuous Medical 
Education (PEACE) 523,524 and The Nordic Specialist Course in Palliative Medicine.525 The latter is a 
joint venture between the Associations for Palliative Medicine in the Nordic countries (Denmark, 
Sweden, Norway, Finland and Iceland) and has resulted in a theoretical specialist training course in 
six modules over two years combined with a clinical stay at a specialized palliative care unit. 
However, in Finland palliative medicine has recently become a speciality and in Sweden a 
subspecialty. Denmark and Norway may also be moving towards higher levels of accreditation.499  
 
The heterogeneity in specialty status with a lack of clearly defined competencies for palliative care 
physicians is probably associated with variability in the content and quality of care delivered and 
represents a challenge for the advancement of clinical palliative care. Further, as it can be depicted 
from Table 11 - especially looking at clinical practice and theoretical training - the classification and 
definitions of a speciality and a sub-speciality differ considerably between countries. A substantial 
proportion of those attending the programs are oncologists who have been recruited for the 
subspecialty model for palliative medicine, which may enhance integration.  
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Country Accreditation Denomination in English Clinical 
practice in 
years 
Theoretical 
training 
Research 
Australia/New 
Zealand 
Specialty Palliative Medicine (medical specialty) 3 NS 1-3 projects 
Canada Subspecialty Subspecialty of Palliative Medicine 2 350 hours 1 project 
Czech Republic Subspecialty Palliative Medicine 1 12 months NS 
Denmark Special 
denomination 
Competence in the field of Palliative Medicine 2 6 weeks 1 project 
Finland Special 
denomination 
Special Competence in Palliative Medicine 2 150-270h 1 project 
France Special 
denomination 
Diploma of Complementary Specialised 
Studies in Pain Medicine and Palliative 
Medicine 
2 170 hours 1 project 
Georgia Subspecialty Palliative Care and Pain Medicine 0·5 75 hours NS 
Germany Subspecialty Palliative Medicine 1 40 hours Not required 
Hungary Subspecialty Subspecialty in Palliative Medicine 1 80 hours NS 
Ireland Specialty Certificate of Completion of Training as 
Specialist in Palliative Medicine 
4 Varying between 
the different 
universities 
Not required 
Israel Subspecialty Palliative Medicine Sub-Specialty 2 NS NS 
Italy Special 
denomination 
Master’s Programme in Palliative Care for 
Specialist Physicians 
0·5 1500 hours 1 project 
Latvia Special 
denomination 
Special Competence in Palliative Care 2 400 hours 80 hours 
Malta Specialty Palliative Medicine Most of 
the 
training 
acquired 
Most of the 
training acquired 
abroad 
Not required 
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abroad  
Norway Special 
denomination 
The Formal Competence Field of Palliative 
Medicine 
2 180 hours  1 project 
Poland Specialty Specialisation Program in Palliative Medicine 
for Physicians 
2 NS 1 project 
Portugal Special 
denomination 
Palliative Medicine Competence 1 400 hours 3 project 
Romania Subspecialty Diploma of Complementary Studies in 
Palliative Care 
0·25 2 months NS 
Slovakia Special 
denomination 
Specialisation Study in the Field of Palliative 
Medicine 
0·5 NS NS 
Sweden Subspecialty Subspecialty in Palliative Medicine 2·5 120 hours Not required 
United 
Kingdom 
Specialty Certificate of Completion of Training as 
Specialist in Palliative Medicine 
4 Varying between 
the different 
universities 
Not required 
United States Subspecialty Hospice and Palliative Medicine Certification 1 Varying between 
the different 
universities and 
states 
 Varying 
between the 
different 
universities 
and states 
Table 11. Accreditation of Palliative Medicine Education. Modified from Bolognesi et al 2014  526 and Centeno et al 2015 522 NS: not specified 
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Palliative care and oncology curricula for physicians 
Several documents specify a framework for competence for physicians, developed by their 
respective national medical associations. Our literature review demonstrated that education in 
palliative medicine is generally recommended to be included in undergraduate and post-graduate 
curricula, updated by continuing education, lectures, courses, and conferences. The EAPC Steering 
Group on Medical Education and Training has published prototypes of postgraduate and 
undergraduate curricula for palliative medicine; in 2009 and 2013, respectively. In addition, rotation 
of trainees and fellows is common and supposed to promote integration 151,444,474,516 (Table 12). Thus, 
it is recognized that curricula in palliative medicine may facilitate integration of oncology and 
palliative care from an early stage in the education.527 The European Association of Palliative Care 
(EAPC) recommends that the curricula at medical schools should cover six domains, achieving six 
overall learning goals.527 Recommended educational goals include experiential learning, active 
techniques, multi-professional learning, and experience in PC and must cover more than 40 hours in 
total. It should be included in the exams and teaching should be performed by palliative scare 
specialists and professional groups other than doctors (nurses, psychologist, chaplains etc.) 
integrating ethical and, psychological social and existential issues. Additionally, education in palliative 
care should be removed from oncology and anaesthesiology, and taught as an independent subject. 
Educational strategies Levy et al.; 
2014 474 
Gamondi et 
al.; 2013 516 
Hui, Bruera; 2015, 2016 
Hui et al.; 2015 45,151,444 
PC* in undergraduate curricula X X X 
Lectures and curricula on PC for oncology 
professionals 
X  X 
Oncology rotations for PC fellows X  X 
PC rotations for oncology fellows   X 
Conferences on PC for professionals X  X 
Continuation education for practicing 
oncology professionals  
X X X 
PC skills formal examinations X  X 
Combined PC and oncological educational 
activities for fellows and trainees 
  X 
Post-graduation in PC  X X 
Table 12. Suggested educational strategies to improve competences *PC: palliative care  
The aforementioned survey by Bolognesi 526 demonstrated a wide variety of subjects, present in the 
post-graduate palliative care specialization programs in Europe. Examples of subjects were pain and 
symptom management, pharmacology of opioids and other essential drugs, psychosocial issues, 
ethical issues, communication, team working, organization of delivery of care, end- of –life care, 
normative and legal issues, oncology, non-malignant diseases, supplemented by community 
palliative care, culture, language and religion, grief and bereavement plus applied teaching from 
other disciplines, including radiology, psychiatry and public health. Thus, specialist palliative care 
curricula should provide sufficient theoretical and practical knowledge and skills to handle 
oncological emergencies, i.e. clinical detection, emergency management and referral to specialists 
(e.g. radiotherapy, neurosurgery) for spinal cord compression, pathological fractures, raised 
intracranial pressure, superior vena cava obstruction, hypercalcemia, etc. Secondarily, knowledge 
about prognostication of different cancer diseases, chemotherapy lines and radiation therapy should 
be implemented in the curricula. However, there exist no over-all recommendations on the exact 
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amount of oncological teaching in post-graduate palliative care accreditation programs and the 
actual amount is probably highly variable in different countries.   
The American Society of Clinical Oncology (ASCO) have deliberately included current best evidence of 
palliative care in oncology curricula, aiming at enhancing oncologists’ understanding of the basic 
principles of palliative care, while acknowledging that complex scenarios and refractory suffering 
should be referred to palliative medicine specialists.447 The third edition of the Recommendations for 
a Global Core Curriculum in Medical Oncology outlined specific competencies for oncologists related 
to supportive and palliative care, was published in 2004 and updated in 2010 and 2016, and was 
endorsed by ASCO and ESMO, Box 6.528 However, there exist no over-all statistics of the amount of 
palliative care teaching in post-graduate oncological accreditation programs and the actual amount is 
probably highly variable in different countries.   
 
 
The National Cancer Institute has developed EPEC-O (Education in Palliative and End-of-Life Care for 
Oncology), a multimedia curriculum that can be used as a self-study tool or presented by seminar or 
webinar.529 Further, the North-western University Feinberg School of Medicine offers the EPEC 
Trainer conferences that are ‘train-the-trainer’ courses to facilitate wide dissemination of the 
curriculum via ‘Certified EPEC® Trainers’.530 The Accreditation Council for Graduate Medical Training 
in the US has also mandated competency in hospice and palliative care for medical and 
haematological oncology fellowship programs.467 
In addition, educational curricula have been organized as the Pallium Canada’s Learning Essential 
Approaches to Palliative and End-of-Life Care (LEAP and LEAP Onco) 498 and the Virtual Learning 
Collaborative (VLC) a web-based education module under development by ASCO and American 
Academy of Hospice and Palliative Medicine (AAHPM).531 Moreover, US and European organizations, 
such as the National Comprehensive Cancer Network (NCCN) and European Society for Medical 
Oncology (ESMO), have published clinical-practice guidelines on palliative care.331,474,532,533 These 
initiatives represent a step towards in the integration processes. Moreover, an international Delphi 
survey identified four major educational strategies, related to post-graduate oncology programs. 
Box 6. Main objectives of the Recommendations for a Global Core Curriculum in Medical 
Oncology.   
• to screen, assess, prevent and manage symptoms of patients with cancer such as pain, 
fatigue, anorexia, anxiety, depression, breathlessness and nausea 
• to communicate effectively with patients and families about illness understanding and 
coping with it, prognosis, difficult decisions, end-of-life and its preparation including 
psychosocial and existential dimensions 
• to recognize the role of cancer rehabilitation, including physical therapy and nutrition 
• to recognize the importance of culturally competent, multidisciplinary care that also 
includes the families 
• to understand how to integrate palliative interventions in routine multidisciplinary 
cancer care 
• to recognize the difference between burnout, compassion fatigue and depression 
• to ensure timely referral to specialist palliative care teams  
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These were a didactic palliative care curriculum for oncology fellows provided by palliative care 
teams, continuing medical education in palliative care for attending oncologists, combined palliative 
care and oncological educational activities for fellows and trainees, and routine rotation in palliative 
care for oncology fellows.151 
Box 7. Existing curricula - Key Messages 
Large variations between countries  
Little systematic content in most countries 
Few standardized programs 
Are present recommendations too broad? 
 
The heterogeneity in education programs, i.e. the competence defined as needed in palliative care, 
probably mirrors the heterogeneity in organization and as well as what is delivered in clinical 
palliative care across countries and maybe even within countries. The present recommendations 
have similarities, but perhaps more striking are the variations which create a broad scope.  
 
Educational barriers and facilitators for integration of palliative care and 
oncology 
Lack of education and training and the common perception of palliative care as being end-of-life care 
only, have been identified in different settings.151,511,512,534,535 Further, a recent review stated that 
education (in addition to policy and implementation) represents a key barrier to palliative care 
integration in the US.534 The education barrier is both of quantitative and qualitative nature. The 
quantitative aspect includes the insufficient numbers of health care workers with adequate training 
and education for providing palliative care at their level in the health care system. The latter is not 
confined to the US settings only. The qualitative aspect includes the large variations in content across 
countries both regarding undergraduate and postgraduate education and training.  
These workforce-related issues represent significant barriers, as palliative medicine is the fastest 
growing medical specialty/subspecialty world-wide.536 It is important to acknowledge that this is not 
only related to low staffing levels, but also to the level of competences and practical skills, 
inadequate training in communication, lack of knowledge about the quality of the health care 
delivered by other professions or specialists, and resistance to refer patients to specialized palliative 
care or hospices.450,537,538 Therefore, expansion and support of educational programs for newly 
educated as well as midcareer physicians are crucial in order to meet the workforce shortage in 
palliative medicine.534 
Proposals exist on how to develop and enlarge the contents of curricula for oncologists and for 
palliative care specialists at different levels of specialist education. However, budget constraints and 
absence of administrative support can hamper the development of educational and training 
programs intended to enhance integration. Despite the fact that Europe is considered the pioneer 
region of palliative care, a descriptive EAPC study of undergraduate medical education in Europe (43 
countries) identified low investments in education.539 In only 30% of the countries palliative medicine 
was taught in medical schools, being a compulsory course in six (14%), with 40% of the countries 
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having a full professorship in palliative medicine.540 The study did not explore the reasons for these 
low numbers. Knowledge of oncology and palliative care congruent with the level of care that is 
given, constitute the underlying premise for integration of palliative care and oncology. Thus, this 
must be compulsory in all curricula from under- to postgraduate and specialist education programs.  
In a recent study exploring attitudes and beliefs among oncology trainees regarding palliative care, 
67% believed that a mandatory palliative care rotation was important; those who had completed 
palliative care rotations were more aware of the role of palliative care services than those who had 
not done so (96% versus 74%).541 Further, a survey of Canadian oncologists found that oncologists 
were more likely to refer to TPC services when they had completed a rotation in palliative care.167 
Thus, being part of a larger, multidisciplinary team alongside palliative care colleagues allows 
oncologists to share the burden of complex care delivery, potentially also preventing burnout and 
compassion fatigue.166 Oncologists’ willingness to engage with palliative care services correlates 
positively with self-reported comfort around managing end-of-life issues.177  
The integration of oncology and palliative care should be a two-way street. A clinical rotation is 
essential for integration of these disciplines, because it could help oncology fellows to acquire 
knowledge of the basic principles of symptom management and communication, understand when 
referral is appropriate, and build a working and research relationship with the palliative-care team. A 
rotation could also help to destigmatize palliative care, and might result in increased interest among 
oncologists for sub-specialization in palliative oncology. The latter may enhance recruitment to an 
emerging discipline. As many palliative care specialists have another background than oncology, 
clinical rotation the other way round to oncology is also warranted. Similar to the way in which 
patient care might be improved by educating oncologists in palliative care, rotations in medical and 
radiation oncology for palliative-care fellows, to increase their familiarity with the natural history of 
cancer, cancer-treatment modalities, and the complex decision-making process surrounding cancer 
treatment at the end of life, could be of benefit. Such rotations might also help palliative care 
specialists and oncologists nurture a mutual understanding, strengthen their partnerships, develop 
common clinical pathways for their patients and enhance research collaboration. 
To ensure and justify the investments in the integration of oncology and palliative care, future 
research should study the effectiveness of different teaching methods in palliative care education 
and the benefits of uni- and multi-professional education. There is a need to document the effect of 
how education and training programs impact treatment, patient care and organizational issues, e.g. 
care, economy, collaboration, and map the delivery and effects of undergraduate and postgraduate 
education on promoting palliative care integration. Health care organizations increasingly require 
evidence for the impact of education, so a robust evidence base to justify the cost and time of 
delivering education in palliative care must be established.  
TPC specialists are often located in comprehensive cancer centres and/or university hospitals, and 
are commonly also engaged in academic activities. Therefore, leveraging the skillset of TPC specialists 
to support primary and secondary providers of PC and expanding the scope of TPC beyond the cancer 
centre setting through education and mentorship programs may help to upskill primary and 
secondary providers and clarify the respective roles of each. Further, the TPC specialists working in 
comprehensive cancer centres or in close conjunction with oncological departments must have skills 
and competence in oncology.  The level of skills has to a little extent or not at all been concretized 
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but include skills and knowledge making them capable to handle oncological emergencies, to 
prognosticate different cancer diseases and have sufficient knowledge about chemotherapy and 
radiation therapy that enables them to cooperate with the oncologist in deciding the optimal 
treatment proposal for each patient.   
As has been demonstrated, there is a substantial heterogeneity in education programs in palliative 
medicine at all levels and across countries and perhaps also within regions. This in itself represents a 
substantial barrier for further integration of oncology and palliative care. One may speculate if this is 
related to the immaturity of palliative care as a medical activity, lacking recognition of the added 
value of including palliative care in the standard treatment lines, financial issues or difference in 
scope, the tumour versus the host, between oncology and palliative medicine. In line with others 320  
we think a shift of paradigm towards models based upon patient-centred care is highly warranted at 
all levels. Education programs should reflect this. Patient-centred care does not exclude targeting the 
tumour but makes a combined approach, the tumour and the host, the focus for the health care that 
need to be taught.  In our view, it is a general challenge that contemporary medicine strives to 
include the patient in education and practice. Models are available such as shared-decision making, 
but these are still strangers in most medical curricula.  
 
Communication skills are mandatory in order to provide patient-centred care. For patients with 
advanced cancer the patient-centred approach is of pivotal importance to ensure best possible care 
whether oncological or palliative. Training and education to improve physician-patient 
communication as part of patient-centred education programs should therefore be emphasized in 
curricula across different specializations. Communication must be learnt and consequently be part of 
all curricula in basic, intermediate and specialist medical education. Further, oncologists and 
palliative care specialists should receive specific communication training on regular intervals, to 
maintain and develop their skills, and to share fundamental skills.332,408 Several methods are available 
for teaching communication to clinicians such as communication skills training with role play and 
feedback, e-learning, group discussions, modelling, case evaluations and coaching are some of the 
most used strategies. Overall, strategies that are active and involve practice seem to be most 
efficient.411  
 
Recommendations  
• Palliative medicine must be accredited as a specialty or sub-specialty in all countries 
o How to do: Public awareness of the needs and national/international recommendations of 
accreditation. Adapt the accreditation from successful countries 
o Timeline: Now 
• Palliative care must be mandatory taught in specialization in medical oncology, radiation oncology, 
clinical oncology and surgery oncology 
o How to do: Develop minimum volume and content requirements including mandatory 
clinical rotation in palliative care  
o Timeline: Now  
• Develop international teaching programs on when and how to integrate oncology and palliative 
care  
o How to do: Require program development at health care providers’ level as well as from 
professional organizations (ESMO, EAPC, ASCO, ESTRO etc.) and apply indicators for 
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program development and implementation  
o Timeline: 1-2 years 
• Continuous education of MDT in early integration and in team work 
o How to do: Require education for oncologists and palliative medicine specialists in patient-
centred care and early integration  
o Timeline: Now 
 
Research 
 
Questions to be addressed 
What are some opportunities and challenges for integrating 
oncology and palliative care teams to conduct research 
together? 
What are some key research priorities related to integration of 
palliative care and oncology? 
What are some key research priorities related to symptom 
assessment and treatment? 
What are some key research priorities related to psychosocial 
support, communication and decision making? 
What are some key research priorities for a broad 
implementation of integration of palliative care and oncology 
on regional, national and global level?  
 
Introduction 
With increasing integration of oncology and palliative care, specialist palliative care is no longer only 
involved in the last days and weeks of life, but throughout the disease journey from the time of 
diagnosis of advanced cancer. Patients are often concurrently managed by both the oncology and 
palliative care teams, creating ample opportunities for collaborative research to improve patient 
care.  
A systematic review in 2010 that examined the quantity, design and scope of palliative oncology 
publications identified significant gaps in the literature. Among 1213 articles included over two 6-
month periods, 365 (30%) were reviews or systematic reviews. Over half of the studies (n=438, 52%) 
focused on physical symptoms among cancer patients, with few studies examining the interface 
between oncology and palliative care and how palliative care can be better integrated with oncology 
to improve care.17 Patients with survival of >6 months, 4-6 months and less than 3 months to live 
each constituted approximately 1/3 of studies; however, patients with longer survival (>12 months) 
and very short survival (<1 month) were under-represented.542 Only 6% of studies were randomized 
controlled trials, with low quality of reporting.139 Thus, there remain significant opportunities to 
improve both the quantity and quality of palliative oncology studies. 
 
In this section, we will focus our discussion on three major areas of research opportunities parallel to 
increased integration between oncology and palliative care: (1) system-oriented health services 
studies to examine different models of care and understand the optimal processes and outcomes of 
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improved integration of oncology and palliative care; and (2) patient-centred research to examine 
physical symptoms, psychosocial distress, communication, and decision making preferences 
throughout the disease trajectory; and (3) public health oriented research to examine external 
validity of the integration of palliative care and oncology in the whole society, e.g. a region or a 
country, and to develop and evaluate societal implementation strategies. Table 13 highlights some of 
the opportunities and challenges for Integrating palliative care and oncology to conduct research. 
Opportunities Challenges 
Sharing of clinical and research expertise 
 
Need time to communicate and build the trust 
and relationship between teams 
Access to patients (e.g. enrolling patients from 
oncology clinic to assess palliative care needs) 
Potential conflicts between teams because of 
differences in approaches  
Opportunities for new areas of research and 
discoveries at the interface of disciplines (e.g. 
defining roles and responsibilities for delivery 
of palliative care by oncologists) 
Potential competition for study leadership 
Sharing of work (e.g. expertise) and resources  
(e.g. staffing) may reduce overall cost 
More resources may be needed to allow larger 
research teams 
Table 13. Opportunities and Challenges for Integrating Oncology and Palliative Care Teams to 
Conduct Research 
 
Opportunities for System-Oriented Research 
A growing number of studies have addressed potential benefits from early integration of palliative 
care in oncology.3,5,49-53 The question is no longer whether patients would benefit from palliative 
care, but how  palliative care oncology teams need to provide, when is the optimal timing for referral 
to specialist palliative care, how comprehensive do the palliative care teams need to be, and what is 
the minimum model for care delivery.  A recent Delphi study identified 11 major criteria to refer 
patients with advanced cancer to outpatient palliative care.477 Table 14 summarizes some of the 
main questions regarding system-oriented research in palliative care. 
A recent systematic review highlighted 38 aspects of integration under five main domains: clinical 
structures, clinical processes, administration education, and research.45 Although there are many 
ideas on how integration can take place, empirical data is lacking to demonstrate improved 
outcomes outside of a clinical trial setting. For instance, only few studies have examined how routine 
symptom screening coupled with care pathways can be used to refer patients to palliative care.383,543 
Moreover, there is tremendous opportunity for joint research studies between oncology and 
palliative care teams to investigate the process of collaboration between the oncology and palliative 
care teams, such as MDTs and embedded palliative care clinics.544 
Because of resource limitation, it would not be possible for every cancer patient to receive specialist 
palliative care.  A proportion of patients with lower level of distress may be managed by their 
oncology team. In some countries primary care also plays an important role as front line providers. 
One unanswered question is how much palliative care do oncology teams and primary care providers 
need to know,528 and how much are they expected to deliver in their daily practice.475 In a survey of 
oncologists, greater knowledge and comfort with palliative care was associated with higher levels of 
self-reported palliative care delivery and specialist palliative care referral.177 Oncologists and 
palliative care teams can collaborate to examine how to better integrate palliative care 
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competencies in oncology and primary care, and to document the patient care outcomes associated 
with this integration. 
Another area of development in system-oriented research is the assessment of the level of 
integration among cancer centres. Such metric would allow patients and clinicians to identify 
institutions that offer a high level of palliative care, researchers to examine progress, and 
administrators and policy makers to triage resources and develop quality improvement initiatives. A 
recent international Delphi study identified a high level of consensus for 13 indicators under four 
domains (clinical structure, process, outcomes and education).48 Further studies are needed to 
validate this set of criteria.   
Domains Recommendations of Research Questions 
Specialist 
palliative care 
referral 
• What is the optimal timing for palliative care referral (resource-rich 
vs. resource-poor settings, large vs. community hospitals, cancer vs. 
non-cancer)? 
• Should time-based criteria or need-based criteria be driving palliative 
care referral? 
• Can standardized referral criteria coupled with automatic referral 
streamline the referral process? 
• What strategies can help to overcome barriers to referral among 
patients and oncologists? 
• What is the effect of palliative care intervention on patients’ ability to 
complete cancer treatments? 
• What is the role of palliative care for patients with curable cancer? 
 
Palliative care 
programs 
• What is the standard (minimum requirement) for a palliative care 
program in different healthcare settings? 
• What are the advantages and disadvantages of various novel models 
(e.g. palliative care teams involved in multidisciplinary tumour boards, 
embedded clinics)? 
• What should be the metrics/benchmarks measure the success of a 
hospital, region or nation on palliative care delivery?  
• How to develop and use clinical practice guideline on palliative care 
inform practice? 
• How can primary care teams integrate to provide palliative care? 
 
Education • How much palliative care do oncologists need to know to deliver 
effective palliative care? 
• How much oncology do palliative care specialists need to know? 
• What are the most effective strategies to educate oncologists about 
palliative care? 
• How to standardize the training and accreditation for specialist 
palliative care in different countries? 
 
Public policy • What public policies are most effective to drive palliative care? 
• What are some strategies that professional organizations can adopt to 
support integration? 
• How to optimize investment in palliative care programs to maximize 
the value of healthcare expenditure? 
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Table 14. Research Opportunities related to Integration of Palliative Care and Oncology 
 
What are the Opportunities for Patient-Centred Research? 
Symptom Assessment 
There is considerable evidence that patients with advanced cancer develop multiple devastating 
physical and psychosocial problems 545-547 and that there is also substantial burden on their primary 
caregivers. 548,549 Frequent monitoring of these important clinical problems will allow oncologists and 
palliative care specialists to identify patients who would benefit from various pharmacological and 
non-pharmacological interventions (see Background and Prognostication). More systematic 
prospective monitoring of symptoms might contribute to better prognostic models, which is 
warranted (see Prognostication). However, the adoption of regular monitoring of patient reported 
outcomes has been erratic. This is partially due to the lack of standardization or consensus on what 
domains require monitoring, the limited degree of validation of some instruments, the barriers to 
implementation of routine screening, and the need for more research to ascertain the real impact of 
screening on patient outcomes.550,551  
Patients with chronic progressive diseases including cancer frequently receive care in multiple 
settings including their home, acute care hospitals, palliative care units, inpatient hospices, and long 
term care facilities.36 The monitoring and screening of patient and caregiver reported outcomes 
needs to accompany the patient to those multiple settings. The Edmonton Regional Palliative Care 
Program conducted some pioneer research on adoption in multiple areas of care552-554 which was 
followed by several international initiatives.555,556 More research is needed to define the best ways to 
provide valuable information to clinicians throughout the trajectory of patient care in multiple 
settings and clinical circumstances. Table 15 summarizes possible research opportunities in the area 
of screening and monitoring of cancer patients and their caregivers. 
Palliative care and oncology teams need to work together to develop and validate novel assessment 
tools on various patient-reported outcomes, and apply these instruments in clinical and research 
settings to assess health outcomes. For instance, PROMIS has developed multiple assessments based 
on computer adaptive testing but require further testing.557 Recently, the International Consortium 
for Health Outcomes Measurement recommended a standard set of patient-centred outcomes for 
patients with colorectal and breast malignancies.558,559 Assessment of personalized symptom goals 
may allow both oncologists and palliative care teams to determine the individual response to 
symptom interventions and further tailor treatments.560 
 
Domains Recommendations of Research Questions 
Symptoms and 
needs screening 
• Which validated assessments should be used for which domains for 
screening at various clinical settings (oncology, palliative care vs. 
other specialties; inpatient vs. outpatient)? 
• What instruments/assessments should be included in a 
standardized comprehensive palliative care assessment? 
• How can patient function be assessed accurately? 
• How best to conduct screening for some concepts, such as patient 
understanding of illness, communication styles, spirituality and 
caregiver needs? 
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• How to overcome the patient, healthcare professional and system 
barriers to facilitate routine screening in a busy oncology and 
palliative care practice? 
• How electronic data capture may be used to collect and display 
patient reported outcomes? 
Assessment of 
treatment 
response 
• What is the minimal clinical important difference and 
responsiveness to change for various scales? 
• How can personalized symptom goals be used to augment 
practice? 
• What are the predictors of treatment response? 
Table 15. Research Opportunities Related to Symptom Assessments 
Symptom management 
There are multiple contributors to physical and psychosocial distress including cancer location and 
burden, toxicities of cancer treatment, and comorbidities. As cancer treatment evolves new 
treatments such as targeted and immune therapies have dramatically modified the risk-to-benefit 
ratio, adding another layer of complexity to cancer treatment decisions at the end-of-life. 184,561-563  
Oncology teams are experts in the use of many of these new modalities and palliative care teams are 
experts in symptom evaluation and management.   
Many symptoms, such as fatigue, pain, anorexia and dyspnea are highly prevalent throughout the 
disease trajectory.564,565 In a meta-analysis of 52 studies, cancer pain was present in over 50% of 
patients, and with one third of patients reporting moderate or severe intensity.566 This high 
prevalence calls for more research and resources to improve the detection and treatment of pain by 
oncologists, palliative care specialists, pain medicine specialists and other professions.  
Although specialist palliative care involvement has clearly been found to improve symptom control 
compared to oncology care alone,64 many symptoms have few effective therapies and remain under-
treated even by a comprehensive palliative care team.560,567 For example, anorexia-cachexia is 
reported in up to 60% of patients with advanced cancer.  Management of cachexia should begin at 
the pre-cachexia phase, when patients are seen predominantly by their oncologists. Here, 
multimodal multidisciplinary interventions targeting nutrition, physical activity, inflammation, 
appetite and nutritional impact symptoms are essential.568,569 Here, collaborative research between 
oncologists and palliative care teams to develop evidence-based palliative interventions can be 
fruitful (Table 16). In contrast, other issues such as delirium and signs of impending death mostly 
occur in the last days and weeks of life, and do not require a high degree of collaboration.262,570,571 
Domains Recommendations of Research Questions 
Treatment 
toxicities 
• How to better assess adverse effects in clinical trials and daily practice? 
• What is the pathophysiology of adverse effects related to novel 
therapies? 
• What are novel supportive care interventions for various treatment 
related adverse events? 
Cancer related 
symptoms 
• What is the pathophysiology? And what are the potential therapeutic 
targets? 
• What combination of multimodal therapy has the greatest impact on 
symptom outcomes? 
• What validated outcomes are required for regulatory approval for 
symptoms such as fatigue, cachexia and dyspnea? 
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• How to address chemical coping and opioid addiction in cancer patients 
while providing good pain control? 
Table 16. Research Opportunities related to Symptom Management 
Psychosocial Issues and Communication 
Palliative care teams can support oncology teams in the delivery of psychosocial support and 
excellent patient and family communication. 52,312,362 There is a great opportunity to conduct research 
on the best methods for the delivery of effective psychosocial support. There is also need for 
research on methods of communication with patients and their families.  Randomized controlled 
trials can be conducted on areas such as physician posture, 572,573 discussions regarding resuscitation 
574 and the impact of the content of the message.476 Better prognostication and prompt sheets may 
also enhance communication.281,413,575,576 Table 17 summarizes important areas of psychosocial 
support, communication, and advance care planning where palliative care teams can develop 
research initiatives together with oncology teams. 
Domains Recommendations of Research Questions 
Psychosocial, 
spiritual and 
caregiver care 
 
• What interventions are best for adjustment disorders? 
• What are the strategies to screen for spiritual care needs in the medical 
setting? 
• What are the best interventions to support caregivers along the disease 
trajectory? 
• What are the strategies to support decision making? 
• How to support bereaved caregivers at risk of complicated grief? 
Communication 
and decision 
making 
 
• How to accurately predict survival in advanced diseases and use that 
information to support decision making? 
• What are the strategies to communicate prognosis and help patients 
gain a better understanding of their illnesses without jeopardizing the 
patient-clinician relationship? 
• How to facilitate serious illness conversations over the continuum of 
disease? 
• How can decision making aids and prompt sheets be standardized? 
• How can physicians tailor the decision making process to different 
decision making preferences among patients and families? 
Table 17. Research Opportunities related to Psychosocial Support, Communication and Decision 
Making 
 
Opportunities for Public Health Research 
Public health and implementation impact 
The clinical as well as the social context of death and dying in cancer is rapidly changing. Globally, the 
WHO also strongly supports advocacy efforts to make the essential medicines available for palliative 
care. This public health policy work is grounded in the theory that palliative care programs at a 
country level needs to be context dependent and implementable. Place of death, place of care at the 
end of life, access to palliative care, circumstances of dying, and even end-of-life decisions are 
strongly related to the health care system, the legal context, type and models of palliative care 
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available within a country. Therefore, more implementation research is needed regarding integration 
of palliative care and oncology. 
Most evidence on integration of palliative care and oncology is based on clinical or health service 
evaluation studies conducted in only one or few hospitals.3,5,49,52,59 In most countries it is yet 
unknown how well integration of early palliative care and oncology has been implemented 
throughout the health care system. Palliative care is indeed increasingly recommended in cancer 
patients, but yet seldom practiced to all in need. In an observational study of 4466 deaths in four 
European countries it was shown that palliative care was delivered to 50% of patients in Belgium, 
55% in Italy, 62% in the Netherlands and 65% in Spain.577 Palliative care specialist services attended 
to 29% of patients in the Netherlands, 39% in Italy, 45% in Spain and 47% in Belgium. In this 
international study, cancer patients were two times more likely to receive palliative care as 
compared to patients with non-curable diseases. Furthermore, if palliative care is delivered, it is 
often being initiated at the very end of life for most patients, when the patient is within few weeks 
prior to death. A nationwide study in Belgium shows that the time of onset of palliative care is 
median 20 days prior to death for cancer patients, as compared to 12 days in heart failure and 10 
days in COPD.578  
Hence, we cannot talk of palliative care for the majority of cancer patients early in their disease 
trajectory. This demonstrates that there is a major difference between university hospital experience 
of cancer patients in which most of the palliative care trials have been conducted  and the 
experience of a full population of cancer patients in one country, hence the impact of 
implementation of integrated palliative care across a country. 
New Public Health studies 
A new research perspective is coming also from the “New public health approaches”, using evidence 
from the field of health promotion, health behaviour and public awareness building.579,580 Cancer 
patients are taken care of by oncologists or physicians for only a small part of the time, it is the 
spouses, families and the broader community that takes care of these people 24/7. Hence, the 
impact of family, volunteers and the larger community is extremely important for cancer patients. 
They support cancer patients not just in their wellbeing, but also for expressing their care 
preferences, participating in shared decision making, and eventually in the decisions at the end of 
life.  
In this perspective one should also bear in mind that the general public and the public opinion have 
not yet a full understanding of the potentials of integration of early palliative care in an oncology 
treatment trajectory. The reality in most countries is that palliative care is still very much of a taboo 
or a stigma because awareness and experiences of palliative care potential is limited to terminal 
care, hence associated with imminent death. Therefore, we need also research into the development 
of palliative care public awareness campaigns and into studying human behaviour in health crisis 
situations, and empowerment of patients and families in making the right decisions both for their 
cancer treatment as for their wellbeing and quality of life. 
92 
 
In order to increase the level of evidence concerning implementation of early palliative care in 
oncology and improving the involvement of patients, families and the broader community, next to 
clinical and health services research, also more public health oriented research is needed. Table 18 
summarizes important domains, possible research methods for monitoring the implementation of 
integration across a country, and possible research aims fort public health studies relevant to 
integration of palliative care and oncology. 
 
 
Domains Recommendations of Research Methods 
Monitoring 
implementation 
scope 
 
• Administrative databases 
• Health care registries, e.g. nationwide sentinel networks 
• Nationwide post-mortem surveys 
• Auditing of integrated care services 
 Recommendations of Research Aims 
Evaluating the 
quality of 
integration of 
palliative care and 
oncology 
 
• Developing of palliative care quality indicators for the evaluation of 
the quality of the integrated services 
• Cross-country and cross-setting (university hospital vs local hospital) 
validation of the indicators 
• Implementation of the quality indicators 
• Development of quality improvement interventions 
Health promoting 
early palliative 
care in cancer 
• What are the perceptions of palliative care potentials among cancer 
patients and their families, among health care professional, and 
among the general public? 
• Developing of health promotion campaigns to empower cancer 
patients and their families to talk to their health professionals early 
in their illness trajectory about palliative care needs and care 
preferences. 
• Developing of palliative care awareness campaigns to improve 
knowledge and attitudes towards early palliative care in cancer 
patients and in the general public. 
Table 18. Research Opportunities related to Public Health and Population Health 
 
What are the opportunities for collaborative research regarding cancer treatments? 
Palliative care teams are increasingly involved in the care of patients undergoing palliative therapies 
for advanced cancer, including systemic therapies, radiation and surgical procedures. They have a 
critical role in helping to maximize the quality of life of patients undergoing cancer treatments, and 
also facilitating the complex decision making process surrounding treatments at the end-of-life (i.e. 
last months before death). The advent of novel therapies such as immunotherapies creates even 
more opportunities for collaborative research between the oncology and palliative care teams to 
optimize patient outcomes. 
There are exciting opportunities for joint research from the collaboration by these two groups by a 
better understanding of the pathophysiology of treatment-related adverse effects. The interaction 
between cancer burden, treatment toxicity, and comorbidities is complex and variable. As an 
example, a highly effective immunotherapy will reduce symptoms related to the tumour mass and 
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also improve the patient’s and caregiver’s psychological wellbeing but will add symptoms related to 
fatigue and immune related adverse effects such as dermatitis, colitis and hypophysitis.581 Figure 7 
summarizes the complex interaction between tumour mass, tumour treatment, and comorbidities in 
the generation of symptom and psychosocial burden. Cancer, through its direct effect on organs and 
tissues or it indirect effect on systemic mediators can result in multiple symptoms, decreasing 
patients’ function and quality of life.  Cancer treatments may control tumour growth, but may also 
lead to significant toxicities.  Co-morbidities could further contribute to the overall symptom burden.  
Supportive and palliative care aim to alleviate symptoms and improve quality of life by modulating 
the afferent signals and enhancing the coping mechanisms. 
Palliative care specialists not only need to collaborate with surgeons, radiation oncologists, medical 
oncologists and haematologists clinically, but also in research studies to identify the best ways to 
optimize patients’ functional status and nutrition status before, during and after treatments.  More 
research is also needed to determine the best strategies to prevent and/or treat various treatment-
related adverse events.   
Cancer treatments close to the death are associated with lower quality of end-of-life care.582,583 Novel 
targeted therapies and immunotherapies are generally associated with fewer side effects than 
conventional chemotherapy and are being increasingly offered to patients with lower performance 
status.563 A small proportion of these patients experience a remarkable treatment response, altering 
the natural history in a significant manner and adding to the prognostic uncertainty.  While 
oncologists can offer hope through new treatment opportunities, palliative care teams can nurture 
hope for better quality of life throughout the disease trajectory and help patients to balance the ever 
shifting priorities. More collaborative research is needed to better understand patients’ goals of care, 
illness understanding and treatment preferences, to develop better prognostication tools and 
decisions aids to inform the complex decision making process regarding treatment continuation and 
discontinuation as death approaches.184,304   
 
Evolving Models to Support Collaborative Research 
Compared to established medical disciplines such as oncology, palliative care focuses on personhood 
care instead of management of specific diseases. Thus, palliative care specialists are uniquely 
positioned to conduct research by drawing upon the similarities among different diseases to derive 
common principles of patient-centred care (e.g. management of dyspnea, serious illness 
conversations), while personalizing management based on the unique differences among the 
different disease (e.g. cancer trajectory is more predictable).   
Although there is no lack of academic oncologists, palliative care researchers are in small supply.  
Thus, educational programs and funding opportunities are needed to train more palliative care 
clinicians in the principles of research and unique aspects of conducting palliative care studies. Such 
investments will likely result in more opportunities for research collaborations and accelerate 
development of innovative interventions to improve patient care.  
As new therapies become available to cancer patients there are opportunities for oncology and 
palliative care teams to prepare proposals aimed at measuring carefully the impact of those 
therapies in the physical and psychosocial wellbeing of the patients and the ideal management of the 
symptomatic complications secondary to those therapies. These proposals will provide access to 
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sources of funding from industry that traditionally have been largely unavailable to palliative care 
research teams. At times when academic funding is becoming less available in most countries these 
joint efforts will provide support for logistics and career development of academic palliative care 
physicians and oncologists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Conceptual Model of Interaction among Cancer, Cancer Treatments, Comorbidities and 
Supportive and Palliative Care Interventions on Symptoms and Quality of Life.   
 
Conclusion 
There are many unanswered questions related to the optimal delivery of palliative care in cancer 
patients, with many challenges to conduct high quality research.  With increased integration 
between oncology and palliative care, there are tremendous opportunities to identify novel research 
questions at the interface of disciplines, combine the resources to complete high quality research, 
generate new knowledge to advance symptom management and care delivery, and develop better 
models of integrated care towards improving patient outcomes. 
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Recommendations  
• Research into new public health approaches for integration of oncology and palliative care is 
needed  
o How to do: Establish international and national research programs to support research on 
content, methods and how to verify the effects  
o Timeline:  1-2 years 
• Develop a minimum and maximum set of indicators for the follow up of successes in the 
implementation of early integration of oncology and palliative care 
o How to do: Initiate research programs internationally and nationally 
o Timeline: Now  
• Initiate collaborative research programs in oncology and palliative care for symptom management 
(needs) and their application in SPC and in the discussion in MDTs 
o How to do: Initiate research programs internationally and nationally 
o Timeline: Now 
• Top academic positions in palliative medicine/care (professors) must be present at all academic 
cancer centers and medical schools 
o How to: Professional awareness programs and advocacy groups needs to be initiated  
o Timeline: 1-2 years 
 
Summary and call for action 
During the work with this commission it has become evident how heterogeneous the organizations, 
the content of the models and the performance in clinical practices are. The heterogeneity goes even 
further into the content of the education programs. That includes the presence of palliative care in 
oncology training, if present at all, as well as the structure, the content and (lack of) formalization of 
palliative medicine as a specialty in many countries. This heterogeneity with a lack of international 
agreements and standards of palliative care in oncology is probably one main barrier for a successful 
integration. “If one of the partners in a relationship is undefined, ambiguous, the probability to build 
a long lasting relationship will probably be low and very challenging”.    
Policy 
Internationally, strong and clear resolutions and recommendations are given by the WHO, OECD, 
professional organizations (ASCO, ESMO, EAPC) and international charters (EAPC, IAHPC, WPCA) on 
the place for palliative care as a part of the cancer care programs. The content and directions can be 
summarized by the statement given by the World Health Assembly (WHO) in 2014: “Strengthening 
palliative care as a component of comprehensive care throughout the life course” which states that 
palliative care should be covered under national universal health coverage plans. It has been shown 
in several high quality studies that an integration of palliative care into oncology care improves 
several outcomes, like symptom management, patients’ and family members’ quality of life and 
possibly survival for patients with short life expectancy. Systematic use of PROMS improves symptom 
control, reduce psychological distress and can improve survival. The need for integration is further 
supported by the increase in incidence and prevalence of patients living with advanced cancer. 
 
These clear and strong recommendations given during the last couple of decades are contrasted by 
the findings in this commission: Lack of integration of oncology and palliative care. In most national 
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cancer care plans, palliative care is not formulated as an integrated approach together with 
oncology. If it is present, it is often an add-on to the tumour directed approaches. It seems to be a 
lack of willingness and capability to implement and prioritize palliative care in the cancer care plans, 
in care programs as well as in clinical care pathways.  
The lack of true implementation may in addition to the above mentioned factors also be related to 
the heterogeneity of the organizational models of palliative care, the lack of systematic education in 
palliative medicine in medical schools and during specialization in oncology as well as lack of 
education of oncology during palliative medicine specialization. 
One may ask if palliative care has become even more under-prioritized during the last decade. In this 
time period much attention has been given to the advances of new systemic tumour directed 
therapies and a non-anticipated attention away from patient-centred care may have occurred. The 
marketing of the new treatments may have created the budget winners? 
In order to achieve improvements in complex systems like health care, several approaches are 
needed by combining top-down and bottom-up actions. It is recommended in this commission that 
the strong political recommendations are followed up at national and regional levels. The politicians 
and the health care bureaucracy together need to develop plans and implementation strategies and 
combine these plans with economic incentives and basic funding of the integration between 
oncology and palliative care. It is well documented that palliative care may reduce cost and improve 
patients’ quality of life and the quality of life of their family members. 
 
  
Cultures  
Cultures in health care play important roles by serving as invisible “roadmaps” for interpersonal 
interactions like how a doctor communicates with a patient or how physicians with different 
specialties interact. Cultures also act as barriers in the process of changing and improving practice. 
The oncology culture can be described as a tumour directed culture with its positive implication 
when the treatment goal is to cure and thereby achieve tumour control and ideally total eradicate 
the tumour. Undoubtedly this culture has been and is essential to improve cure for many cancer 
diagnosis. However from a patient perspective if cure is not achievable, like in patients with 
advanced lung, pancreatic, colon or breast cancer, a combined tumour-directed and patient-centred 
approach is needed and strongly recommended in this commission.  In the palliative care culture the 
primary focus is to improve patients’ quality of life. In this commission, patient-centred care 
including shared decision-making with a primary focus on the patient (the host) is recommended. 
The palliative patient-centred culture therefore differs from the oncology culture, it has different 
players and has until recently in many countries been organized separate from mainstream health 
and oncology care. From a patient perspective being in a non-curative situation, the palliative culture 
need to be present and should not be considered to be in competition but rather synergetic – 
integrated - with the tumour directed culture.  
 
Action: “True integration” must be recommended by national health care authorities, 
followed up with resource allocation and priorities and monitoring of successful 
implementations. It is a need for international valid indicators of successful integration 
of oncology and palliative care.  
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One of several ways to understand why the patient-centred palliative care approach is not 
implemented into oncology clinics is the gap and antagonisms between the two cultures. When 
different approaches from two cultures are to be blended in cancer care programs one need to 
understand the differences and the shared values, and plan the implementation according to a 
multicultural reality. The antagonisms held by the two maintain status-quo, i.e. we versus them, but 
represents in our view a substantial barrier towards integration. 
 
 
 
Organization and competence 
The overall aim of the organizational model is that patients and their families have access to the care 
they need, when they need it, resulting in improved health care outcomes. In the integrated 
oncology and palliative care model, early integration is a key concept. It clearly illustrates that the 
content and competence of palliative care is much more than end of life care. 
 
 The MDT approach can be used as a key component of the organizational model in the hospitals to 
link oncology and palliative care services. However the organizations need also to outreach to the 
community and home care. The models need to have a clear and robust organization but also be 
flexible according to the patients’ needs. Several organizational models of palliative care have been 
developed and evaluated. This commission recommends dividing the models into three levels: 
primary, secondary and tertiary care and that the place, competence of oncology and palliative care 
need to be adjusted to the level of care and the patients’ needs. At the primary health care level, the 
GPs need also to have the necessary competence in palliative care. Their role is central in home care.  
 
One limitation of the organizational models identified in the literature and discussed in this 
commission is their heterogeneity. This hinders generalization of findings. This commission has 
identified a need to develop international standards for the structure and content of the 
organizational models as well as to further evaluate the effects in public health care research.  
 
For a successful integration of oncology and palliative care a multidisciplinary approach is needed. 
The health care providers need skills in patient-centred care. Wide variations in education have been 
identified for oncologist and for palliative medicine specialists and also exist for education of the 
other participants in the multidisciplinary teams. The general lack of competence in palliative care is 
also a barrier for successful implementation of the integrated models.  
 
Action: Culture analysis need to be performed and the implementation of palliative 
care need to be conducted based upon involvements of the leaders of the oncology and 
palliative care programs. The unofficial leaders at all levels also need to be mapped and 
involved in the implementation plans. 
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Patient-centred care 
The concept of total pain which is central in palliative care infers a broad understanding of patients’ 
needs during a disease trajectory. Many cancer patients undergo life-prolonging treatment for years 
or are cancer survivors with manifest or latent late effects of treatments.  Therefore the chronic 
disease model is highly relevant in oncology but is seldom referred to or utilized.   
 
The patients and his family are expecting and demanding to be actively involved in the care planning, 
at all stages of the disease trajectories. A central part of involvement and engagement of patients is a 
systematic collection of “the patients’ voice”. Furthermore there are expectations about information 
and communication to patients about treatment and care plans which often are not fulfilled when 
comes to patients with advanced disease and a limited life expectancy. Often they are not aware of 
their disease status and the expected effects of tumour-directed treatment.  
 
The fragmented nature of the cancer care system calls for a methodology to implement the planning, 
coordination and to perform resource allocation according to patients’ needs. Standardized care 
pathways (SCP) is a method to plan and implement complex health services and to assure that the 
right people, are at the right place, to the right time. This commission proposes to use the method of 
SCP as a model to develop a seamless patient flow in a customized organizational model. 
 
Symptom assessment by systematic use of patient reported outcome measures (PROMs) performed 
by using validated PROMs is pivotal for patient-centred care throughout the whole cancer disease 
trajectories. It can be considered as a key method to engage patients into the decision making 
processes where PROMs are key information to customize the SCPs. PROMs were traditionally 
collected in paper based questionnaires. This commission recommends development of electronic 
tools for collection of PROMs, e-PROMs that can be integrated into the electronic patient record 
systems.  
 
Shared decision making (SDM) is another central component of patient-centred care. It is highly 
relevant in all phases of cancer treatment, but is even more central for patients with advanced non-
curable disease. SDM is an active and continuous process combining the tumour-directed and the 
patient-centred approach in the care planning. This commission recommends that SDM is included as 
a mandatory part of oncology guidelines and is visualized in the content of the SCPs.  
 
Action: International standards of oncology and palliative care are needed for:  
• Integrated oncology and palliative care models are needed to evaluate 
the effects of these models clinically.  
• Palliative care education in oncology and oncology education in palliative 
medicine. 
• Defining the necessary competence and the content of the education at 
the three different layers need to be performed at a high level, preferably 
internationally, and not governed by tradition or local preferences 
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Research  
An early integration of oncology and palliative care gives new arenas and opportunities for 
collaboration in addressing new research questions. Some key questions to answer are related to 
health services issues and others related to patient-related issues such as assessment and treatment 
of physical symptoms, psychological distress, communication and decision making processes and 
performances.  
 
New tumour directed treatments such as targeted and immune therapy have added another layer to 
the complexity to the end of life. It gives new opportunities for collaborative research in addressing 
the interactions between tumour burden, treatment toxicity and comorbidities. At the health service 
arena some examples of questions to answer are: how to optimize integration of oncology and 
palliative care? What are the optimal organizational models at the primary, secondary and tertiary 
levels of care for integrated oncology and palliative care? How to optimally utilize the human 
resources in the SCPs? 
 
Research competence and funding are basic. Few resources are allocated to palliative and end of life 
care research. Data from several countries indicate that 0·3 to 1 % of resources allocated to cancer 
research goes to cancer palliative care research. Lack of research funding also minimizes the 
opportunities for training physicians in palliative care research and thereby qualify clinicians to be 
researchers and to apply for academic positions.  
 
 
 
 
 
 
 
 
 
 
 
Actions: Patient-centred care must be actively implemented into oncology care 
by means of systematic use of SCPs where oncology and palliative care is fully 
integrated. PROMs and SDM are methods which should systematically and 
actively be used in all parts of cancer care.  
Action: It is urgently needed to invest in research in palliative care in order to 
develop an evidence base on how to organize and how to perform palliative care in 
oncology practice. National earmarked grants for research programs are needed, 
which are sufficiently funded for 3-5 years.  
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